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Abstract 
 
 
 
 
Global medical investigations have shown that cardio-vascular diseases cause 29% of all 
deaths that is 17 million people annually. Cardio-vascular diseases cause more deaths than car 
crash, cancer, tuberculosis and AIDS combined. In Australia 40% of total deaths are from 
cardio-vascular diseases, and the annual budget for cardio-vascular treatment is about $8.8 
billion. Internationally about 80% of lethal cardio-vascular diseases occur in developing 
countries with low income.  
 
In most cases of cardio-vascular disease a life can be saved by an operation that replaces 
organs or parts. One of the most common implants are heart implants or implants concerned 
with heart or vascular systems. An implantation of donor organs has many ethical problems 
and is limited by donor possibilities. Many patients die waiting for a donor organ to become 
available. Therefore, artificial implants may be the preferable way to save lives. 
  
Modern artificial implants work successfully in organisms for more then 20 years. The 
success of the medical implant industry and surgery practice is proved by a high number of 
operations. Research has shown that 73% of people who received artificial heart implants 
survived after 9 years and 65% survived after 18 years, while only 48% of people who 
received the therapeutic treatment survived after 5 years. In the case of artificial aorta 
implants 85% of people survive after 5 years, while only 10% of people who received the 
therapeutic treatment survived after 5 years. Further development of the biomaterial science 
and surgery techniques can increase this difference.  
 
Full biocompatibility of the implant with the organism is the goal. However, an intrusion of 
any artificial material into an organism causes a reaction of the organism’s immune system. 
The immune reaction on the foreign body protects the organism against bacteria, viruses and 
injuries, and causes an isolation of the implant from the organism tissue that can break a 
functionality of the implant. In the worst case scenario the implant must be removed or 
replaced. This involves a secondary operation that increases the risk of lethality significantly, 
especially for elderly people who mostly need the implants. Research has shown that 100% of 
all artificial implants cause an immune reaction, and 35% of them require a secondary 
operation.  
 
Therefore, the immune response of the organism on the artificial implant is a problem and 
must be solved. The artificial implant with absent or decreased immune response is necessary 
to save patients and to improve quality of life.  
 
This research proves that the cross-linked non-soluble polyurethane can be synthesised so that 
it has adjustable mechanical properties comparable to soft tissue with low stiffness and 
sufficient mechanical strength, and which also has low residuals, is non-toxic and stable in the 
organism. We have modified the polyurethane with Plasma Immersion Ion Implantation (PIII) 
and created the active carbonised layer. The modified polyurethane implant was characterised 
with different physical and chemical methods and it was shown, that: 
- Modified polyurethane has thin carbonised surface layer consisting of condensed aromatic 
structures like graphite or grapheme. The carbon atoms on the edge of this surface layer have 
unpaired electrons known as free radicals;  
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- These free radicals are responsible for the polyurethane implant’s high hydrophilicity and 
high chemical activity, which allows the organism’s protein to covalently attach to the 
implant surface forming total stable coverage. 
 
The carbonised layer provides fast total endothelialisation of the implant surface like control 
TCP surface.  
 
The polyurethane implants as disks were implanted subcutaneously in mice and the 
polyurethane graft replaced the abdominal aorta of a rat. The animal experiments and 
following histological investigations showed that the PIII treated implant causes significantly 
weaker immune response of the organism than the untreated implant. This is evidenced by the 
thinner collagen capsule (p<0.001), lower number and activity of macrophages (p<0.001), 
specific distribution of macrophages near the implant surface, less cell proliferation activity 
(p<0.001), less pro-inflammatory factor activity (p<0.001). In some cases the capsule and 
macrophages activity was absent. The absence of the immune reaction on an artificial soft 
polyurethane implant with PIII treatment is possible.  
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Fig.5.12. Fluorescent image of cells proliferated for 3 days on untreated (a) and ion 
implanted (b-d) PTFE with nitrogen ions of 20 keV energy and fluence of 6 x1013 (b), 
1x1014 (c) and 5x1014 (d) ions/cm2. 
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Fig.5.13. Cell density attached on PTFE after 3 days of proliferation with fluence of 
ion beam implantation. The mark “*” corresponds to significant difference, p<0.05 
and “ns” to not significant difference, p>0.05. 
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Fig.5.14. Fluorescent image of the cells adhered and proliferated in 2 days to 
polyurethane surface treated by PIII with different time. TCP control and untreated 
polyurethane samples are presented above. 
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Fig.5.15. Fluorescent image of the cells adhered and proliferated for 6 days on 
polyurethane surface treated by PIII for different times. TCP control and untreated 
polyurethane samples are presented above. 
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Fig.5.16. Fluorescent image of the cells adhered and proliferated for 2 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. 
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Fig.5.17. Fluorescent image of the cells adhered and proliferated for 6 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. 
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Fig.5.18. Fluorescent images of the cells adhered and proliferated for 2 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. Images on the 
left correspond to the cell nuclei staining. Images on the right correspond to the cell 
cytoskeleton staining. Image size is 0.68x0.5 mm2. 
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Fig.5.19. Fluorescent images of the cells adhered and proliferated for 6 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. Image size is 
0.68x0.5 mm2. 
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Fig.5.20. Optical microscope image of the living cells attached to polyurethane 
surface treated by PIII for different times. No fixing or staining was applied. 
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Fig.5.21. Number of cells on TCP and PU with and without tropoelastin after 2 days 
of attachment. The difference is significant (***), p<0.001 and not significant (ns), 
p>0.05. 
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Fig.5.22. Number of cells on TCP and PU with and without tropoelastin after 6 days 
of attachment. The difference is insignificant, p>0.05. 
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Fig.6.1. Polyurethane graft sewed with aorta in rat. 121 
Fig.6.2. Images of the histological samples of polyurethanes stained in Milligan. 
Objective x4. The implant position was in the centre of the ovals. For example, the 
position of the implant in PPG-DI-PEG-0.7 sample is marked as “Implant”. Usually, 
the polyurethane sample was removed at the microtome cutting, but sometimes the 
small pieces of the polyurethane samples remain. 
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Fig.6.3. Microphotographs of the histological tissue samples stained in Milligan for 
untreated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures is the 
implant position. 
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Fig.6.4. Microphotographs of the histological tissue samples stained in Milligan for 
40 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position. 
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Fig.6.5. Microphotographs of the histological tissue samples stained in Milligan for 
80 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position. 
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Fig.6.6. Microphotographs of the histological tissue samples stained in Milligan for 
200 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position. 
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Fig.6.7. Microphotographs of the histological tissue samples stained in Milligan for 
400 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position. 
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Fig.6.8. Microphotographs of the histological tissue samples stained in Milligan for 
800 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position. 
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Fig.6.9. Thickness of the collagen capsule near the polyurethane implant treated by 
PIII with different treatment time. “Ini” means the untreated (initial) samples. 
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Fig. 6.10. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the untreated PPG-DI-PTHF-0.35 polyurethane implants. An 
empty space on the figures is the implant position. 
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Fig.6.11. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 40 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows. 
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Fig.6.12. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 80 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows. 
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Fig.6.13. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 200 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows. 
 
 
 
134 
Fig. 6.14. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 400 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the top figure is the implant position. Positions of 
macrophages are shown with arrows. 
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Fig.6.15. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 800 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows. 
 
 
 
135 
Fig.6.16. Microphotographs of the histological tissue samples stained in F4-80 
antibody for the PPG-DI-PTHF-0.35 polyurethane implants. An empty space on the 
figures is the implant position. 
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Fig.6.17. Relative area of the tissue stained by F4-80 antibody near the PIII treated 
polyurethane implants with time of PIII treatment (s). “0” means the untreated 
(initial) samples. 
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Fig.6.18. Relative staining density of the tissue stained by F4-80 antibody near the 
PIII treated polyurethane implants with time of PIII treatment (s). “0” means the 
untreated (initial) samples. 
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Fig.6.19. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for untreated polyurethane PPG-DI-PTHF-0.35. An empty space on the 
figures is the implant position. 
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Fig.6.20. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 40s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position. 
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Fig.6.21. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 80s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position. 
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Fig.6.22. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 200s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position. 
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Fig.6.23. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 400s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position. 
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Fig.6.24. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 800s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position. 
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Fig.6.25. Relative area of the tissue stained by Ki-67 antibody near the PIII treated 
polyurethane implants with time of PIII treatment (s). “0” means the untreated 
(initial) samples. 
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Fig.6.26. Relative staining density of the tissue stained by Ki-67 antibody near the  
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PIII treated polyurethane implants with time of PIII treatment (s). “0” means the 
untreated (initial) samples. 
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Fig.6.27. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for untreated polyurethane PPG-DI-PTHF-0.35. An empty space 
on the figures is the implant position. 
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Fig.6.28. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 40 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position. 
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Fig.6.29. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 80 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position. 
 
 
148 
Fig.6.30. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 200 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position. 
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Fig.6.31. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 400 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position. 
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Fig.6.32. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 800 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position. 
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Fig.6.33. Result of von Willebrand Factor staining analysis of the tissue near the PIII 
treated polyurethane implants with time of PIII treatment. “0” means the untreated 
(initial) samples. 
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Fig.6.34. Scheme of foreign body reaction with main stages from the time of first 
contact of the implant with organism tissue. The scheme is adapted from literature 
data [3] for untreated and PIII treated polyurethane. Red crosses show low or absent 
activity observed in the experiments with PIII treated implants. 
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Chapter 1. Introduction 
 
 
 
 
The results of global medical investigations show that cardio-vascular diseases are the 
cause of about 29% of all deaths, that is 17 million people annually. Cardio-vascular 
diseases cause more deaths than car crash, cancer, tuberculosis and AIDS combined. 
Internationally about 80% of lethal cardio-vascular diseases occur in developing 
countries with low income. In Australia 40% of total deaths are from cardio-vascular 
diseases. The treatment of cardio-vascular disease is very expensive: higher than for 
all other diseases. In Australia the annual budget for cardio-vascular treatment is 
about $8.8 billion.  
 
In most cases an operation replacing organs or parts could save lives. One of the most 
common implants are heart implants or implants concerned with heart or vascular 
systems. An implantation of donor organs has many ethical problems and is limited 
by donor possibilities. The long waiting list for donor organs kills many patients. 
Therefore, the most preferable way is to use artificial implants.  
 
The success of the medical implant industry and surgery practice is proved by a high 
number of operations. In the USA annually more than 13 million devices are 
implanted. 
 
Modern artificial implants work successfully in organisms for more then 20 years. 
Research has shown that 73% of people who received artificial heart implants 
survived after 9 years and 65% survived after 18 years, while only 48% of people 
who received the therapeutic treatment survived after 5 years. In the case of artificial 
aorta implants 85% of people survive after 5 years, while only 10% of people who 
received the therapeutic treatment survived after 5 years. Further development of the 
biomaterial science and surgery techniques can increase this difference.  
 
1.1. Materials for medical implants and biocompatibility problems  
 
Artificial implants for soft tissue are made of polymer materials such as 
polyvinylidene fluoride (PVDF), polyethylene (PE), polypropylene (PP), 
polydimethylsiloxane (PDMS), parylene, polyamide (PA), polyimide (PI), 
polytetrafluoroethylene (PTFE), poly-methyl-methacrylate (PMMA) and 
polyurethane (PU) [1-4]. These materials satisfy the requirements for biomedical 
devices approved by the USA’s Food and Drug Administration (FDA). Australia 
follows their regulations. 
 
Following FDA classification cardiovascular implants such as pacemaker, 
implantable cardio defibrillator, ventricular assist device, heart valve, blood vessel, 
catheter are made of PP, PE, PTFE, PA, PET, PDMS; cochlear, staples and nasal 
implants are made of PDMS, parylene, PE; penile implant, Foley implant, urinary 
sphincter, hernia or vaginal mesh are made of PDMS, PE, PTFE, PA, PP; breast 
implant, cheek, jaw and chin implants, lip implant, hip implant are made of PP, PET, 
PTFE, PDMS; intrauterine device, intravaginal ring, urogynecologic mesh implant, 
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fetal micro-pacemaker are made of PDMS, PP, PU; retinal prosthesis, intraocular 
lens, glaucoma valve, orbital implant, ophthalmic implant are made of PMMA, PE, 
PTFE, PA.  
 
These materials have been tested and approved by the FDA as providing an 
acceptable level of cytotoxicity, sensitization, irritation, acute systematic toxicity, 
sub-chronic toxicity, genotoxicity, hemocompatibility, chronic toxicity, 
carcinogenicity, reproductive developmental and biodegradation [5]. The most 
stringent requirements are applied to the materials used for long term implants (more 
then 30 days of an implant in the organism are considered as permanent) and sensitive 
organs such as ophthalmic devices. Materials for implants are selected based on 
conditions in the organism such as mechanical loading and movement, pH 
environment, aggressive liquids, and on the functionality of the implant such as 
electro-conductivity or electro-resistivity, mechanical strength, softness and elasticity, 
multiple cyclic loads, low or high friction, required biodegradation rate, and 
corrosiveness. The product of biodegradation must satisfy the biocompatible 
requirements too. Also the materials for implant must be sterilisable by certified 
methods such as ethylene oxide, steam, UV irradiation or γ-irradiation. 
  
In practice, however, even a complete satisfaction of these requirements does not 
always mean a full biocompatibility. An intrusion of any artificial material into an 
organism will cause a reaction of the immune system of the organism [6]. This 
reaction on the foreign body protects the organism against bacteria, viruses and 
injuries. The immune reaction causes an isolation of the implant from the organism 
tissue and can break a functionality of the implant. Most of the implantable materials 
that have been approved cause acute and chronic inflammatory response. In the worst 
case scenario the implant must be removed or replaced. A secondary operation 
significantly increases the risk of lethality, especially for elderly people who mostly 
need the implants. Research has shown that 100% of all artificial implants cause an 
immune reaction, and 35% of them require a secondary operation.  
 
Patients are selected for cardio vascular surgery based on the health of their immune 
systems. Patients who are rejected are left to die, never being given an opportunity to 
have the surgery. However, many of the people who require an operation are elderly 
and suffer from a number of different diseases, such as diabetes, which compromise 
the immune system. Whatever one’s views on the prolongation of human life, cardio 
vascular operations can significantly improve the functionality and quality of life for 
the sufferer and their family. 
 
The immune response of the organism on the artificial implant is therefore the 
problem that must be solved. An artificial implant with absent or decreased immune 
response is the simplest and cheapest way of saving patients’ lives and improving 
quality of life.  
 
1.2. Surface of medical implants and reaction of organism  
 
An organism contacts the medical implant via an implant surface. The surface can be 
characterised by surface energy and its polar and non-polar parts, surface chemistry as 
active chemical groups accessible to any kind of organism molecules, surface 
topography and the mechanical properties of the surface layer. The surface energy of 
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a polymer implant is in the range from 20 to 45 MJ/m. Most of the implant materials 
are hydrophobic with low polar part of the surface energy. The hydrophilic implants 
such as hydrogels have high polar part of the surface energy due to swelling in water. 
However, such implants have limited application due to low mechanical properties.  
When an implant is placed into the organism, the implant surface contacts the 
organism’s liquids such as blood and intercellular liquids. At this contact the proteins 
are firstly absorbed on the implant surface [7].  
 
The proteins can be absorbed on the surface via intermolecular interaction of different 
kinds [8, 9]. The proteins have hydrophobic and hydrophilic aminoacid residuals that 
create a wide range of interactions depending on the protein conformation. In the 
water media the hydrophilic residuals are predominantly on the external side of the 
protein molecule. When the polymer implant is placed in the organism, the proteins 
contact the polymer surface and adjust their conformation to minimise the free energy 
[10-12].  
 
The immune reaction is a complex of biochemical reactions and immune cell activity 
[13]. The insertion of the implant begins with a cut of the soft tissue. Even without the 
implant, the immune system reacts on the tissue damage. A few seconds after the cut 
the blood vessels are activated, the blood stream increases and the immune cells 
within the blood stream come to the wound. The interaction between blood and air 
changes the conformation of the blood proteins such as fibrinogen, the albumin, the 
laminin, the tissue factors, the complement cascade (5) and others on the surface 
liquid-gas due to surface tension [14].  
 
The immune cells recognise the conformation of the proteins and release cytokines to 
start the intrinsic coagulation cascade, thrombosis, complement systems, platelets and 
leukocytes. As a result, the thrombus clot forms. In a few minutes the cells such as 
polymorphonuclear leukocyte (PMN), neutrophils and monocytes come and take part 
in the lysis process of the tissue’s damaged cells. If the wound is small, the tissue can 
be regenerated after the lysis of the damaged cells and the cell damaging products are 
removed. In the case of bacterial infection or a big wound the macrophages and 
monocytes come to the damaged tissue and take part in the lysis of the bacterial cells 
creating a capsule, which isolates the damaged tissue from the rest of the organism. 
This can take days. The damaged tissue, the bacteria and all the products of the lysis 
must be removed from the blood for the immune reaction to be stopped. The worse 
case scenario is that scar tissue remains after the complete immune reaction.  
 
An ideal candidate for an implant is expected to have a similar reaction of the immune 
system. When the implant is placed in the cut, the blood contacts the implant surface. 
The proteins from the blood stream come to the interface blood-implant. If the 
proteins do not change the conformation of this interface, the immune cells are not 
activated. However, the materials used for the modern implant change the 
conformation of the proteins due to the different interaction of proteins with the 
implant surface. As a result, the immune cells are activated and a cascade of immune 
reactions starts.  
 
In contrast to the simple cut, the permanent presence of the implant causes a 
permanent immune reaction. The immune reaction on the implant has three stages. 
During the first stage the proteins are absorbed on the implant surface and PMN, 
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neutrophils and monocytes are activated and collected near the implant. In the case of 
a biodegradable implant, the lysing factors (enzymes, proteases, reactive oxygen 
species) can degrade the implant material. When the degradation of the material is 
complete, the immune reaction stops. However, usually the implants are made of 
stable materials and lysing factors cannot degrade the implant. The neutrophils release 
large amounts of signalling factors to attract more cells including factors to 
differentiate monocytes into macrophages, which play a significant role in the 
following stages of the immune response. During the second stage the immune 
reaction is characterised by the presence of macrophages, foreign body giant cells and 
lymphocytes and the formation of granular tissue. At this stage the macrophages, 
giant cells, T-lymphocyte and other cells release a number of cytokines and growth 
factors such as PDGF, TNF, TGF, IL-1 and others. These cytokines and growth 
factors regulate cell migration, differentiation and proliferation that heal wounds by 
growing new blood vessels with endothelial cells or collagen tissue growing with 
fibroblasts. If the activity of immune cells is high and the signalling factors continue 
to be released, the collagen capsule can grow into a thick fibrosis shell and calcify in 
the later stages.  
 
Regulating immune cell activity by stopping or decreasing the release of active 
factors like cytokine secretion decreases the resistance of the whole organism to 
bacterial disease and other wound healing. The immune reaction can be minimised or 
stopped with medications. However, an implant with drug release to regulate immune 
cell activity has a limited time frame for the drug release, and a high probability of  
causing local bacterial infection at the time of operation. The decrease of the immune 
reaction intensity can be achieved with fast endothelialisation of the implant’s surface 
[15]. However, the endothelialisation process of modern materials is not fast enough 
to avoid the immune reaction. 
 
For example, two materials clinically approved are mostly used for synthetic 
conduits: polyethylene terephthalate (PET) and expanded polytetrafluor ethylene 
(ePTFE). However these materials remain thrombogenic, cause permanent immune 
response with chronic inflammation, and a luminal coating of endothelial cells is not 
formed. As a result the conduit’s size is limited to a minimal diameter of 6 mm for a 
successful operation. The problem is that smaller diameter conduits show a 
significantly higher risk of occlusion [16].  
 
Therefore, the immune response on artificial implants remains a significant problem 
for polymer implants.  
 
 
1.3. Synthesis of medical polyurethanes  
 
Of the various prospective biomaterials, polyurethanes (PU) are considered one of the 
best materials for implants. Polyurethane is a broad class of materials that always has 
the urethane group in its chain. Most ways of synthesis are based on poly-
condensation reactions of the isocyanate group with hydroxyl, carboxyl or amine 
groups. Modern PUs are block copolymers with ‘hard’ and ‘soft’ domains of 
macromolecule, having glass transition temperatures above and below room 
temperature respectively. They are extensively used in medicine due to their 
biological inertness, low toxicity and the wide range of mechanical properties. 
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Modern polyurethanes are used for short-term devices such as blood and urinary 
catheters [17], syringe tips, pipes and bags for blood circulation system, tissue 
scaffolds [18, 19], as well as long-term devices such as artificial diaphragm 
membranes, artificial joints, meniscal prosthetics [20], breast prosthetic shells [21], 
artificial hearts [22, 23], bones [24] and other orthopaedic devices [25]. PU has also 
been widely used in the manufacture of vascular grafts [26-31], because of its ability 
to create compliant, durable materials. Past iterations of PU constructs have suffered 
from a combination of lack of appreciation of their biological destination (see below) 
and a failure to tune their biological interface prior to implantation [32]. The 
development of hybrid materials has the potential to increase biocompatibility [33]. 
 
The mechanical and biodegradation properties of polyurethanes vary depending on 
the selection of specific monomer groups for inclusion in the backbone [34]. Polyester 
oligomers used as soft blocks, are susceptible to hydrolysis facilitating the high 
biodegradability required for dissolving sutures and surgical glue [35]. The products 
of glycolysis and hydrolysis of biodegradable PU are non-toxic and released from the 
body in the urine. Highly stable polyurethanes, like the ones required for long-term 
implants, on the other hand, can be obtained by using carbonate oligomers and co-
polymers [36].  
 
The mechanical properties of PU can be varied over an extremely wide range through 
the chemistry of isocyanate ‘hard’ domain, the length of the polyol ‘soft’ domain, the 
soft/hard domain ratio and by controlling microphase separation during synthesis. The 
extent of microphase separation can be increased through annealing, exposure to 
solvents and/or the addition of plasticiser during synthesis [37, 38]. Short chain PU, 
with a low soft/hard domain ratio, are used for prosthetic implants where mechanical 
strength is required. Long chain polyols, with high soft/hard domain ratio are used for 
soft implants where mechanical properties similar to soft tissue are required. The 
large range of mechanical properties attainable makes PU a universal material suitable 
for augmenting the wide range of tissues and organs that can be implanted [39]. PU is 
particularly attractive for meeting the challenge of vascular conduits matching 
surrounding vessels with sufficient strength at high pressures. The tunability of PU 
formulations allows for close matching of these target vessels, whose mechanical 
properties vary depending on anatomical location. 
 
Despite its popularity as a biomaterial, the less than ideal biocompatibility of PU still 
presents problems in most applications. When PU implants come into contact with 
body fluids the immune system recognizes them as foreign bodies and initiates an 
immune response. This foreign body response is typically triggered by interactions 
between the PU surface and proteins of the organism. The surface of polyurethane is 
hydrophobic and proteins that are adsorbed on the PU surface become denatured and 
change their conformation.  
 
There are polyurethanes certified for medical applications including long-term 
implants. All these polyurethanes are much harder than the soft tissue of an organism 
[40-44]. The hard material causes mechanical damage in the surrounding tissues, 
which also causes an immune response. When very soft polyurethane is synthesised to 
tune the stiffness of the polyurethane implant to the stiffness of the soft tissue it is 
difficult to keep sufficient mechanical strength. 
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The modern commercial polyurethanes are mostly linear polymers or thermoplastic 
[45]. These polyurethanes can be softened with high temperatures in preforms or can 
be dissolved in selected solvents for casting. Such polyurethanes are limited. They all 
have a high stiffness because high mechanical strength of linear polyurethanes is 
associated with high stiffness. Usually polyurethane contains residuals as byproducts 
of the synthesis. Such residuals cannot be washed out from linear polyurethane in 
solvents, and an adhesion of casted or moulded linear polyurethane coating to a metal 
medical device is usually weak. It would be more effective to synthesise the 
polyurethane coating directly on medical implantable devices [46].  
 
It follows that polyurethane synthesis suitable for medical implants in soft tissues 
remains a significant problem.  
 
 
1.4. Plasma and ion beam methods modification of polymer materials  
 
Plasma treatment methods are used for improvement of biocompatibility for different 
kinds of polymers [47-49]. The plasma’s effect is based on macromolecule 
destruction with the formation of active groups predominantly oxygen-containing 
groups in the surface layer, improved wettability, developed surface roughness and 
hardening of the surface layer [50, 51]. An advantage of the plasma methods is the 
thin surface modification while the bulk polymer remains virginal. Therefore, all the 
polymer implant’s exploitation properties remain in their initial form and only the 
surface can be adjusted to fulfil the requirements of biocompatibility.  
 
The plasma methods can be classified according to the energy of ions. One of the 
methods, ion beam implantation, bombards ions with high energy so that the kinetic 
energy of ions is much higher then any chemical bond in the polymer [52, 53]. 
However, ion beam implantation methods require large machines with a small 
diameter ion beam. The most practical method is plasma immersion ion implantation 
(PIII), where the ion beam is formed in the plasma chamber over the polymer implant 
[54]. Such PIII system consists of a vacuum chamber with a rotary pump and a 
turbomolecular pump providing basic pressure of 1e-5 Torr, a plasma generator in 
high frequency (MHz) or ultrahigh frequency (GHz) range, a pulsed high voltage 
power supply generating pulses of high voltage (1-20 keV) in microsecond range 
duration. To prevent the polymer burning the total average current must be in the µA 
range.  
 
Ion beam implantation and PIII have been used for the treatment of many kinds of 
polymers to improve adhesion, wettability, hardness, optical properties, crosslinking, 
stability and so on [55, 56]. Polyurethanes have also been treated by ion beam 
implantation and PIII to form a carbonised layer on the surface [57, 58].  
 
Biocompatibility of polyurethanes was improved by ion beam implantation as 
reported by Suzuki [59] and others [60-63]. Later it was shown that the polyurethane 
in mammary implants can also be improved with ion beam implantation [64]. The 
cells and protein adsorption was improved with PIII treatment for PTFE, 
polyethylene, polystyrene, nylon and other polymers [65-69]. It was shown that the 
ion bombardment creates a carbonised layer on the surface, which is rich with 
condensed aromatic structures like graphene or graphite. Such structures stabilise 
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unpaired electrons at carbon atoms on the edges of aromatic rings [70, 71]. These 
carbon atoms at the edge of the aromatic structures with unpaired electrons are called 
free radicals and are very active to any molecule able to donor a proton [72]. The 
stabilised unpaired electrons can be preserved in condensed aromatic structures for a 
long time before they take part in chemical bond formation with protein molecules 
[73]. The formed chemical bond between the condensed aromatic structures and 
protein molecules is stable and cannot be destroyed with any detergent.  
 
At the same time, the unpaired electrons are very energetic providing high surface 
energy of the carbonised layer with high contribution of polar interactions. The polar 
interactions provide high hydrophilicity of the carbonised surface in such a way that 
the protein adsorbed on such surface does not change conformation [74.]. 
Consequently, the high activity of the ion beam implanted surface of the polymer 
attaches the protein molecule to the stable covalent bond, which provides preservation 
of the initial conformation of protein [75]. The activity of the carbonised layer can be 
sufficient to provide total protein coverage of the surface. Therefore, the ion beam 
implantation and PIII treatment has the potential to create a carbonised surface layer, 
which can provide a stable bioactive protein layer totally covering the polymer 
surface.  
 
This research investigated the PIII treatment of newly synthesised polyurethane and 
the reaction of the organism to it. 
 
 
1.5. Aims of this research and structure of this thesis  
 
The aim of this study was to develop a new polyurethane formula with adjusted 
mechanical properties and plasma related methods of surface modification, which 
decrease the immune response of the organism when the polyurethane medical device 
is implanted into the organism.  
 
The study had the following stages: 
 
1. To synthesise cross-linked non-soluble polyurethane with adjusted mechanical 
properties to soft tissue with low stiffness and sufficient mechanical strength so that it 
has low residuals, is non-toxic and stable in the organism, and then to modify the 
polyurethane with PIII to get an active carbonised layer with its characterisation. The 
synthesised material should comply with FDA and ISO 10993 standards for 
implantable materials suitable for long-term functionality in organisms. These results 
are described in Chapter 3 and 4.  
 
2. To investigate in vitro the interactions of the modified polyurethane surface with 
biologically significant components of an organism such as proteins and cells. These 
results are described in Chapter 5. 
 
3.  To investigate the immune response of the organism in vivo to the modified 
polyurethane implant and to consider the applications of PIII treated polyurethane for 
biomedical devices. These results are described in Chapter 6. 
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The chemicals and experimental methods used in the present study are described in 
Chapter 2.  
 
Appendices contain the supporting results and the applications of modified 
polyurethanes in biomedical devices.  
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Chapter 2. Materials and methods  
 
 
This chapter describes the general methods and materials used in this thesis. Particular 
materials and methods applied in experiments are described in subsequent chapters.  
 
 
2.1. Materials and chemicals  
 
Polyurethane pellets of Pellethane 2103 and Pellethane 2363-80 were purchased from 
Dow Chemical (Germany). Pellethane 2103 is a polyurethane for general use. 
Pellethane 2363-80 is a polyurethane for biomedical applications. 
  
A co-polymer of polyoxitetramethylene (POTM) and polyoxipropylene (POP) glycol 
(trademark PF-OP-15, MM=2000) with an oxitetramethylene/oxipropylene monomer 
chain ratio of 85:15 was purchased from Kirovskiy plant (Perm, Russia). Chemicals 
2,4-toluenediisocyanate (TDI), 3,3’-dichlor,4,4’-diaminediphenylmethane (DA), 
dibutyl dilaurate of Stannum (DBD), polytetrahydrofuran (PTHF), polyethylene 
glycol (PEG), ethylene diamine (EDA) and polypropylene glycol (PPG), ethylacetate, 
acetone, toluene, tributylphosphate and dimethylformamide (DMFA) were purchased 
from Aldrich (Sydney, Australia). Oligomer of polyoxypropylene glycol with MDI 
extender was purchased from ERA Polymers Pty Ltd (Sydney, Australia).  
 
Polypropylene glycol terminated by toluenediisocyanate (PPG-TDI) was purchased 
from Aldrich (Germany). Polyglycol Lapronol 1200 was purchased from BASF 
(Germany).  
 
ePTFE sheets, vascular stents with PLGA coating and PLGA pellets were provided by 
Boston Scientific SCIMED, USA. Polytetrafluorethylene (Teflon) film of 20 mm 
thickness was purchased from Galogen plant (Perm, Russia).  
 
Stainless steel urinary catheters with variable geometry from URINAE Frommelius 
GmbH used in experiments were 1500 mm in length and 2 mm in wire diameter. 
Starting at a distance of 300 mm from the end of the catheter, the diameter decreases 
gradually reaching 0.2 mm at the other end.  
 
Acrylamide with 0.1% of Tetramethylethylenediamine inhibitor of polymerization 
was purchased from Aldrich (Germany). 
 
 
2.2. Methods for implant preparation and analysis 
 
Ion beam treatment 
The ion beam accelerator “Pulsar” (Institute of Technical Chemistry, Perm, Russia) 
was used for ion beam treatment of the polymers. The accelerator has a vacuum 
chamber with ultimate pressure of 3x10-3 Pa provided by rotary and diffusion pumps. 
The working pressure of 5x10-2 Pa was provided by nitrogen flux via needle valve. 
The plasma was generated in hollow cathode under 2 kV pulse of 300 µSec duration 
with 1 Hz frequency repetition. The permanent high voltage potential was applied to 
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the electrostatic optical system to extract the nitrogen ions from the plasma cloud and 
to accelerate to the polymer target with energy of 20 and 30 keV. The beam diameter 
with uniform current distribution was about 100 mm.  
 
The ion current on the target was measured using Faraday cap, which has additional 
screening electrode under 2 kV potential to bring back secondary electrons from the 
bottom of the cap. Average ion current density was not higher then 1 µA/cm2 to 
prevent overheating of the samples. The bulk measurements of temperature after the 
longest treatment time and highest ion current density 1 µA/cm2 was not higher then 
400C. The pressure, bias, plasma density and ion current were monitored during the 
treatment.  
 
Some samples of polyurethane were treated by ion beam accelerator ILU-3 (Physical-
technical Institute, Kazan, Russia). The pressure in the vacuum chamber was 10-3 Pa 
achieved by rotary and diffusion pumps. The samples were treated by nitrogen ions 
with energy of 20 keV and fluence range of 1013-1016 ions/cm2. The current density of 
the ion beam was 10 µA/cm2 at the area of 100x5 mm2. The beam was scanned on the 
target surface with the frequency of 10 Hz to prevent overheating. The average ion 
current was about 1 µA/cm2. The temperature of the sample was lower then 400C.  
 
Plasma immersion ion implantation (PIII) 
The Plasma immersion ion implantation (University of Sydney, Sydney, Australia) 
used for treatment consists of a vacuum chamber equipped with dry scroll pump and 
turbomolecular pump. The pumps provide a basic pressure up to 10-6 Torr. The 
working pressure of 2 mTorrs was provided by nitrogen flux via needle valve of flow 
controller (MKS, USA). The plasma of 100 W was generated by rf-generator EMI 
(13.75 MHz). Plasma power was transported to the chamber via an inductive antenna 
through the glass part of the vacuum chamber. The magnetic coils were placed on the 
top part of the vacuum chamber made of aluminium. The coil current was adjusted to 
get uniform distribution of the plasma bar to intensify the treatment and to exclude 
aluminium deposition from the chamber walls to the polymer samples. The high 
voltage electrode used as a sample holder of 150 mm diameter was made of stainless 
steel and mounted on top of the vacuum chamber. The holder was cleaned with 
ethanol. The sample of polyurethane was fixed on the sample holder with springs or 
scotch tape. The sample was covered by mesh electrode made of stainless steel, which 
was electrically connected to the sample holder. The distance from mesh to the 
sample was 50 mm. The mesh electrode provided uniform distribution of the ion 
current on the sample surface. The high voltage pulse from Pulse high voltage supply 
(ANSTO, Sydney, Australia) was applied to the sample holder via high voltage 50 
Ohm inductive resistivity cable and high voltage input. The pulse amplitude was 20 
kV at 20 mSec duration and 50 Hz repetition frequency. The average current 
including capacitance charge current in the cable was 1.4-1.5 mA.  
 
The fluence of the PIII treatment was estimated from UV-spectra of LDPE film of 50 
mM thickness. This LDPE film was treated for different time periods with 20 keV 
energy nitrogen ions and calibrated using UV spectra of the same film treated by the 
“Pulsar” accelerator with the same parameters and known ion fluence measured with 
the Faraday cap. The used fluence range of 5x1013-1016 ions/cm2 corresponded to 40-
800 sec of the treatment time.  
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The same experimental setup was used for the polyurethane capillary internal 
treatment. The geometry and parameters of this treatment are described in Chapters 4 
and 7.  
 
Some samples of polyurethane were treated in PIII system in Rossendorf Centre 
(Dresden, Germany). The system consists of a vacuum chamber equipped with rotary 
and turbomolecular pumps providing basic pressure of 10-4 Pa. The working nitrogen 
pressure of 10-2 Pa was provided by the flow controller. The plasma was generated by 
electron cyclotron resonance source with density of 1010 cm-3 and electron 
temperature of 9 eV. The high voltage pulse of 20 keV energy and 5 µSec duration 
was applied to the sample holder. The sample of polyurethane was placed on the 
sample holder and covered by stainless steel mesh. The distance between the sample 
surface and the mesh was 30 mm.  
 
Wettability 
A contact angle device DS-10 (KRUSS, Germany) was used to measure contact 
angles of deionized water and diiodomethane (Aldrich, Australia) on the surface of 
polyurethane. The sessile drop method was used for an analysis of the drop shape. 
The surface energy of polyurethane was calculated using Owner-Wendt-Rabel-
Kaelble method developed for total surface energy, dispersive and polar parts 
analysis. Rabel method parameters such as 53.6 MJ/m for polar part of surface energy 
and 18.7 MJ/m for dispersive part of surface energy for water and 0 MJ/m for polar 
part of surface energy and 50.8 MJ/m for dispersive part of surface energy for 
diiodomethane were used for calculation of the surface energy for polyurethanes. The 
measurements of the contact angle were done for a minimum of 5 drops for one 
sample on the smooth polyurethane surface central area. The edge area of the samples 
was excluded. Every new drop was placed on a virgin part of the surface to exclude 
any contamination from the previous drops. The drop was kept for 5-10 seconds after 
it was dropped to ensure the drop had a stable shape for analysis. The results of the 
measurements of untreated polyurethane were compared with the literature data for 
polyurethanes.  
 
Fourier transform infrared spectra 
Fourier transform infrared (FTIR) spectra were recorded using a Digilab FTS7000 
FTIR spectrometer (Agilent, Australia) and Bomem (Toronto, Canada) FTIR 
spectrometer with DTGS detectors. The number of scans was 100 with a spectral 
resolution of 4 cm−1. 
  
Fourier transform infrared attenuated total reflection (FTIR ATR) spectra were 
recorded using a Digilab FTS7000 FTIR spectrometer equipped with a multi-bounce 
ATR accessory with a trapezium germanium crystal at an incidence angle of 45° 
(Harrick, USA). The number of scans was 500 with a spectral resolution of 4 cm−1. 
Analysis of spectra was made with Grams software (Galactic, USA). 
  
Micro FTIR ATR spectra were recorded with Vertex 70 FTIR spectrometer (Bruker, 
Germany) equipped with FTIR microscope and Ge prism crystal and MCT liquid 
nitrogen cooled detector. The sample area for the spectra recording was 100 µm 
diameter. The number of scans was 100 with a spectral resolution of 1 cm−1.  
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FTIR ATR spectra were recorded at an IFS-66 spectrometer (Bruker, Germany). 
FTIR ATR spectra were recorded with the ATR accessory on KRS-5 and Ge crystal. 
The number of scans was 100 with a spectral resolution of 1 cm−1. Analysis of spectra 
was made with the help of the OPUS program (Bruker, Germany).  
 
FTIR ATR spectra were recorded on Nicolet Magna spectrometer with Ge ATR 
crystal with a 450 incident angle. The number of scans was 100 with a spectral 
resolution of 2 cm−1.  
 
Quantitative measurements of the characteristic line absorbance were conducted using 
Bouger-Lambert-Beer law and basic line methods. For ATR spectra the ratio of 
absorbance for analytical line and internal standard line was used.  
 
X-ray photoelectron spectroscopy 
X-ray photoelectron spectra (XPS) were recorded on spectrometer equipped with Al 
Kα X-ray source (1486.6 eV exciting line) and X-ray beam monochromator (SPECS, 
Germany). The X-ray source power was 200 W. PHOIBOS 150−9 MCD 
hemispherical analyser with a detector of 9 channeltrons working simultaneously with 
energy shift calibrated by the software was used. The energy was calibrated by Au4f7/2 
83.98 eV line of the gold sample. The electron gun was used to compensate a surface 
charge on the surface of polyurethane sample. The survey spectra were recorded at 30 
eV passing energy and 2 scans with 1 eV step in 50-1200 eV range of energy for an 
analysis of surface contamination. The detail spectra of C1s, O1s and N1s regions of 
high spectral resolution were recorded at 23 eV passing energy and minimum 10 
scans with 0.1 eV step. The peaks were fitted with Gaussian-Lorentzian components 
using Marquardt-Levenberg fitting procedure in CASA software. The peaks were 
quantified with the sensitivity factor individualised to each element and used for 
atomic concentration calculations. The charge shift was calibrated on C1s line 
corresponded to C-C bond at 285 eV position.  
 
Raman spectroscopy 
Micro-Raman spectra were recorded in 1800 degree geometry excited by Nd:YAG 
laser line of secondary harmonic (532.14 nm wavelength) on a diffraction double 
monochromators HR800 (Jobin Yvon) equipped with LabRam 010 positioning 
system (Lastek, Australia). Corresponding notch filters were used to exclude parasite 
lines and the laser beam line. The CCD matrix was used for detection of the Raman 
scattering signal. The optical microscope was used to focus the laser beam in thin 
polyurethane surface. The objective 100 was used. The laser beam power was 
adjusted to avoid any trace of carbonisation on the surface. The absence of burning 
under the laser beam was proved with repeating the spectra at the same place. The 
method of delay measurements was used to bleach the sample with the laser beam to 
exclude a fluorescence signal. The spectral resolution was 4 cm-1. The spectral range 
of survey spectra was 100-4000 cm-1. The detail spectra were recorded in 200-2000 
cm-1. The number of scans between 10 and 100 and the dwelling time of 0.1-1 sec 
range were selected to get sufficient signal noise ratio.  
 
Near edge X-ray absorption fine structure (NEXAFS) spectra of polyurethane 
X-ray absorption spectroscopy was performed on untreated and 800 sec PIII treated 
polyurethane using the soft X-ray beam line of the Australian Synchrotron. The near 
edge X-ray absorption fine structure (NEXAFS) on the C1s and N1s regions was 
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recorded using the MCT detector (spectra from bulk) and channeltron detector 
(spectra from surface). The X-rays were polarised horizontally and the sample was 
tilted at an angle of 90°o to the incoming beam. Variations in X-ray intensity with 
energy were extracted from the measured spectra using the signal generated from a 
standard gold covered grid. Contributions to the C1s NEXAFS from contamination in 
the beam line were determined by replacing the sample with a reference photodiode 
and collecting a spectrum, which was then used to correct the spectra from the 
polyurethane samples. 
 
Electron spin resonance spectra 
The electron spin resonance spectra (ESR) were recorded using Adani electron spin 
resonance spectrometer (Minsk, Belarus). The polyurethane samples of 20x40 mm2 
area were rolled and placed inside a quartz capillary tube. The tube was placed into 
the cavity of the spectrometer. The spectrometer was calibrated using a weak pitch 
KCl sample. Measurements were taken in X band at 200C. Ten scans were taken per 
sample to get sufficient signal/noise ratio.  
 
Atomic force microscopy  
The surface topography of the polyurethane was measured with Atomic force 
microscopy (AFM) using Park System device (Park System, South Korea) in tapping 
mode with a speed of 1 Hz and amplitude 10 nm. Statistics from 3 to 5 different 
places of one sample were measured with 10x10, 1x1 mm and 0.3x0.3 mm areas. The 
resulting images were analysed with Gwyddion software and WM&S software. 
  
The hardness of the surface polyurethane layer was measured with AFM Dimension 
3100 (Digital Instruments Veeco Metrology Group, USA) in a contact mode. A 
silicon probe with a cantilever spring constant of 20 nN/nm and a resonance 
frequency 300 kHz was used. The tip radius of curvature was measured by imaging 
standard gold particles and determined to be 20 nm. The tip vibration frequency in the 
contact mode was 0.5 Hz. Digital Instruments’ software with compensating lateral 
motion was used for data analysis. A silicon wafer, LDPE plate and PTFE plate were 
used as reference materials for analysis of the hardness of the polyurethane.  
 
Optical microscopy 
The surface of polyurethanes were analysed with optical microscope 
Axioplan2Imaging (Zeiss, Germany) in reflective mode with 10, 20 and 50 
objectives. The microscope was equipped with CCD camera. The standard plate was 
used to calibrate the scale of images.  
 
Ellipsometry 
The thickness of the modified layer and the optical constants were measured with 
optical ellipsometry using Woollam M2000V spectroscopic ellipsometer. The spectra 
in 250-1000 nm wavelength were collected for 55, 60, 65, 70 and 75 degrees of the 
incident angle of the light beam. The number of spectral scans was selected to get 
sufficient signal/noise ratio. Cauchy layer was used for fitting the experimental data 
of the untreated polyurethane to get the optical constants. These optical constants of 
untreated polyurethane were used for analysis of multilayer model of the modified 
polyurethane.  
 
Friction measurements 
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The friction experiments were done using a friction measurement system (Rossendorf 
Research Center, Germany). The measurements were done with a Cr6 alloy ball of 5 
mm diameter that moved periodically on the polyurethane surface. Polyurethane 
coatings were synthesised on stainless steel for the friction measurement. The 
amplitude of the balls motion was 6 mm and its speed was 6 mm/s. The normal force 
applied to the ball was 0.65 N. The friction coefficient was averaged over the first 50–
80 cycles of the indenter. Longer motion caused a damage of the polyurethane coating 
and was not used for analysis.  
 
Leaching residuals from polyurethane 
The polyurethane samples (0.3 mm thick) were pre-weighed and placed in deionized 
water for 7 days in a sealed glass beaker. Samples were then dried in air for 24 h and 
then in a vacuum oven for 8 h. The samples were then re-weighed and the relative 
mass loss attributed to leached components was calculated. For an analysis of leached 
components, water from the beaker was placed on a germanium ATR crystal and 
dried. Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectra were 
measured using a Digilab FTS7000 FTIR spectrometer fitted with ATR accessory. A 
control spectrum was taken using water from a beaker stored in the same environment 
but without PU.  
 
Crosslinking test for polyurethane 
Polyurethane samples were tested for swelling in a “good” solvent to assess cross-
linking of macromolecules [ASTM D 471-97(1998)]. PU film samples (0.3 mm thick) 
were weighed, placed in dimethylformamide and hexane in sealed beakers. Samples 
were allowed to swell for 24 h. The samples were weighed immediately after removal 
from the beakers, then dried for 24 h in open air and re-weighed.  
 
Mechanical tests for polyurethane  
Mechanical properties of the polyurethanes were tested using an Instron 5943 with a 
100 N load cell according to the ASTM D412-06a (ASTM International, 2006) 
protocol. The samples were cut to 1×0.8×5 cm3 size. Each kind of polyurethane was 
tested with 3 identical samples. The load sensor and extensometer were calibrated 
prior to the test. To prevent specimen slipping during the test, hydraulic clamps were 
used. The polyurethane was loaded at a constant strain rate of 500 mm/min to 100% 
stretch and then relaxed to 0% stretch. This cycle was repeated 3 times before the 
polyurethane samples were stretched to failure. The Young’s modulus was obtained 
by calculating the slope of the stress–strain curve at 100%. The tensile strength and 
modulus at breakage was calculated using the maximum strain at the breaking point.  
 
A lower load cycling test was also carried out to assess performance during loads 
compatible with those experienced in the vasculature. One hundred cycles up to 10% 
strain at a constant strain rate were applied at a frequency of 1 Hz.  
 
 
2.3. Methods in vitro investigations 
 
Protein attachment 
The polyurethane samples were incubated in protein (Tropoelastin, Poly-L-Lysine, 
BSA or HRP) solution for 24 hours at room temperature in 75 mm sterile Petri dishes 
with the samples on the bottom totally covered with the solution. Protein was diluted 
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to 20 µg/ml in 10 mM sodium phosphate buffer pH 7. After incubation, the samples 
were removed from the Petri dish, dried with Kim-Wipe tissue for 3-5 seconds, placed 
into glass beakers with the buffer for 1 minute, then dried with Kim-Wipe tissue for 
3-5 seconds and placed into another new Petri dish with 15 ml of wash buffer (10 mM 
sodium phosphate buffer pH 7) for 1 hour. After that the samples were placed into 
glass beakers with the buffer for 1 minute, dried with Kim-Wipe tissue for 3-5 
seconds, placed into glass beakers with deionised water for 1 minute and dried with 
Kim-Wipe tissue for 3-5 seconds. The samples were then placed into new dry Petri 
dish and dried overnight. Spectroscopic analysis was then conducted on these 
samples.  
 
Washing protein with detergent 
The polyurethane samples were placed into falcon tubes with 45 ml of 2% sodium 
dodecyl sulphate (SDS) solution in deionised water. The tubes were placed into a 
water bath at 700C temperature and kept there for 1 hour. After that the samples were 
washed with deionised water 6 times. In some experiments the Tween 20 detergent 
was used instead of SDS.  
 
Activity assay 
HRP activity was measured by clamping the polyurethane samples between two 
stainless steel plates separated by an O-ring (inner diameter was 8 mm, outer diameter 
was 11 mm). The top plate contained a 5 mm diameter hole. 3,3,5,5’- 
Tetramethylbenzidine (TMB; Sigma T0440) was added to the hole. After 30 s TMB 
was removed and added to 50 µl of 2 M HCl followed by 25 µl of unreacted TMB to 
make up the volume to 100 µl. Optical density was then measured at a wavelength of 
450 nm using UV spectrophotometer.  
 
Cell attachment 
In experiments with cells, polyurethane discs with the surface area of 0.58 cm2 
ethanol sterilized were mounted in Minusheets (Minucells and Minutissue, Bad 
Abbach). The bovine aortic endothelial cell line GM7373 (Coriell) was used for the 
experiments. 4×104 cells in 200 µ ︎L medium (MEM-Earle supplemented with 10% 
fetal bovine serum (FBS), 1 × MEM vitamins, 2 mM N-acetyl l-alanyl l-glutamine, 
1×amino acids) were seeded directly on the samples. They were allowed to adhere for 
2 hours at standard cell culture conditions, then the medium was filled up to 1 mL per 
sample. Three days after seeding the cells were fixed in 0.2% paraformaldehyde in 
PBS and stained with rhodamine. Images were taken by fluorescent microscopy with 
a video camera.  
 
 
2.4. Methods in vivo investigations 
 
Mouse operations 
In this experiment the strain “wild-type” C57Bl/6 male mice were used. The mice 
were provided by the Laboratory Animal Services (LAS) of Sydney University. The 
weight of the mice was about 20g each. An intra-peritoneal injection of Avertin of 
0.125 mg per gram of mouse weight was used for anaesthesia. Sterile conditions were 
maintained during the surgery. The back of each mouse was shaved and smeared with 
a betadine solution. Polyurethane samples were implanted subcutaneously in 6 
pockets (two rows side by side) on the back of each mouse. The sample order in each 
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mouse was done in such a way that some mice held the samples with different PIII 
treatment time and some mice held similar samples in different pockets. The position 
of the samples in mice and in the pockets was taken into account at the histological 
and immunohistochemistry analysis as described in Chapter 6. The cuts were sewed 
with silk sutures. The mice were marked on tails with non-toxic permanent marker.  
 
After the surgery 5 mice were kept in each cage with food and water provided. All 
mice were housed under standard conditions in the Bosch Animal facility and 
observed on a day-to-day basis following the standard protocol for post-surgery. The 
mice were euthanized (cervical dislocation) after 7 days.  
 
Preparation samples from the mice 
Freezing and Paraffin tissue fixing:  
Samples of tissue with ingrown implants (10x10 mm) from euthanized mice were 
collected and immediately immersed in 75% ethanol at 40C. The samples were left in 
the fridge overnight, then immersed to 100% ethanol for fixing (4 hrs at 40C). The 
samples were placed into an automated tissue processor for overnight tissue 
processing program. 
  
Table. 3.1 Step by step description of automated tissue processing program.  
 
Solution  
 
Conditions  
70% Ethanol   40 mins  
80% Ethanol  40 mins  
95% Ethanol  40 mins  
100% Ethanol  2 change 1hr and1.5 hrs  
Xylene   2 change 1hr and 1.5 hrs  
Liquid paraffin under vacuum  600C, 4 changes 1.5hrs each 
 
Embedding and sectioning tissue:  
Fixed samples of tissue with ingrown PU disks were embedded in molten paraffin 
wax and hardened at room temperature. Each sample was cut on a rotary microtome 
into 5µm sections. The sections were lifted from the 45°C floated bath onto glass 
slides. The Aquadhere 5% v/v (Menzel-Glaser, Germany) was used for histochemical 
staining. SuperFrost Plus (Australia) was used for immunohistochemical staining. The 
slides were dried in an oven at 37°C overnight.  
 
Histopathology  
Transverse sections (5 µm) of the capsule with the implants were deparaffinised and 
hematoxylin-eosin stained (H&E) to determine total cell number in the capsule.  
 
The protocol of H&E was followed:  
- Deparaffinising slides in 2 changes of xylene for 10 mins each; 
- Rehydration in alcohol 100%, 95%, 70% then in tap water of 2 mins each;  
- Application of Harri’s haematoxylin for 3 mins;  
- Washing in tap water;  
- Dipping 3 times in acid alcohol (70% of ethanol in HCl); 
- Dipping in a solution of Scott’s bluing for 30 secs;  
- Washing in tap water;  
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- Checking the quality of colour with microscope;  
- Dipping once in 70% ethanol solution; 
- Application of Eosin twice for 30 sec each time;  
- Dehydration in alcohol of 70%, 95%, 100%; 
- Clearing in xylene twice for 10 mins each;  
- Mounting with DPX.  
 
Milligan’s Trichrome staining:  
- Deparaffinising slides in 2 changes of xylene for 10 mins each; 
- Rehydration in alcohol of 100%, 95%, 70% then in tap water for 2 mins each;  
- Application of Weigert’s haematoxylin for 5 mins;  
- Application of Scott’s solution for 30 sec;  
- Application of Mordant solution for 6 mins;  
- Rinsing in water;  
- Placing in 0.1% acid fushin solution for 6.5 mins; 
- Placing in 1% phosphomolybdic acid solution for 3.5 mins;  
- Placing in 2% orange G solution for 7.5 mins;  
- Washing in deionized water for 8 mins;  
- Placing in 1% of acetic acid for 3 mins;  
- Dipping quickly into 95% of ethanol 4 times;  
- Drying in air;  
- Dehydration in alcohol of 70%, 95%, 100%;  
- Clearing in xylene twice for 10 mins each;  
- Mounting with DPX.  
 
The micro-photos were taken with the Nikon microscope (Japan), and the software 
ImageJ Pro Plus 7 with macros was used for statistical analysis of the capsule 
thickness. The statistical analysis was done using software GraphPad Prism Version 
5.0. The ANOVA analysis and Bonferroni Post-test were used to compare the results 
between the two groups, and in each group. The significance of the difference 
between the two groups was accepted at p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
 
Immunohistochemistry 
A number of protocols were applied to the slides to analyse specific cells and their 
activity.  
 
Endothelial cells Von Willebrand Factor IHC staining protocol: 
- Deparaffinising slides in 2 changes of xylene for 10 mins each; 
- Rehydration in 2 changes of xylene 10 mins each, in alcohol of 100%, 95%, 70% 
then in tap water for 2 mins each;  
- Quenching for 20 mins in H2O2 endogenous peroxidase (solution of 49.5 ml of 
methanol and 0.5 ml of 30% H2O2);  
- Washing slides in TBS (Tweens) for 3 times for 3 mins each;  
- Incubating in DAKO Target Retrieval solution of pH 9.0 at 370C for 20 mins;  
- Cooling at room temperature for 10 mins;  
- Rinsing in TBS (Tweens) twice;  
- Applying monoclonal rabbit anti-human VWF primary antibody at 1:200 dilution 
for 60 mins;  
- Rinsing in TBS (Tweens) 3 times;  
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- Applying DAKO labelled polymer-HRP anti-Rabbit secondary antibody for 30 
mins;  
- Rinsing in TBS (Tweens) 3 times;  
- Applying 2 drops of DAB for 6 mins;  
- Stoping reaction with tap water;  
- Counterstaining slides in haematoxylin (1/20 dilution) for 2 sec;  
- Washing in tap water;  
- Dehydrating and mounting with DPX.  
 
F4/80 monocyte and macrophage staining IHC Protocol:  
- Deparaffinising slides in 2 changes of xylene for 10 mins each;  
- Rehydrating twice in xylene for 10 mins each, in alcohol of 100%, 95%, 70% and 
then in tap water for 2 mins each;  
- Quenching for 20 mins in H2O2 endogenous peroxidase (solution of 49.5 ml of 
methanol and 0.5 ml of 30% H2O2);  
- Washing slides in TBS (Tweens) 3 times for 3 mins each;  
- Applying 1 antibody Rat anti-mouse F4-80 monoclonal antibody (1:250) for 2 
hours;  
- Washing slides in TBS (Tweens) twice;  
- Applying 2 antibody DAKO anti-rat HRP polyclonal antibody (1:200) for 30 mins;  
- Washing in TBS (Tweens);  
- Applying DAB for 6 mins;  
- Stoping reaction in tap water;  
- Counterstaining slides in haematoxylin (1/20 dilution) for 10 sec;  
- Washing in tap water;  
- Dehydrating and mounting with DPX.  
 
Proliferation Marker Ki67 staining protocol:  
- Deparaffinising slides in 2 changes of xylene for 10 mins each 
- Rehydrating twice in xylene for 10 mins each, in alcohol of 100%, 95%, 70% and 
then in tap water for 2 mins each;  
- Quenching for 20 mins in H2O2 endogenous peroxidase (solution of 49.5 ml of 
methanol and 0.5 ml of 30% H2O2);  
- Washing slides in TBS (Tweens) 3 times for 3 mins each;  
- Steaming in 200ml of DAKO Target Retrieval solution of pH 9.0 for 15 mins;  
- Cooling (in retrieval solution) in a cold water bath for 20 mins;  
- Rinsing in TBS (Tweens) twice;  
- Applying polyclonal Rabbit anti-Mouse Ki67 primary antibody at 1:2000 dilution 
for 60 mins;  
- Rinsing in TBS (Tweens) 3 times;  
- Applying DAKO labelled polymer-HRP anti-Rabbit secondary antibody for 30 
mins;  
- Rinsing in TBS (Tweens) 3 times;  
- Applying DAB for 6 mins;  
- Stoping reaction in tap water;  
- Counterstaining slides in haematoxylin of 1/20 dilution for 10 sec;  
- Washing in tap water;  
- Dehydrating and mounting with DPX.  
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The micro-photos were done with the Nikon microscope (Japan). The objectives x4 
for low resolution image and x20 for high resolution image were used. The low 
resolution images were used for general view of the sections. The sections with 
ruptured tissue, not contrasted or any kind of mistake were removed from the 
analysis. The high resolution images of selected sections were used for the analysis.  
All high resolution images for each staining were recorded in one day with constant 
illumination and microscope setup. The software ImageJ Pro Plus 7 with macros was 
used for statistical analysis of the coloured area and the density of colour, which 
results from the amount and intensity of activity of specific cells and their 
components. The images of each staining were uploaded to the software and analysed 
simultaneously. An empty space in each image was cut away from the analytic area of 
the tissue image and was not used for the colour analysis.  
The total number of mice use in the experiment was 15, each mice had 6 pockets with 
one sample in each pocket, the total number of implants was 90, minimum 3 sections 
from one sample were cut, selected and analysed, minimum 10 microphotos were 
proceeded from one section. Total number of images for one staining used for the 
analysis was minimum 2700. The total number of images used for the statistical 
analysis was minimum 13500.  
The statistical analysis was conducted with the software GraphPad Prism Verion 5.0. 
The ANOVA analysis and Bonferroni Post-test were used to compare the results 
between the two groups, and in each group. The significance of the difference 
between the two groups was accepted at p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
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Chapter 3. Synthesis of polyurethane 
implants and evaluation of them 
 
 
 
 
The limitations of commercially available polyurethanes are evident in their 
mechanical properties, in the making of devices, and in biocompatibility. In 
particular, most of the medical grade polyurethanes are stiffer then the soft tissues of 
organisms. The mechanical stresses appear in the soft tissue at the point of contact 
with the polyurethane implant. These stresses can cause a mechanical injury of the 
tissue. In order to avoid the injury the modulus of the implantable polyurethane must 
be similar or less than the modulus of the soft tissue surrounding the implant. 
Moreover an elastic modulus of soft tissue is different from other tissues. Therefore, a 
synthesis of soft polyurethane with adjustable elasticity can avoid the mechanical 
injury of the soft tissue at the point of contact with the implant. However, a low 
stiffness is associated with a low mechanical strength and soft polyurethane does not 
provide integrity of the implants under mechanical loads in an organism. It is this 
contradiction that was solved in the present study. 
 
The synthesis of soft polyurethane with sufficient mechanical strength was based on 
an investigation of the preliminary studies of the polyurethane synthesis as presented 
in Appendix I and II. The synthesis of different kinds of polyurethanes for a number 
of medical devices was considered. The synthesis of polyurethane was based on the 
polymerisation reaction of the isocyanate groups with amine or hydroxyl groups. The 
different compositions and conditions of synthesis were used for adjustment of 
polyurethane mechanical, chemical and biocompatible properties to particular medical 
devices in accordance with the requirements for each device. FDA-approved 
components were selected for synthesis, where possible, and the commercial 
availability of components was considered, bearing in mind the future availability of 
the materials to medical companies. On this basis the polyurethanes for drug release 
coating, X-ray contrast coating and catheter coating vascular grafts were synthesised 
as presented in Appendix I and II. These results were then used to synthesise the 
polyurethane with low Young’s modulus and sufficient mechanical strength. 
  
In the present study new low Young’s modulus polyurethane implants have been 
synthesised to minimise a mechanical injury of the soft tissue at the point of contact 
with the implant. The surface of the implant was modified by high energy ions to 
improve biocompatibility of the implant. Major required tests corresponding to FDA 
regulations and standards have been done for the new polyurethane implants.  
 
 
3.1. Synthesis of low modulus implant for soft tissues 
 
The modern polymer implants have Young’s modulus in a range of 1-10 MPa, while 
the organism’s soft tissue has Young’s modulus in a range of 10-100 kPa. Such 
biomechanical behaviour of soft tissue and polymer implant can lead to local injury of 
the tissue and cause a permanent inflammatory reaction. To adjust the biomechanics 
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of polymer implant to soft tissue a new, very soft polyurethane was synthesised in 
order to create a material with Young’s modulus as close as possible to the soft tissue, 
and with strength, residual stresses, elongation, inertness, toxicity, bio-stability and 
other exploitation parameters which would satisfy the requirements for medical 
implants. The contradiction of the low modulus and high strength can be solved by 
using segmented polyurethane with hard domains to provide high mechanical strength 
and soft segments to provide low modulus. 
 
To satisfy the low modulus and high strength requirements a new composition of the 
polyurethane is proposed. The polyurethane was synthesised from polyoxypropylene 
glycol (PPG) oligomer with hydroxyl groups terminated by 2,4-toluene diisocyanate 
(PPG-DI). Polytetrahydrofuran (PTHF) with hydroxyl end groups was used as a chain 
extender, as the reaction is shown (1).  
 
    (1) 
 
The general formula of PPG-DI-PTHF polyurethane is shown (1).  
 
(2) 
 
In some compositions dibutyl dilaurate stannum was used as a catalyst to accelerate 
the reaction. In some compositions polyethylene glycol (PEG), ethylene diamine 
(EDA), polypropylene glycol (PPG) and atmospheric moisture were used as a chain 
extender and crosslinker. For comparison, a commercial oligomer based on 
polyoxypropylene glycol with MDI was used for synthesis.  The synthesised 
compositions are presented in Table.  
 
Table.3.1. Polyurethane compositions used for synthesis.  
Prepolymer Chain extender 
and crosslinker 
OH (or NH) / 
NCO ratio 
Catalyst Comments 
PPG-DI PTHF 0.35 DBD Soft, sheets 
PPG-DI PTHF 0.35 - Soft, sheets, tubes 
PPG-DI PTHF 0.5 DBD Soft, sheets 
PPG-DI PTHF 0.7 DBD Soft, sheets 
PPG-DI PEG 0.35 DBD Soft, sheets 
PPG-DI PEG 0.5 DBD Soft, sheets 
PPG-DI PEG 0.7 DBD Soft, sheets 
PPG-DI Moisture n/a  Soft, sheets 
PPG-DI EDA 1 DBD Very hard 
PPG-DI PPG 0.7 DBD Very hard 
R-	N=C=O		+		HO-R’		à		R-NH-CO-O-R’	
 
 
 
 
 
NHCO [-O-CH2-CH-]n-O-CONH 
CH3 
CH3 CH3 
NHCO CONH 
[-O-CH2-CH2-CH2-CH2-]m-O 
k 
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PPG-DI PPG 0.9 DBD Very hard 
PEG-MDI EDA 1  Hard 
PPG-DI TETA 0.5 DBD Hard 
 
The synthesis of polyurethane is sensitive to air humidity. The isocyanate groups can 
react with water molecules from the air to give inert products to active groups of 
glycols or amine [1] as shown in (3).  
 
2R-N=C=O + H2O à 2R-NH-CO-OH à R-NH-CO-NH-R + CO2 ñ  (3) 
 
The study found the properties of the polyurethane cured in the open air varied widely 
depending on weather conditions. The sensitivity to moisture and the consequent 
variations of the reaction were found to be very significant: the cured polyurethane 
was sometimes sticky with a low mechanical strength, and sometimes very strong and 
hard. The influence of weather conditions and seasons on the quality of cured 
polyurethane was clearly observed.  
 
These uncontrollable conditions were overcome during the synthesis by using the 
hermetic box (Sigma-Aldrich) with controlled humidity and temperature. For 
controlled synthesis of polyurethane a polyethylene box was equipped with a frame, 
analytical balance, temperature and humidity sensor, inlet of dry air and outlet with 
the regulators of the air flow, motorised support for the polyurethane preforms, gloves 
and isolating port. The box was placed in a permanently air-conditioned room. The 
components for synthesis were placed inside the box and the box was vented by dry 
air from Parker Dry air system for a week. The airflow rate in inlet and outlet valves 
was regulated to achieve sufficient positive pressure in the box to exclude air 
penetration through the holes and to prevent rupture of the polyethylene walls. The 
synthesis of polyurethane was started only when the level of humidity was 20-25% or 
lower. The dry air ventilation remained throughout synthesis. All operations in the 
box were done with inserted gloves.  
 
The components were weighted on analytical balance, mixed in glass for 5 minutes 
and poured on the substrates (glass plate, Teflon plate or silicon wafer). In order to 
synthesise uniform coating a motorised stage of 6 continuously rotating glass tubes 
was designed and installed in the box. A ratio of active groups in oligomer and chain 
extender was selected to have residual isocyanate groups for crosslinking reaction. 
The ratio of isocyanate and hydroxyl or amine groups is presented in Table. The 
amount of mixture to cover the substrates with the requisite thickness was calculated. 
The mixture cured for 3 days at the stabilised temperature in the box.  
 
After that the samples of polyurethane were taken from the polyethylene box and 
immediately placed into the vacuum oven, where the sample were annealed at 1200C 
for 3 hours. Then the polyurethane samples were placed into mQ-water for 1 hour and 
peeled off from the substrate. The cured polyurethane was swollen in heptane, an 
approved solvent for medical application [2], for 3 hours to remove all low molecular 
fraction components. The amount of heptane was about 100 times higher then the 
polyurethane film. Then the polyurethane was dried in the open air with protection 
against dust for a week.  
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The final thickness of the polyurethane films was 100 um, 200 um, and 300 um. For 
mechanical tests the thick polyurethane sheets of 8 mm thickness were synthesised. 
Area of the films and sheets was 100x100 mm2.  
 
 
3.2. Synthesis of artificial blood vessel (shunt) 
 
A complex shaped implant can be made by direct synthesis from liquid components in 
a mould. The advantage of direct synthesis was demonstrated on a synthesis of 
polyurethane blood vessels. The artificial blood vessel was synthesised from liquid 
PPG-DI and PTHF components using the procedure described above. The 
components were weighed and mixed in the polyethylene box under dry airflow 
conditions. The liquid reaction mixture of the components was poured on glass tubes. 
The glass tubes were turned during the pouring to cover the tubes uniformly. When 
necessary the reaction mixture was poured a second time to make the coating thicker. 
The polyurethane was cured for 3 days at room temperature and then annealed at 
1200C for 3 hours. Then the cured polyurethane tubes were swollen in hexane for 3 
hours to remove all low molecular fraction components. The swollen polyurethane 
tubes were peeled off the glass tubes and dried in the open air with protection against 
dust for a week. Then the polyurethane tubes were washed for 1 hour in mQ-water 
and dried. The polyurethane tubes were evaluated for uniform thickness of the walls 
with an optical microscope and cut to the required length.  
 
 
Fig.3.1. Photograph of synthesised polyurethane tubes for example. Left tube has 2 
mm inner diameter, centre tube has 5 mm inner diameter, right tube has 2.5 mm inner 
diameter.  
 
Finally, the polyurethane tubes of 50, 100 and 200 µm wall thickness and 6, 5, 3, 2, 
2.5 and 1 mm inner diameter were synthesised (Fig.3.1). The length of the tubes was 
from 5 mm to 100 mm.  
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3.3. Mechanical evaluation of polyurethanes implants 
 
In accordance with FDA regulations, the medical implant should provide certain 
mechanical parameters. The breaking stress, available elongation, Young’s modulus 
and residual stresses are key mechanical parameters for the implant. In organisms the 
implant works under cycling loads without a break. To understand the mechanical 
behaviour of the implant in an organism the extensive mechanical tests of the newly 
synthesised polyurethanes were conducted. 
 
The mechanical behaviour of polyurethane is non-linear. The polyurethanes show 
usually viscoelastic stress-strain curves with residual stresses. The relaxation 
processes have significant contribution to the stress curve. Therefore the history of the 
mechanical load is essential for understanding the test results. A typical strain-stress 
curve for PPG-DI-PTHF-0.35 is presented in Fig.3.2. The test was done with 3 
preload cycles up to 100% of elongation, and a final load up to breaking point. The 
time dependence curve of the force during the test is presented in Fig.3.3. The strain-
stress curve has 3 parts. The first part (up to 100% of strain) is strongly non-linear. 
The stress grows fast with the strain, and corresponds to more elastic behaviour. The 
second part (100-400% of strain) shows a constant slope. This part corresponds to the 
restructuring of the material. The stress causes flowing of the material and re-
orientation of the macromolecules along the stress direction. The third part has a 
higher slope, and is more elastic up to breaking point.  
 
 
Fig.3.2. Representable strain-stress curve of PPG-DI-PTHF-0.35 polyurethane film 
stretched up to break with first 3 cycles of preloading. The curve shows non-linear 
behaviour. Low residual stresses are observed. The stress at the break is more than 1 
MPa at the 600% of elongation. These are much higher values than the required 
values for the implant in organisms.  
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Fig.3.3. Representable time-tensile stress curve of PPG-DI-PTHF-0.35 polyurethane 
up to break with first 3 cycles of preloading. The stress curve shapes in the preloading 
3 cycles are similar.  
 
The cycling load up to 100% strain shows a hysteresis. The cycling part of the strain-
stress curve is enlarged in Fig.3.4. The hysteresis effect is caused by restructuring and 
re-orientation of the polyurethane macromolecules along the stress direction, with the 
stress decreased with time. As a result of restructuring, the residual stresses in the 
polyurethane film after the load is released remain in the polyurethane. The sample 
remains elongated after complete release of the stress. The second and third cycle 
loads cause lower stress at the same strain (100%). However, the second and third 
cycles do not increase the residual stress significantly. The level of the residual stress 
remains about 10% of strain, which is in the range of the usual value for rubber 
materials. Consequently, the stability of the polyurethane structure is sufficient for a 
mechanical loading during exploitation.  
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Fig.3.4. Representable cycling strain-stress curve of PPG-DI-PTHF-0.35 polyurethane 
with first 3 cycles of preloading. Number marks an order of the curves. The arrays 
show the direction of the load and release. After first loading cycle, the residual 
stresses remain constant at the following loads.  
 
The strain-stress curve of PPG-DI-PTHF-0.7 has a different character (Fig.3.5). The 
part of the restructuring was not observed. The non-linear increase stress goes up to 
breaking point. The residual stresses of 12% are larger than in PPG-DI-PTHF-0.35 
polyurethane. The elongation at breaking point is lower. The strength of breaking 
point is lower. This difference in mechanical properties is due to lower concentration 
of residual isocyanate groups and consequently less crosslinking of the 
macromolecules. For such material, the crosslinking increases the strength and 
elongation at breaking point. The polyurethane is stronger and shows less residual 
stress. Consequently, the shape of the crosslinked polyurethane recovers better after a 
deformation than for non-crosslinked polyurethane.  
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Fig.3.5. Representable strain-stress curve of PPG-DI-PTHF-0.7 polyurethane with 
first 3 cycles of preloading and enlarged cycling part of the curve. The residual 
stresses are similar, but the strength is lower.  
 
The mechanical properties of polyurethane with PEG are worse (Fig.3.6-3.7). 
Character of the strain-stress curves is similar. But the tensile strength of polyurethane 
films is less then for polyurethane with PTHF. The residual stresses in polyurethane 
with PEG are larger then in the polyurethane with PTHF. In the case of PPG-DI-PEG-
0.7 polyurethane the residual stresses are a quarter of the strain that is unacceptable 
for elastomers.  
 
The mechanical properties of the different compositions of measured polyurethanes 
and the statistical analysis is presented in Fig.3.8-3.10. The strength and elongation at 
break point and residual elongation show that the best polyurethane with high 
mechanical strength and long elasticity at low residual elongation is the polyurethane 
PPG-DI-PTHF-0.35. This polyurethane has 1.0±0.1 MPa tensile strength, 580±20% 
elongation at break, 11±1% residual elongation after 100% preload, 100±20 kPa 
modulus at 10% elongation and 410±50 kPa modulus at 100% elongation. This 
composition was accepted as a prospective material for implants and the following 
studies have been done with this polyurethane.  
 
0"
100"
200"
300"
400"
500"
600"
0" 50" 100" 150" 200" 250"
Te
ns
ile
'st
re
ss
,'k
Pa
'
Tensile'strain,'%'
Breaking"point"
Residual"stresses"
Cycling"test"
0"
50"
100"
150"
200"
0" 10" 20" 30"
 32 
 
Fig.3.6. Representable strain-stress curve of PPG-DI-PEG-0.35 polyurethane with 
first 3 cycles of preloading and enlarged cycling part of the curve.  
 
 
Fig.3.7. Representable strain-stress curve of PPG-DI-PEG-0.7 polyurethane with first 
3 cycles of preloading and enlarged cycling part of the curve. The residual stresses are 
high.  
 
0"
100"
200"
300"
400"
500"
0" 50" 100" 150" 200" 250" 300" 350"
Te
ns
ile
'st
re
ss
,'k
Pa
'
Tensile'strain,'%'
0"
50"
100"
150"
0" 5" 10" 15" 20"
Breaking"point"
Residual"stresses"
Cycling"test"
0"
50"
100"
150"
200"
250"
300"
350"
400"
0" 200" 400" 600" 800" 1000" 1200"
Te
ns
ile
'st
re
ss
,'k
Pa
'
Tensile'strain,'%'
Breaking"point"
Residual"stresses"
Cycling"test" 0"
25"
50"
75"
100"
0" 10" 20" 30" 40" 50"
 33 
 
 
Fig. 3.8. Averaged tensile test results for different polyurethanes: stress and 
elongation at break point. The polyurethane PTHF,0.35 provides highest mechanical 
strength and longest elongation at the break with low (10%) of residual stresses 
(Fig.3.9).  
 
 
 
Fig.3.9. Tensile test results of polyurethanes: residual elongation after 100% 
elongation load. The polyurethanes based on PTHF show lowest residual elongation.  
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Fig. 3.10. Tensile test results of polyurethanes: Young’s modulus at 10% and 100% of 
elongation. Despite the finding that the polyurethanes based on PEG provide the 
lowest modulus, the mechanical strength and residual stresses are not acceptable. 
Therefore, only the polyurethanes based on PTHF with higher modulus were 
considered for the medical implants.  
 
The comparison of selected polyurethane with other commercial polyurethanes and 
other materials are presented in Fig.3.11. A rank soft tissue modulus from the 
literature’s data is added for estimation [3-7]. Medical grade commercial 
polyurethanes show significantly high values. Silicon rubber has modulus, which is 
closer to the modulus of some tissues. New polyurethane SIBSTAR PSU shows 
modulus closer than the silicon rubber, but higher than the soft tissue [8]. The most 
promising material is TPE1. However, there is not enough experimental data on the 
biocompatibility of such material. The synthesised PPG-DI-PTHF-0.35 polyurethane 
has the closest modules to the soft tissue average modulus. For some tissues, this 
polyurethane has a lower modulus and an injury of implant caused by the local 
stresses can be expected to be negligible.  
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Fig.3.11. Young’s modulus of medical polymers, tissues and selected polyurethane 
PTHF, 0.35. The synthesised polyurethane (PTHF, 0.35) has lower modulus then the 
used commercial polyurethanes and other materials (TPE and silicone) as well as the 
new polyurethane with low modulus proposed for medical applications.  
 
 
3.4. Implant stability in water media 
 
Following FDA regulations an implant material must be stable in an organism for a 
long time. In general, the organism’s environment is aggressive for a polyurethane 
implant. The processes of polyurethane degradation in water are based on hydrolysis 
reaction of ether and urethane groups. The reactions of hydrolysis are following: 
 
R-CH2-O-CH2-R1 +H2O à R-CH2-OH + HO-CH2-R1 
 
R-O-CO-NH-R1 +H2O à R-OH + HOOC-NH-R1 
 
As the result of these reactions, the polyurethane backbone is cleaved and short chain 
molecules are released into the water. The reaction depends on the temperature 
following the Arrhenius law. This fact is used for acceleration test of materials. In 
experiment, a polyurethane mass should decrease.  
 
Using the FDA regulations to evaluate a stability of the polyurethanes in a water 
environment, the samples of polyurethanes were exposed in water with different 
temperatures. The newly synthesised polyurethane PPG-DI-PTHF-0.35 was tested 
(Fig.3.12 –Fig.3.14). For comparison the commercially available polyurethanes of 
medical grade Pellethane and SKU-PFL were tested as controls. The temperature 
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range was 40, 60 and 80 degrees. The temperature of 40 degrees was selected for the 
organism environment. The temperature of 80 degrees was selected as the condition 
close to water boiling temperature. The polyurethane PPG-DI-PTHF-0.35 was tested 
at 40 and 60 degrees because phase transition in this polyurethane occurs at 80 
degrees. The samples were stored in individual sealed glass beakers filled with 
sufficient amounts of water (mass ratio of water to polyurethane sample was 20:1). 
The beakers were placed into the automatic ovens with stabilised temperature. The 
temperature variations were ±10C. The test was done over 3 months. In the required 
time periods the samples of polyurethanes were taken from the beakers, dried with 
Kim Wipe tissue and weighed with analytical balance. After that the samples were 
immediately returned to the beakers.  
 
The results of mass loss measurements show that in the range of temperature and time 
the mass of the samples slightly increases due to the swelling effect of polyurethane 
in water during the first day. After that the mass of polyurethane samples does not 
change over the 3 months. Following the Van Goff law the 60 and 80 degrees tests 
corresponds to degradation under body temperature at 17 months and at 29 months. 
Therefore, the investigated polyurethane PPG-DI-PTHF-0.35 shows similar stability 
as the certified SKU-PFL and Pellethane polyurethanes.  
 
 
Fig.3.12. Mass change of PU Pellethane in hot water. The polyurethane swells in 
water in the first hour and stable thereafter. No mass loss was observed. The 
temperature in Celsius is noted.  
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Fig.3.13. Mass change of polyurethane SKU-PFL in hot water. The polyurethane 
swells in water in the first hour and stable thereafter. No mass loss was observed. The 
temperature in Celsius is noted. 
 
 
Fig.3.14. Mass change of polyurethane PPG-DI-PTHF-0.35 in hot water. The 
polyurethane swells in water in the first hour and is stable thereafter. No mass loss 
was observed. The temperature in Celsius is noted. 
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3.5. Leaching residuals from implant 
 
In accordane with FDA regulations, an implanted material must not release low 
molecular components with toxic or carcinogenic activity. Polyurethane materials like 
any other material leaches some low amount of residuals into water media. For 
medical grade polyurethane to satisfy the biocompatibility requirements the leached 
components should be of a low amount and not toxic. The leaching test was done for 
Pellethane as the control certified medical grade polyurethane (Fig.3.15), and PPG-
DI-PTHF-0.35 polyurethane (Fig.3.16). The polyurethane samples were exposed in 
mQ-water for 7 days at room temperature, then a drop of solution was placed on Ge 
ATR crystal and dried in the open air. After complete water evaporation, the spectra 
of FTIR ATR with the dry drop on the ATR crystal were recorded.  
 
The Pellethane leaches residuals that are non-reactive, low molecular weight 
components and were not linked to the long chain molecules. The spectra of leached 
components from PPG-DI-PTHF-0.35 polyurethane show lines of OH group (3350 
cm-1), CH group (2975-2875 cm-1 region), carbonyl group (1728 cm-1), aromatic ring 
(1603 cm-1) and ether group (1106 cm-1). The largest substance is PTHF non-
crosslinked to PPG-DI component and a low amount of PTHF bonded to PPG-DI. 
The PPG-DI molecular fragment with active isocyanate group was not observed. No 
isocyanate groups were observed in the spectra of both polyurethanes. The amount of 
leachable components from both polyurethanes was lower than the detectable limit of 
the weight method, which was used for the evaluation of the medical grade materials. 
Therefore, the leached components and its amount from PPG-DI-PTHF-0.35 
polyurethane satisfy the requirements for medical grade polymers such as certified 
Pellethane polyurethane.  
 
 
Fig.3.15. FTIR ATR spectra of polyurethane Pellethane (blue, top) and leached 
substrate from polyurethane Pellethane 2363-80 (Dow Chemicals) into mQ-water 
during 7 days (green, bottom).  
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Fig.3.16. FTIR ATR spectra of leached substrate from PU PPG-DI-PTHF-0.35 into 
mQ-water during 7 days.  
 
 
3.6. Implant non-toxicity evaluation  
 
In accordance with FDA regulations, an implantable material must not have 
cytotoxicity effect. The PPG-DI-PTHF-0.35 polyurethane was tested for cytotoxicity 
in cell culture experiments and in organisms. In the experiment the endothelial human 
cells (HCAEC) were seeded on the polyurethane film and proliferated for 2 days. As 
the control, the tissue culture plastic (TCP) was used. The analysis of cells after 
staining of the attached cells showed that the cells were attached, spread and 
proliferated on polyurethane as on TCP. Cell bodies are elongated (Fig.3.17). Cell 
lysis or membrane disintegration was not observed. However, the amount of the cell 
after proliferation in 2 days on the polyurethane is lower then on TCP control. This 
indicates that the untreated polyurethane surface does not provide cell adhesion as 
sufficient as TCP. Therefore, the polyurethane does not show a toxicity while the cell 
adhesion is lower.  
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Fig.3.17. Cell images on polyurethane (left) and TCP (right) without staining. The 
cytotoxic effect for the polyurethane was not observed.  
 
For toxicity tests in organisms the polyurethane films were implanted under the skin 
area of mice for 7 days. After 7 days the block of tissue with the implant was cut, 
sectioned and stained in H&E dye. The microphotos of the sections are presented in 
Fig.3.18. The results show that there is no toxic reaction in the surrounding tissues for 
all kinds of polyurethanes. The capsule with activated cells is well visible. The 
thickness of the capsule is equal or less then 100 µm which is normal for immune 
reaction. The capsule is intact which shows that the implants are strong enough in the 
body. No tissue necrosis was observed.  
 
 
PPG-DI-PTHF-DBD (0.35) 
 
PPG-DI-PTHF-DBD (0.5) 
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PPG-DI-PTHF-DBD (0.7) 
 
PPG-DI-PEG-DBD (0.35) 
 
PPG-DI-PEG-DBD (0.5)  PPG-DI-PEG-DBD (0.7) 
 
PPG-DI-PTHF-DBD (0.35). The implant 
has been synthesised on a silicon wafer. 
 
PPG-DI-PTHF (0.35). The implant has 
been synthesised without catalyst. 
Fig.3.18. Microphotos of histological sections of mice tissue with the implant stained 
in Hematoxylin-Eosin. Objective is x4. The empty area surrounded by the tissue was 
filled by the polyurethane implants. The implant film was removed at the microtome 
sectioning due to high elasticity of the polyurethane implants, while in two shown 
samples some pieces of polyurethane implants remain and are visible as uniformly 
coloured films. The cytotoxic effect was not observed. The immune reaction was not 
strong.  
 
The presence of catalyst DBD in the implant used for the curing reaction in 
polyurethane synthesis does not play a role in organism reaction. No difference was 
observed in the organism reactions between the polyurethane synthesised on silicon 
wafer or on glass plate.  
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For the quantitative results, the images were analysed with calculations of the capsule 
thickness. The results are presented in Fig.3.19. The average thickness of the capsule 
does not depend on the polyurethane composition. The thickness of the capsule for all 
polyurethane is close to the thickness of the capsule for polyethylene implant. 
Therefore, the synthesised polyurethane does not show the toxic effect in organisms.  
 
Fig.3.19. Capsule thickness around polyurethane implants of different composition. 
LDPE is used as a well-known standard. The average thickness of the capsule for all 
investigated polyurethanes is similar to the capsule around polyethylene implant as a 
control.  
 
 
3.7. Discussion  
 
The modern artificial materials used for soft tissue implantation have a significant 
problem due to the very different mechanical properties of these two materials [9-11]. 
As a result, the surrounding tissue is under extremely high mechanical stress near the 
implant surface [12, 13]. The stress causes damage to the cell membrane with 
consequent apoptosis and activation of an immune reaction. The continuing immune 
reaction leads to a chronic inflammation and, in the worst case, heavy encapsulation 
and calcification. However, the modern medical grade polyurethane materials do not 
provide a low or comparable value of the modulus to the soft tissue modulus. 
  
With the synthesis of this new polyurethane with low modulus it was shown that the 
low modulus polyurethane could be synthesised from the components approved for 
use in an organism. The PPG-DI-PTHF-0.35 polyurethane synthesised in the present 
study has similar or even lower modulus than soft tissue. Therefore, the soft tissue of 
the organism near the polyurethane implant would be under similar mechanical stress 
as without the implant.  
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The residual stress and strain is important for functional implants such as heart valves 
and blood vessels [14-16]. For example, the residual stresses could significantly 
decrease the effectiveness of the heart valve as the insufficient closing of the valve 
could lead to patient death. The PPG-DI-PTHF-0.35 polyurethane has low residual 
stress (10% after 100% of elongation) so that the implant shape will recover 
sufficiently after a deformation.  
 
The synthesised polyurethane has chemically cross-linked macromolecules. In 
comparison with linear polyurethane, the cross-linked polyurethane has higher 
mechanical strength and stability in aggressive environments such as an organism [17, 
18]. Thus the diffusion of aggressive low molecular components from organisms such 
as enzyme ferments is lower in the cross-linked polyurethane in comparison with 
linear polyurethanes [19]. Intensive swelling and washing of the implant facilitates 
the removal of unreacted low molecular components in cross-linked polyurethane. 
Therefore, the leaching of residual components from the implant to the organism 
could be significantly decreased in comparison with the linear polyurethane where 
swelling and washing does not reliably remove unreacted low molecular components.  
 
The synthesis of polyurethane directly on modern medical devices is now recognised 
as a prospective method for ensuring sufficient adhesion, which cannot be achieved 
with other methods.  
 
The synthesised polyurethane was successfully tested for cytotoxicity and stability 
satisfying FDA requirements [20]. Given all these advantages of synthesised 
polyurethane, it could provide new medical implants with increased functionality and 
improved stability in organisms.  
 
However, the synthesised polyurethane shows the usual immune reaction for the 
foreign body’s intrusion into an organism. The next chapter shows how the plasma 
modification process can decrease the immune reaction of the polyurethane.  
 
 
3.8. Conclusions  
 
The results of this Chapter are:  
- A number of polyurethanes for medical applications with new compositions and 
structures have been synthesised. The advantage of direct synthesis for complex 
shaped implants was shown. For example, the polyurethane tube for blood vessel 
shunt has been synthesised.  
- The synthesised polyurethanes have been tested and compared with known 
polyurethanes for biomedical applications. A polyurethane based on PTHF 
component with low Young’s module as close as possible to the soft tissue Young’s 
module to prevent mechanical injury in the surrounding tissues was synthesised and 
proposed for forthcoming investigations.  
- The proposed polyurethane has been tested for tensile strength, cyclic mechanical 
stress, completeness of the curing reaction, stability in water media, leaching of 
residual components, and toxicity for cells and organism reactions according with 
FDA requirements.  
- The proposed polyurethane has low Young’s module, low residual deformations, 
sufficient mechanical strength for using as a material for medical implants in soft 
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tissue, low residual components, sufficient stability in water and low or absent toxic 
effect in comparison with existing polyurethane for medical applications. This 
polyurethane was considered for medical application and used in this study.  
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Chapter 4. Surface modification and 
characteristics of polyurethane implants 
 
 
 
 
A polyurethane surface is chemically inert for proteins and other bioactive molecules. 
The newly synthesised polyurethane has similar inertness to proteins. Ion beam 
treatment and plasma immersion ion implantation methods have been used to modify 
the polyurethane surface. The chemical structure, topography, wettability, hardness 
and other parameters of the surface layer are dramatically changed after the 
modification. These changes depend on the parameters of the modification process 
and the kind of polymer. An analysis of the newly synthesised polyurethanes treated 
by method of plasma immersion ion implantation (PIII) is presented in this Chapter.  
 
The following questions are considered in this Chapter:  
- the physical model of ion penetration and energy transfers was used to estimate the 
thickness of the modified layer in dependence on the energy of ions;  
- the wettability and surface energy changes of the synthesised polyurethanes are 
analysed in dependence on regimes of PIII and storage time after the treatment;  
- the chemical structure changes in the synthesised polyurethanes in dependence on 
the parameters of PIII, composition of polyurethane and storage time;  
- the surface topography of the synthesised polyurethane in dependence on PIII 
treatment regimes.  
 
Most results are presented for PPG-DI-PTHF-0.35 while other polyurethanes are 
noted.  
 
4.1. Simulation of ion penetration into polyurethane implant 
 
A physical model of collisions between the penetrating ion into the polyurethane with 
electrons and atoms of the polyurethane macromolecules was used to understand the 
modification process in the surface layer. The penetration of a high energy ion into 
any polymer causes collisions with electrons and atoms of the polymer 
macromolecules. The simplest model of the collisions is based on ion-atom 
interactions developed by Ziegler and Biersack [1, 2]. The computer code 
SRIM/TRIM was designed for a simulation of such collisions and following physical 
effects in a target under ion bombardment. The model includes the physical effects 
such as ion/atom and ion/electron collisions, phonon excitation, atom and electron 
recoils and stopping of the penetrating ions (Fig.4.1). The code gives a depth and 
lateral distribution of these effects.  
 
However, the code does not include chemical effects of the ion bombardment. The 
code also does not include an initial chemical structure of the target and structure 
transformation in the target with fluence of the ion bombardment. Taking into account 
these limitations, the simulation of ion penetration into polyurethane was done for 
nitrogen ions with energy of 1, 5, 10, 15 and 20 keV. The results of the calculations 
are presented in Fig.4.2-4.4.  
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Fig.4.1. Example of SRIM calculation of nitrogen ion penetration into polyurethane 
and scheme of the calculation geometry. Red lines are trajectories of nitrogen ions, 
blue lines are trajectories of displaced hydrogen atoms, green lines are trajectories of 
displaced carbon atoms, pink lines are trajectories of displaced oxygen atoms, and 
green lines are trajectories of displaced carbon atoms in the screens from SRIM 
program after 10 nitrogen ion penetration. The calculations are based on Monte Carlo 
algorithm of the collisions. The following results are based on statistical averaging of 
10000 ions penetrations.  
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Fig.4.2. Vacancy atom distribution by SRIM calculations after 20 keV nitrogen ion 
bombardment caused by displacing of carbon, hydrogen, oxygen and nitrogen atoms 
from macromolecule of polyurethane. Mostly hydrogen atoms are displaced.  
 
 
 
Fig.4.3. Dangled bond depth distribution caused by displaced of carbon, hydrogen, 
oxygen and nitrogen atoms in macromolecule of polyurethane by 20 keV nitrogen ion 
bombardment. The results of SRIM simulation. The most dangles bond appear after 
carbon atoms displacement.  
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Fig.4.4. Dangled bond depth distribution (vacancy per Angstrom per Ion) in 
polyurethane by SRIM calculations after nitrogen ion penetration. The results of 
SRIM simulation. The thickness of the modified layer with dangled bonds is about 
130 nm for 20 keV ion energy, 110 nm for 15 keV ion energy, 75 nm for 10 keV ion 
energy, 45 nm for 5 keV ion energy, 10 nm for 1 keV ion energy.  
 
The results of calculations for 10 nitrogen ions are presented in Fig.4.1. The nitrogen 
ions penetrate into the polyurethane and knock the atoms of the macromolecule and 
transfer the kinetics energy from ions to atoms. The displaced atoms with high kinetic 
energy fly away from the mother macromolecule and knock another atom of 
macromolecules, transferring the kinetic energy to them. Each penetrating nitrogen 
ion removes many atoms. After cascades of collisions the kinetic energy is dissipated 
to phonon excitations and the process of collision finishes. The result is a number of 
displaced atoms, which travelled from the mother macromolecules. The area of the 
affected macromolecules has a shape of a large falling drop.  
 
For quantitative estimation the calculation of 10000 ion penetrations was done. The 
distribution of displaced carbon, hydrogen, oxygen and nitrogen from polyurethane 
macromolecule with chemical formula of C30.8O9.88N0.598H58.6 is presented in Fig.4.2. 
For example, the chemical formula corresponded to PPG-DI-PTHF-0.35 polyurethane 
formula. The layer of about 130 nm is affected by the bombarding nitrogen ions with 
kinetics energy of 20 keV. Mostly the hydrogen atoms are displaced from the 
macromolecule, but carbon and oxygen atoms are also displaced. Nitrogen atoms are 
less affected. The different amounts of displaced atoms is due to different 
concentrations of these atoms in polyurethane macromolecule.  
 
The displaced atoms move from the mother macromolecule over a long distance from 
the initial position so that each displaced atom leaves all their bonds in the mother 
molecule. For hydrogen atoms, one bond becomes dangled. Displaced oxygen, 
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nitrogen and carbon leave two, three and four dangled bonds in the mother 
macromolecule respectively. The displaced atoms are stopped after some collisions in 
new places and hold all their unpaired electrons. Therefore, these atoms bring dangled 
bonds to new places. Corresponding atom valencies of displaced carbon gives eight 
dangled bonds, nitrogen gives six, oxygen gives four and hydrogen gives two. The 
corresponding distribution of the displaced atoms and distribution of dangled bonds in 
the surface layer of polyurethane is presented in Fig.4.3. Displaced carbon atoms give 
the highest contribution, then hydrogen, oxygen and nitrogen. The total average 
number of displaced atoms from polyurethane macromolecule is 194 and the 
corresponding average number of dangled bonds generated by one bombarding ion of 
20 keV energy is 722. All these dangled bonds are generated in a thin surface layer of 
about 130 nm thickness. Such a high concentration of the dangled bonds causes a 
number of free radical reactions immediately after the displaced atoms stop. These 
reactions are finalised with deep structural transformations of the surface layer.  
 
The penetration depth of bombarding ions depends on the energy of the ions. Lower 
energy gives shallower modified layer Fig.4.4. The energy of 1 keV gives the 
thickness of the modified layer of about 5-10 nm, which is close to the size of the 
isolated macromolecule globule.  
 
As a result of ion penetration and following deep molecular transformations, a 
chemical structure of the polyurethane surface changes dramatically after ion beam 
treatment. Chemical activity as well as other surface characteristics change 
correspondingly and are important for interactions with proteins, surrounding tissues 
and the organism as a whole. Therefore, efforts were made to understand the 
chemistry of the surface, the influence of ion beam parameters and storage kinetics 
after surface modification. The analysis of chemical structure was done with modern 
spectroscopy methods developed for a surface analysis.  
 
 
4.2. Wettability and surface energy of modified polyurethane implant 
 
One of the simplest methods of surface analysis and an important parameter for 
biocompatibility is wettability. Protein molecules are very sensitive to wettability of 
the implant. The surface of untreated polyurethane is hydrophobic. The water drop on 
the polyurethane surface shows the contact angle of about 90 degrees while the 
diiodomethane drop shows the contact angle significantly lower (Fig.4.5). This 
difference between drops of water and diiodomethane shows that the polar 
interactions on polyurethane surface are much weaker then non-polar (dispersic) 
interactions.  
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Untreated PU, water drop 
 
 
Untreated PU, Diiodomethane drop 
 
 
PIII treated PU, water drop 
 
 
PIII treated PU, Diiodomethane drop 
 
 
Fig.4.5. Images of water and diiodomethane drops on polyurethane surface untreated 
and 800 sec PIII treated after 2 weeks of ageing after the treatment. KRUSS wetting 
device was used for the images. The most changes caused by PIII treatment were 
observed for water drops.  
 
After the PIII treatment the drops of water and diiodomethane were similar. It shows 
that the PIII treated surface becomes more hydrophilic and the polar interactions on 
the modified surface are similar to the non-polar interactions. The quantitative 
measurements of the drops show significant decrease of the contact angle from 93 
degrees up to 35-45 degrees in 15 minutes after PIII treatment (Fig.4.6). The contact 
angle increases with the storage time after PIII treatment. The angle is stabilised a 
week after PIII treatment. The stabilised value for the treated surface is lower than for 
the untreated surface. These changes were observed to be in a similar statistical range 
for all treatment times from 40 sec to 800 sec corresponding to 5*1014 and 1016 
ions/cm2 fluence.  
 
The contact angles of the water and diiodomethane were used for calculation of 
surface energy and its parts (Fig.4.7.). The surface energy is an energetic parameter of 
the surface to describe an interaction with the adsorbed molecules. The surface energy 
increases from 33 mN/m for untreated polyurethane to 65-67 mN/m for freshly 
treated polyurethane. A week after PIII treatment the surface energy decreases with 
stabilisation at 45-50 mN/m. The stabilized level of the surface energy is much higher 
then the surface energy of untreated polyurethane.  
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Fig. 4.6. Water contact angle of PIII treated PU as a function of storage time after the 
treatment. PIII treatment time is: violet circle – 40 sec, blue triangle – 80 sec, green 
rhomb – 400 sec, red square – 800 sec. The dashed line is untreated PU. The water 
contact angle decreases significantly after PIII treatment and increases with the 
storage time.  
 
 
 
Fig.4.7. Total surface energy of PIII treated PU as a function of storage time after the 
treatment. PIII treatment time is: violet circle – 40 sec, blue triangle – 80 sec, green 
rhomb – 400 sec, red square – 800 sec. The dashed line is untreated PU.  
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The dispersic part of the surface energy increases from 31 mN/m to 40-44 mN/m for 
untreated polyurethane and decreases with storage time up to 37-39 mN/m (Fig.4.8).  
 
The polar energy changes more dramatically (Fig.4.9). The polar part calculations 
show a value of 2 mN/m for untreated polyurethane. This value is usual for untreated 
polymers [3]. A short time after PIII treatment the polar part of surface energy 
increases to 17-27 mN/m and then decreases and is stabilised at 8-14 mN/m. The 
difference between the samples treated with different fluences is weak. There is no 
correlation trend of the surface energy and its parts with PIII fluence.  
 
 
Fig.4.8. Dispersive part of surface energy of PIII treated PU as a function of storage 
time after the treatment. PIII treatment time is: violet circle – 40 sec, blue triangle – 
80 sec, green rhomb – 400 sec, red square – 800 sec. The dashed line is untreated PU.  
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Fig.4.9. Polar part of surface energy of PIII treated PU as a function of storage time 
after the treatment. PIII treatment time is: violet circle – 40 sec, blue triangle – 80 sec, 
green rhomb – 400 sec, red square – 800 sec. The dashed line is untreated PU.  
 
 
4.3. Chemical structure of the modified implant surface 
 
To understand the chemical activity of the modified polyurethane implant surface, the 
analysis of the chemical groups and its stability was done. Due to the very thin 
modified layer (100 nm or less) of the polyurethane implant after PIII the modern 
methods of chemical structure surface analysis were used.  
 
The effect of PIII treatment is visible by darkening the surface layer of polyurethane. 
A similar darkening previously observed for ion beam treated polymers was 
considered to be connected with carbonisation of the thin surface layer. The surface 
layer of polyurethane was analysed with X-ray photoelectron spectroscopy (XPS). 
XPS signal comes from very thin layer estimated as 5-10 nm of top layer. The survey 
spectra of the PU surface before and after PIII treatment are shown in Fig.4.10. The 
spectrum of untreated polyurethane shows lines of C1s of carbon, O1s of oxygen and 
N1s of nitrogen corresponding to the chemical formula. No other elements were 
detected.  
 
After PIII treatment by nitrogen ions of 20 keV energy during 800 seconds the XPS 
spectrum shows the same lines of carbon, oxygen and nitrogen however the intensity 
ratio of the lines changed. The intensity of nitrogen lines increases following the 
nitrogen ion incorporation into the surface. The intensity of carbon line increases and 
the intensity of oxygen line decreases show the structure’s changes. The treated 
surface becomes richer with carbon. No other elements are observed in polyurethane 
surface after PIII treatment.  
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Untreated polyurethane 
 
 
PIII treated polyurethane 
 
Fig. 4.10. Survey XPS spectra of polyurethane untreated and PIII treated polyurethane 
with nitrogen ions of 20 keV energy 800 seconds.  
 
The detailed analysis of the XPS spectra shows that the chemical structure of 
polyurethane has been changed after PIII treatment. For the analysis XPS spectra with 
high resolution were recorded and the lines were fitted with Gauss functions. The 
results of the analysis are presented in Fig.4.11. The C1s line contains 3 components 
of carbon atoms in C-C and C-H groups (284.8 eV), in C-O groups (286.3 eV) and 
O=CN-O groups (289.3 eV), that corresponds to polyurethane formula. The 
component of carbon atom in ether group is mostly intensive. After PIII treatment the 
line contains a minimum 4 components: 284.9 eV of carbon in C-C and C-H groups, 
286.4 eV line of carbon in C-O and C-N groups, 288.0 line of carbon in C=O and 
C=N groups, and 288.9 line of carbon in O-C=O groups. The most intensive 
component is 284.9 eV of carbon in C-C and C-H groups.  
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C1s, untreated 
 
 
C1s, PIII treated 
 
 
O1s, untreated 
 
 
O1s, PIII treated 
 
 
N1s, untreated 
 
 
N1s, PIII treated 
 
Fig.4.11.  High resolution XPS lines of polyurethane before and after PIII treatment 
fitted with individual components.  
 
The O1s oxygen line has been changed from the singlet line at 532.7 eV (oxygen in 
ether group) to doublet at 531.0 eV and 532.7 eV (oxygen in carbonyl and ether 
groups). The N1s nitrogen line has been changed also from the singlet line at 400.0 
eV of nitrogen in urethane group to 398.9 eV and 400.0 eV of nitrogen in C=N and C-
N groups. All these spectral changes show that the polyurethane structure is 
significantly damaged. The carbon structure with oxidation and nitrization is 
observed.  
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The optical properties of the polyurethane surface layer were analysed using 
spectroscopic ellipsometry. The polyurethane surface is relatively rough for precise 
optical measurements. Therefore the reflected light beam has a very low intensity that 
makes the signal noisy. An example of Ψ and delta functions of untreated 
polyurethane is presented in Fig.4.12. The region below 400 nm is undetectable while 
the region higher then 600 nm is well detectable. The Ψ and delta functions of the 
untreated and PIII treated polyurethane have different characters (Fig.4.12 and 4.13). 
The spectra of untreated polyurethane does not have interference features that show 
uniformity of the material by depth. The spectra of PIII treated polyurethane show 
features related to the interference effect due to different optical properties of surface 
and bulk materials. Using Cauchy model the optical properties n and k have been 
analysed to fit the experimental and theoretical Ψ and delta functions. The model of 
uniform bulk material was used for the untreated polyurethane. The PIII treated 
polyurethane was modelled with two layers: untreated bulk layer with the optical 
parameters from the spectra of untreated polyurethane, and the top layer with fitted 
properties.  
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Fig.4.12. Ellipsometry Ψ and delta functions of untreated polyurethane and the model 
fit of bulk material.  
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Fig.4.13. Ellipsometry Ψ and delta functions of PIII treated polyurethane with 20 keV 
energy nitrogen ions during 800 seconds and the model fitted with two layer 
materials: untreated polyurethane underneath and top fitted layer.  
 
The results of the optical constants’ fitting are presented in Fig.4.14. The thickness of 
the top layer on PIII treated polyurethane fitted in the model was 56 nm. The 
untreated polyurethane has the refractive index about 1.5 of low dispersion and no 
absorption in 450-1000 nm spectral region, when the PIII treated top layer has high 
dispersion of the refractive index between 1.7-1.8 values in 350-1000 nm region with 
absorption in 350-650 nm region. A similar effect of the high refractive index and 
absorption in short wavelength region is observed in other polymers after PIII 
treatment and interpreted as the carbonised top layer with condensed aromatic carbon 
rings like graphite or graphene. Such structures have high refractive index and high 
optical absorption. A similar interpretation can be used in the case of the PIII treated 
polyurethane. Therefore the PIII treated polyurethane has the top carbonised layer 
with high refractive index and optical absorption predominantly in short wavelength 
region of spectra.  
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Fig.4.14. Refractive index and extinction coefficient of untreated polyurethane and 56 
nm top layer of the treated polyurethane (800 sec of 20 keV nitrogen ion PIII) by 
ellipsometry spectra fitting.  
 
The carbonisation of the top layer increases with the number of the bombarding ions 
or PIII treatment time. The spectra of the refractive index and extinction coefficient of 
the top polyurethane layer are presented in Fig.4.15. The refractive index spectra 
show the refractive index consistently increases across the whole diapason of the 
wavelength. The refractive index at the short wavelength increases as the saturation 
increases in the present range of PIII treatment time, while the refractive index at the 
long wavelength increases almost linearly (Fig.4.16). The extinction coefficient 
spectra show an increase of the absorbance in short wavelength region with PIII 
treatment time (Fig.4.15). The absorbance in a wavelength region longer then 500 nm 
does not increase with PIII treatment time. The linear character of the extinction 
coefficient with PIII treatment time was observed for 244 nm and 312 nm wavelength 
(Fig.4.16).  
 
If the short wavelength corresponds to a low number of condensed aromatic 
structures, such structures appear in the top layer at shorter PIII treatment time. The 
long wavelength corresponds to the higher number of condensed aromatic structures 
and such structures need longer treatment time to be generated in the top layer of the 
polyurethane. The curve of the refractive index at long wavelengths and the extinction 
coefficient curves did not reach saturation in the diapason of the PIII treatment time 
that was used. However, a longer PIII treatment would probably make a larger size 
and number of condensed aromatic structures in the top layer of polyurethane.  
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Fig.4.15. Refractive index and extinction coefficient spectra of top surface layer in 20 
keV nitrogen ion PIII treated polyurethane with PIII treatment time (noted in sec) by 
ellipsometry fitting model.  
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Fig.4.16. Refractive index and extinction coefficient of top surface layer in 20 keV 
nitrogen PIII treated polyurethane in dependence on PIII treatment time (noted in sec) 
by ellipsometry fitting model for different wavelength. The increase of refractive 
index and extinction coefficient corresponds to the transformation of the surface 
polyurethane layer to the surface carbonised layer with PIII treatment time.  
 
The carbonisation of the top layer was detected using micro-Raman spectra 
(Fig.4.17). Spectrum of untreated polyurethane contains a number of spectral lines 
interpreted as vibrations of polyurethane macromolecule. The strong line at 1619 cm-1 
is interpreted as a stretching vibration of aromatic ring, 1453 cm-1 and 1320 cm-1 lines 
are interpreted as bending vibrations in hydrocarbon chains. Low intensity 
characteristic lines are interpreted as Amide 1 vibration (1712 cm-1) and Amide II 
vibration (1540 cm-1) in urethane group, skeletal vibrations C-C (1080-1267 cm-1) and 
aromatic ring vibrations (870 and 925 cm-1).  
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Fig.4.17. Micro-Raman spectra of untreated (top spectrum) and 20 keV nitrogen ion 
PIII treated polyurethane at 800 sec (bottom spectrum). Two new strong peaks at 
1348 and 1595 cm-1 show the presence of graphite planes with defects in PIII treated 
polyurethane.  
 
The spectrum of PIII treated polyurethane contains new strong lines at 1348 and 1595 
cm-1. These two lines are interpreted as resonance Raman lines of the carbonised top 
layer: D and G peaks. G-peak is E2g vibrations in graphitic structure with sp2 
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hybridisation of the valence electrons. D-peak is A1g vibrations in graphitic structure. 
The mode A1g is forbidden in Raman spectra of infinite ideal graphitic plane. 
However, due to the edges and disordering of the graphitic structure in real material, 
this mode becomes visible in Raman xx. This effect can be used for estimation of the 
irregularity of the graphitic structure. The ratio I(D)/I(G)=1.77 and G-peak position 
corresponds to I area in Robertson/Ferrari diagram that shows a nanocrystalline 
graphite with characteristic size of graphitic islands of La=2.5 nm separated by 
amorphous carbon with sp3 hybridization.  
 
The surface layer transformations have been detected with NEXAFS spectroscopy. 
The spectra of surface and bulk layers of untreated polyurethane are presented on 
Fig.4.18. The C1s spectrum region of the bulk layer detected by MCP detector and the 
surface layer detected by channeltron contain lines of 285.14 eV of C1s(C-H)à 
1π*C=C transition, 288.87 eV of C1s(C=O)à π*C=O transition, 291.22 eV of C1s(C-
H)à σ*C-O transition, 293.1 eV of C1s(-CH-O-)à σ*C-C transition and broad line at 
about 300 eV of C1s(C-H)à σ*C-C transition. The spectra interpretation of C1s lines 
corresponds to known literature data on NEFAXS spectra of polyurethanes based on 
TDI and polyethers.  
 
 
Fig.4.18. Near-edge X-ray absorption fine structure (NEXAFS) spectra of untreated 
polyurethane with channeltron (surface) and MCP detector (bulk) in C1s region.  
 
The N1s spectrum of bulk layer detected by MCP detector and the surface layer 
detected by channeltron contain two narrow lines and broad band with two 
maximums (Fig.4.19). The weak narrow line at 399.0 eV can be interpreted as N1s(C-
N)à 1π*C=C transition and second narrow line at 403.3 eV can be interpreted as 
N1s(C-N)à π*C=O transition. The broad line at 407.3 eV can be interpreted as N1s(C-
N)à σ*C-N transition and broad line at 412.3 eV is interpreted as N1s(C-N)à σ*C-C 
transition. This interpretation is preliminary because an interpretation of N1s 
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NEXAFS peaks for polyurethane has not yet been found in the literature. The present 
interpretation was done based on similar interpretations for C1s and O1s peaks of 
NEXAFS spectra of polyurethanes.  
 
 
Fig.4.19. Near-edge X-ray absorption fine structure (NEXAFS) spectra of untreated 
polyurethane with channeltron (surface) and MCP detector (bulk) in N1s region. 
 
The NEXAFS spectra of polyurethane after PIII treatment shows differences from the 
spectra of untreated polyurethane (Fig.4.20) while the NEXAFS spectra of the bulk 
layer in untreated and PIII treated polyurethane are identical (Fig.4.21). The intensity 
of 285.14 eV line decreases significantly. The intensity of 288.98 line increases. The 
spectrum becomes similar to a spectrum of deposited carbon. The strong coupling of 
C-H bond with p-orbital becomes weaker and that shows that the aromatic structures 
are condensed or surrounded by amorphous carbon. The line at 403.3 eV disappears 
and a new line at 400.0 eV appears. The first line at 403.3 corresponds to a coupling 
of the nitrogen with p-orbital in carbonyl bond of urethane group. Due to destruction 
of the urethane groups in the surface layer, the line disappears. The second line at 
400.0 eV is interpreted as N1s(C=N)à π*C=N transition as it is observed in carbon 
nitride coatings. Therefore, the nitrogen is incorporated into the condensed aromatic 
structures of the top layer in nitrides form.  
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Fig.4.20. Near-edge X-ray absorption fine structure (NEXAFS) spectra with 
channeltron (surface) of untreated polyurethane and PIII treated polyurethane (N+ 20 
keV, 800 sec) in C1s and N1s region. 
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Fig.4.21. Near-edge X-ray absorption fine structure (NEXAFS) spectra with MCP 
detector (bulk) of untreated polyurethane and PIII treated polyurethane (N+ 20 keV, 
800 sec) in C1s and N1s regions. 
 
The modified polyurethane layer has a signal of unpaired electrons in electron spin 
resonance (ESR) spectra. The ESR spectra of the untreated polyurethane and the PIII 
treated polyurethane at 800 seconds by nitrogen ions with 20 keV energy are 
presented in Fig.4.22. The PIII treated sample was recorded after 3 months storage in 
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humidity). The untreated polyurethane film does not have a signal higher than the 
noise level. The PIII treated film has a strong signal with g-factor about 2.0028. The 
signal with such g-factor corresponds to unpaired electrons of carbon free radicals at 
the edges of aromatic structures in graphite- or graphene-like structures [4]. The 
spectra show that the free radicals in the modified layer appear after PIII treatment 
and then remain when it is stored for a further 3 months. Such long shelf-life free 
radicals are probably stabilised by π-electrons of the aromatic rings of graphite-like 
structures. The presence of nitrogen in the aromatic structures can increase the 
stabilisation effect.  
 
 
 
Fig.4.22. Electron spin resonance spectra of untreated polyurethane (blue) and PIII 
treated polyurethane (red).  
 
The free radicals in the surface layer are able to react with a large number of 
molecules adsorbed on the surface including atmospheric gases like oxygen and 
nitrogen. The reactions of free radicals in the carbonised layer with oxygen from the 
atmosphere can generate a number of oxygen-containing groups [5].  
 
The presence of new chemical groups in the modified surface layer has been observed 
in FTIR ATR spectra of the polyurethane surface (Fig.4.23). The spectra of untreated 
and PIII treated polyurethane surfaces show similar intensive lines interpreted as 
vibrations of the polyurethane structures: Amide A, I and II lines of urethane and urea 
groups, CH stretching and bending vibrations in –CH<, -CH2- and -CH3 groups, 
aromatic ring lines, C-O vibrations in urea and ether groups as well as complex shape 
vibrations in finger-print regions. The spectrum of PIII treated polyurethane shows 
additional lines in 3500-3300 cm-1 region interpreted as hydroxyl group line 
vibrations, and 1700-1600 cm-1 region interpreted as carbonyl, amide and carbon-
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carbon unsaturated group lines overlapped in one wide band. The intensity of these 
lines is low due to the thin modified layer (about 100 nm) in comparison with a depth 
penetration of the infrared beam to the sample from ATR crystal during the spectra 
recording (about 1 µm). Other spectral changes are less visible.  
 
 
Fig.4.23. FTIR ATR spectra of PPG-DI-PTHF-0.35 polyurethane untreated (thin 
black bottom curve) and PIII treated during 800 seconds of 20 keV nitrogen ions 
(thick red top curve).  
 
To recognise all changes, a subtraction method of the spectra is used. The spectrum of 
the untreated sample was subtracted from the treated sample spectrum with 
adjustment of the subtraction factor to minimise the spectral line intensity common 
for both spectra. The result of subtraction is a difference in the spectra caused by the 
different chemical structure of the treated and untreated polyurethane surface layer 
(Fig.4.24). In this way, the subtracted spectra are more sensitive and the contrast of 
the spectral difference is more clearly visible than is suitable for an analysis of the 
modified layer.  
 
The lines of the subtracted spectra strong band in 3500-3000 cm-1 region have a  
complex shape and consist of some visible peaks with maximums at 3625, 3400, 3360 
and 3220 cm-1. The peaks are broad and overlayed with each other. The position of 
the peak maximums and width show that these peaks can be interpreted as –OH 
stretch vibrations of hydroxyl groups in hydrogen bonds. The shape of the line does 
not change much with PIII treatment time.  
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Fig.4.24. Differential FTIR ATR spectra of PPG-DI-PTHF-0.35 polyurethane after 
PIII of 20 keV nitrogen ions with different treatment time (shown on diagram). The 
spectrum of untreated PU is subtracted.  
 
In the middle region, the strong complex lines are observed in 1800-1400 cm-1 region. 
The shape of the lines depends on the PIII treatment time. The spectrum of 40 sec PIII 
treated sample shows strongest peaks at 1613 cm-1 of C=C vibrations, 1465 and 1435 
cm-1 of CH bending vibrations with low intensity 1740, 1715 and 1660 cm-1 peaks of 
C=O vibrations. The spectrum of 80 sec PIII treated sample and spectra of other 
samples with longer PIII treatment time do not show 1613, 1465 and 1435 cm-1 peaks, 
but show strong peaks at 1715 and 1660 cm-1 of C=O vibrations. The low intensity 
peak at 2205 cm-1 observed in spectra of these samples is interpreted as stretching 
vibrations CN in nitrile groups. All these peaks are not related to initial polyurethane 
structures but are related to the modified surface layer.  
 
The quantitative measurements of the absorbance peaks show a dependence of the 
chemical changes in terms of PIII treatment time Fig.4.25-28. The intensity of 
hydroxyl group line was analysed on absorbance at 3400 cm-1 as the most intensive 
peak (Fig.4.25a). The -OH line absorbance was normalised on absorbance of methyl 
group in polyurethane at 2870 cm-1, which is constant with PIII treatment time. The 
intensity of peak increases asymptotically with a saturation achieved after 400 sec of 
PIII treatment time. The saturated character of the OH absorbance shows that the 
maximal effect of modification of the surface layer in term of hydroxyl group 
formation is limited.  
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Fig.4.25. Absorbance of hydroxyl group (3400 cm-1) normalised on absorbance of 
methyl group (2870 cm-1) in FTIR ATR spectra of PU as a function of PIII treatment 
time with 5, 10 and 20 keV energy nitrogen ions: a – PPG-DI-PTHF-0.35 
polyurethane, b – PPG-DI-PTHF-0.5 polyurethane, c – PPG-DI-PTHF-0.7 
polyurethane.  
 
The maximal amount of hydroxyl groups depends on the applied bias during PIII 
treatment. For lower applied bias and correspondingly lower kinetics energy of 
bombarding nitrogen ions, the thickness of the modified layer is proportionally lower 
following TRIM/SRIM calculations (Fig.4.4). The bias of 10 kV and 5 kV was 
applied to the polyurethane samples and the FTIR ATR spectra were analysed. The 
frequency of bias pulses was adjusted for 10 kV and 5 kV to get the same fluence of 
the PIII treatment as described in Chapter 2. Similar asymptotical character of 
hydroxyl group absorbance is also observed for PIII treated polyurethane at lower PIII 
bias of 10 kV and 5 kV (Fig.4.25a). However, the maximal saturated amount of 
hydroxyl groups in the modified layer is proportionally lower for 10 and 5 kV bias 
samples in comparison with 20 kV samples. This fact shows that the hydroxyl group 
amount is proportional to the ion kinetics energy or thickness of the modified layer.  
 
The asymptotical character of hydroxyl group collection and dependence on bias 
voltage is observed for other polyurethanes with different composition (Fig.4.25a, b 
and c). The polyurethanes with 0.5 and 0.7 molar ratio of NCO/OH groups at the 
synthesis (the synthesis is described in Chapter 3) were PIII treated and FTIR ATR 
spectra were analysed. The saturation effect was also observed after 400 sec of PIII 
treatment time. However, the saturation level of hydroxyl group absorbance was 
lowest for 0.7 ratio polyurethane with highest PTHF concentration (Fig.4.26). This 
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polyurethane has the lowest ether group concentration in comparison with 
polyurethanes of 0.35 and 0.5 ratios.  
 
 
Fig.4.26. Absorbance of hydroxyl group (3400 cm-1) in FTIR ATR spectra of “0.35” 
(PPG-DI-PTHF-0.35 polyurethane), “0.5” (PPG-DI-PTHF-0.5 polyurethane) and 
“0.7” (PPG-DI-PTHF-0.7 polyurethane) as a function of PIII treatment time with 20 
keV energy nitrogen ions. 
 
The absorbance of carbonyl group in the PIII treated polyurethanes was analysed by 
peak at 1660 cm-1 (Fig.4.27). Similar asymptotical character of the carbonyl group 
absorbance is observed for all used biases (20, 10 and 5 kV) and all polyurethane 
compositions (0.35, 0.5 and 0.7 NCO/OH ratios). The saturation is observed after 400 
sec of the PIII treatment time for all biases and polyurethane compositions. The 
saturated level of the carbonyl group absorbance depends on the applied bias as it was 
observed for hydroxyl group absorbance: the lowest absorbance is observed for 5 kV 
bias treated samples, when the highest absorbance is observed for 20 kV bias treated 
samples. The saturated level of the carbonyl group absorbance also depends on the 
polyurethane composition: the lowest absorbance is observed for polyurethane with 
highest PTHF concentration, when the highest absorbance is observed for 
polyurethane with lowest PTHF concentration.  
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Fig.4.27. Absorbance of carbonyl groups (1660 cm-1) in FTIR ATR spectra of PU as a 
function of PIII treatment time with 5, 10 and 20 keV energy nitrogen ions: a – PPG-
DI-PTHF-0.35 polyurethane, b – PPG-DI-PTHF-0.5 polyurethane, c – PPG-DI-
PTHF-0.7 polyurethane.  
 
The absorbance of nitrile group at 2205 cm-1 increases with PIII treatment time as 
does hydroxyl and carbonyl group absorbance (Fig.4.28). However, the saturation 
level was not achieved when PIII treatment time exceeded 400 sec. The nitrile group 
absorbance curves tended to increase with applied PIII bias, but the difference 
between the curves for 5, 10 and 20 kV bias was not very different as with the 
hydroxyl and carbonyl group absorbance. Also there was no clear dependence of the 
nitrile group absorbance on the polyurethane composition.  
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Fig.4.28. Absorbance of nitrile CN group in FTIR ATR spectra of PU as a function of 
PIII treatment time with 5, 10 and 20 keV energy of nitrogen ions: a – PPG-DI-
PTHF-0.35 polyurethane, b – PPG-DI-PTHF-0.5 polyurethane, c – PPG-DI-PTHF-0.7 
polyurethane.  
 
The surface of polyurethane is unstable after PIII treatment. The above results are 
related to the polyurethane surface after long storage time (a month). The analysis of 
the surface transformation with time after PIII treatment was done using FTIR ATR 
spectra. The polyurethane samples were treated by PIII and the spectra were recorded 
immediately after removing the sample from the PIII chamber, and after a month’s 
storage under laboratory conditions in closed Petri dishes in darkness. The treated 
surface was preserved against any contact with any material. Every FTIR ATR 
spectra was recorded with new samples that were not previously in contact with ATR 
crystal. The shortest time after switching off the bias voltage before the spectra were 
recorded was 25 minutes. The spectra recording with sufficient signal/noise ratio and 
resolution of 4 cm-1 took 2 minutes for each sample. The differential spectra of 0.35 
ratio polyurethane recorded with storage time after 800 sec PIII treatment time are 
presented in Fig.4.29. The absorbance at selected wavenumbers of the spectra with 
storage time is analysed in Fig.4.30a-c.  
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Fig.4.29. FTIR ATR spectra of PPG-DI-PTHF-0.35 polyurethane: bottom is untreated 
polyurethane spectrum (the spectrum is 1/20 of original intensity). The following 
spectra from bottom to top are differential spectra of polyurethane after PIII treatment 
according to the length of storage time. The treatment was done by 20 keV energy 
nitrogen ions for 800 seconds. 
 
 
a 
 
 
0 
.002 
.004 
.006 
.008 
.01 
.012 
 3500   3000   2500   2000   1500   1000  
Wavenumber, cm-1 
A
bs
or
ba
nc
e,
 a
.u
. 
a.
u.
 
Untreated  
12 days 
5 days 
45 hours 
22 hours 
5 hours 
2 hours 
68 min 
36 min 
25 min 
CN 
OH 
C=O 
C=N 
C-C 
C-O 
0.1$
0.15$
0.2$
0.25$
0.3$
0.35$
0.4$
0.45$
1$ 10$ 100$ 1000$ 10000$ 100000$
A
bs
or
ba
nc
e,
+a
.u
.+
Storage+1me,+min+
800$sec$
400$sec$
Untreated$
40$sec$
80$sec$
 79 
 
b 
 
 
c 
 
Fig.4.30. Absorbance of carbonyl group line at 1708 cm-1 (a), hydroxyl group line at 
3400 cm-1 (b) and nitrile group line at 2205 cm-1 (c) in FTIR ATR PPG-DI-PTHF-
0.35 polyurethane as a function of storage time after N+ PIII treatment of 20 kV bias. 
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The absorbance of these groups was normalised on the absorbance at 1373 cm-1 line 
of methylene group. The PIII treatment time are noted in the diagram.  
 
The spectra show the absorbance growing in 3500-3000 cm-1 and 1800-1400 cm-1 
regions corresponding to hydroxyl, carbonyl and unsaturated carbon-carbon group 
vibrations. The quantitative analysis was done for the absorbance at 3400 cm-1, 2205 
cm-1 and 1708 cm-1 wavenumbers normalised on 1373 cm-1 of methylene group 
absorbance in polyurethane which was strong and stable after PIII treatment. The 
normalised absorbance of hydroxyl and carbonyl groups remained constant with 
storage time for the polyurethane samples treated with PIII for 40 and 80 sec, while 
the absorbance for samples treated for 800 and 400 sec grew with the storage time 
two weeks after PIII treatment. The growth of the absorbance showed an increase of 
hydroxyl and carbonyl groups due to oxidation reactions of free radicals in the surface 
layer of polyurethane.  
 
The absorbance of nitrile group vibrations remained constant for the samples treated 
with PIII for 40, 80 and 400 sec. For the sample treated for 800 sec, the absorbance 
decays with the storage time due to degradation of nitrile group under environmental 
conditions.  
 
 
4.4. Surface topography of the modified polyurethane implant 
 
The surface topography of the medical implant is a very important parameter for the 
tissue reaction in organisms. The analysis of the surface topography was done for the 
polyurethane implants after PIII for different treatment parameters.  
 
The surface topography of PPG-DI-PTHF-0.35 polyurethane was changed 
dramatically after PIII treatment even with a short treatment time (Fig.4.31). The 
surface was wrinkled and cracked. After a short treatment time (40 sec) the surface 
became covered by wave-like structures. The direction of the wave was random. After 
80 sec of PIII treatment, the cracks of the surface layer were well visible. After 800 
sec of PIII treatment, the surface was totally covered by irregular wrinkles and cracks. 
The surface topography remained stable after a month long storage time. The 
topography viewed was similar to polyurethane free standing films and polyurethane 
coating on hard substrate (silicon wafer). Therefore the surface wrinkles and cracks 
are not the result of a deformation of the sample. The surface topography changes are 
due to the PIII treatment process.  
 
Quantitative measurements of the surface topography were done with Atomic Force 
Microscopy. The untreated surface was characterised by random surface structures 
which were formed during the free surface synthesis under the influence of the 
surface tension, folding due to chemical reaction contraction and environmental 
artefacts like dust particles and air flow (Fig.4.32). The amplitude of the height varied 
across a wide range (48-150 nm in 10x10 nm2 area). However the phase image is flat 
showing a uniformity of the surface chemical structure.  
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Fig.4.31. Optical microphotos of PPG-DI-PTHF-0.35 polyurethane after PIII 
treatment by 20 keV energy nitrogen ions. The PU was synthesised and treated on 
silicone wafer to exclude any deformations after the treatment. Objective is x50. The 
developed surface structure with waves and cracks is observed after PIII treatment.  
 
The surface topography of the polyurethane treated with PIII for 40 sec is 
characterised by wave structure (Fig.4.33). The waves are distributed regularly over 
the whole surface (Fig.4.33a). The topography profile crossing the waves shows a 
periodicity of the wave structure (Fig.4.33b). The statistical analysis of the surface 
topography shows parameters of the surface averaged over the whole area. Power 
spectral density gives a peak at 0.0021 nm-1 wavenumber that corresponds to 
characteristic wavelength of 476 nm over the whole surface (Fig.4.33c). Fourier 
transformation 2D analysis shows definite direction of the surface waves (Fig.4.33d). 
 82 
A histogram of the height events is characterised with three Gauss peaks that shows a 
normal distribution of the waves with two characteristic amplitudes of 30 nm and 62 
nm (Fig.4.33e).  
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Fig.4.32. AFM image of untreated polyurethane: topography (left) and phase (right) 
images. The surface of the untreated polyurethane is uniformly rough with uniform 
chemical structure.  
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Fig.4.33. AFM images and statistical analysis of the polyurethane surface treated with 
PIII for 40 sec with 20 keV nitrogen ions: a – 3D image of 10x10 µm area; b - profile 
cross the wave structures; c – power spectral density analysis fitted with Gauss 
function; d – 2D Fourier transformation analysis; e – histogram analysis fitted with 
three Gauss functions. The surface shows wave structures. The waves are oriented. 
The waves have well defined periodicity (467 nm) and amplitudes (30 and 62 nm).  
 
Following the treatment the polyurethane surface cracked. The AFM image of the 
polyurethane surface treated for 80 sec shows cracks in some areas (Fig.4.34a). The 
profile crossing the crack shows a depth of 250-300 nm, which is deeper then the 
thickness of modified surface layer of polyurethane treated with 20 keV energy 
nitrogen ions described above. The width of the crack is about 1.5-2 µm (Fig.4.34b). 
The profile on the bottom of the crack is similar to the surface profile of untreated 
polyurethane with random features (Fig.4.34c). The flat area near the crack shows a 
wave structure as observed for the 40 sec PIII treated surface (Fig.4.34d). The profile 
of the phase image shows that the phase characterising an interaction of the surface 
with AFM tip is different on the flat area near the crack and on the bottom of the 
crack (Fig.4.34e). This means that the surface composition on the flat area and in the 
crack is different. Assuming the flat area is a carbonised layer of polyurethane, the 
bottom of the crack can be assumed to be untreated polyurethane. The polyurethane 
surface treated by 200 sec, 400 sec and 800 sec became more frequently cracked and 
the waves became deeper (Fig.4.35).  
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Fig.4.34. AFM images of the polyurethane surface treated by 80 sec PIII treatment 
time of 20 keV nitrogen ions: a – 3D image of 45x45 µm area; b - profile crosses the 
crack; c – profile along the crack bottom; d – profile crosses the wave structure; e – 
profile of the phase image crosses the crack. The surface shows wave and crack 
structures.  
 
2520151050
140
120
100
80
60
40
20
0
X[µm]
Z[
nm
]
9.0µm
86420
40
30
20
10
0
-10
X[µm]
Z[
de
g]
2.0µm
 88 
 
a 
 
b 
 
c 
 
Fig.4.35. AFM images (45x45 µm) of the polyurethane surface treated by 200 sec (a), 
400 sec (b) and 800 sec (c) PIII treatment time of 20 keV nitrogen ions.  
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4.5. Discussion 
 
The PIII treatment changes the surface layer of the polyurethane significantly. The 
wettability of the treated PPG-DI-PTHF-0.35 polyurethane changes dramatically. The 
water contact angle changes from 90 degrees to 35-45 degree range 15 minutes after 
the treatment. Therefore the surface becomes very hydrophilic. The contact angle 
increases asymptotically after a week up to 60-70 degree range, but it does not reach 
the initial value of 90 degrees. The same changes of the water contact angle were 
observed for other polymers. For example, for polystyrene the water contact angle 
changes from 90 degrees for untreated surface to 27-36 degrees immediately after PIII 
treatment and stabilises in 53-68 degrees after a month [6]. The water contact angle 
changes are also observed for PIII treated polyurethanes of different compositions. 
For example, SKU-PFL polyurethane water contact angle achieves 38-48 degrees 
immediately after PIII and stabilises in 63-73 degrees range after a month of storage 
[7].  
 
The water contact angle of PPG-DI-PTHF-0.35 polyurethane does not depend on the 
PIII fluence. Some polymers do not show this dependence, for example, 
polyetheretherketone, [8] or LDPE [9]. However, some polymers show a dependence 
of the contact angle on the PIII fluence, for example polystyrene [6] or polyurethane 
based on MDI diisocyanate [10].  
 
The surface energy of PPG-DI-PTHF-0.35 polyurethane calculated from the contact 
angles of water and diiodomethane changes from 33 mN/m for the untreated surface 
to 65-67 mN/m for the PIII treated surface. The main contribution to these changes 
comes from the polar part of the surface energy, which increases from 2 mN/m to 27 
mN/m. The same tendency is observed for all other polymers [11, 6, 12, 13]. 
However, the maximal value of the surface energy for other polymers can be as high 
as 75 mN/m for polystyrene [6] and as low as 50 mN/m for polyurethane based on 
MDI diisocyanate [10]. The increase of the surface energy is connected to the free 
radicals in the surface layer [13, 6, 14]. The free radical signal is also observed in the 
ESR spectra of PIII treated PPG-DI-PTHF-0.35 polyurethane. Therefore, the high 
values (65-67 mN/m) of surface energy for PIII treated PPG-DI-PTHF-0.35 
polyurethane could also be caused by the presence of free radicals on the surface, 
because such high values cannot be explained by the presence of other chemical 
groups like carboxyl or hydroxyl, which appear in the surface layer of polyurethane 
after storage time as detected by FTIR ATR and XPS spectra.  
 
The number of oxygen-containing groups generated by oxidation under air was 
observed by FTIR ATR and XPS spectra. These groups observed for all plasma, ion 
beam and PIII treated polymers [15] are the results of free radical reactions with air 
oxygen after the treated samples were removed from the vacuum chamber and 
exposed to open air. The kinetics of the oxygen-containing groups in PIII treated 
PPG-DI-PTHF-0.35 polyurethane shows that the oxidation reactions occur even a 
week after PIII treatment. Therefore, the surface layer remains highly active to the air 
oxygen a week after the treatment. Similar oxidation process was observed for other 
polymers including polyurethanes.  
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However, the kinetics of oxidation for different polyurethane compositions is 
different. The highest concentration of hydroxyl and carboxyl groups was observed 
for PPG-DI-PTHF-0.35 polyurethane and the lowest concentration of hydroxyl and 
carboxyl groups was observed for PPG-DI-PTHF-0.7 polyurethane. It was observed 
for the first time that the composition of polyurethane influences the chemical 
transformation process in the surface layer after PIII treatment.  
 
Also the influence of different ion energies on the oxidation process in polyurethanes 
had not been observed before. The PPG-DI-PTHF-0.35 polyurethane was treated by 
nitrogen ions of different energy and the kinetics of the oxidation was found to be 
sensitive to the ion energy. The higher ion energy caused higher saturation level of the 
oxygen-containing group concentration, while the nitrile group concentration directly 
associated with the carbonised layer remains independent on the ion energy for PPG-
DI-PTHF-0.7 polyurethane. These facts have not been observed before and we do not 
have a clear explanation for them. It could be because of the depolymerised reactions 
in the underneath layers where the free radicals can migrate from the carbonised layer 
and where the oxidation processes could be sensitive to the chemical structure of 
polyurethane. Further investigations are required.  
 
The formation of the carbonised layer was observed by Raman spectra on 
characteristic two lines of graphite planes. These lines are narrower than the lines in 
the Raman spectra of other polymers irradiated by ion beam [15]. The spectra line 
positions and intensity ratio corresponds to the 2.5 nm characteristic size of the 
graphitic clusters. In comparison with other polymers [15], the 2.5 nm cluster is large. 
This means that the average cluster has about 200 condensed aromatic rings. The 
NEXAFS spectra showed the graphitic clusters contains also C=N bonds involving in 
sp2 hybridization. Therefore, the graphitic clusters could have a lot of defects and 
disturbance of π-clouds. The strong ESR spectrum of unpaired electrons confirms that 
the g-factor corresponds to electrons on the edge of graphitic clusters. 
  
The top layer of PIII treated polyurethane has higher density than the untreated 
polyurethane. The refractive index of the top layer achieves the value of 1.85, while 
the untreated polyurethane layer has the refractive index of 1.45-1.55 in visual light 
range of wavelength. The density of this layer is lower than for PIII treated PS [16], 
LDPE [11] and PC [17], and close to the refractive index of PIII treated PMMA [18].  
 
The appearance of graphitic structures forms a hard surface layer. The underneath soft 
layer of polyurethane and hard layer on the top cause the cracks in the surface layer 
penetrating up to the deep layer of unmodified polyurethane. The AFM phase images 
confirm this fact. The cracks are caused by internal stresses in the carbonised layer. 
The thickness of the hard layer from AFM measurements (250-300 nm) is higher then 
the thickness of the modified layer (130 nm) calculated from SRIM model. The 
difference between these values corresponds to the rupture of the untreated 
underneath layer under the internal stresses in the carbonised layer. The thickness of 
the carbonised layer measured from the ellipsometry data (65 nm) is lower then these 
two values. The layer with high refractive index is highly carbonised and dense. 
Therefore, the surface layer has a complicated structure with a gradient of chemical 
structure and stresses.  
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The study proved that the surface of the PIII treated PPG-DI-PTHF-0.35 polyurethane 
consists of carbonised top surface layer with 2.5 nm graphitic clusters with edges rich 
with unpaired electrons shared with π-electron clouds of aromatic structures.  
 
 
4.6. Conclusions 
The PIII treatment forms the carbonised hard layer on the top of polyurethane 
implant. The thickness of the carbonised layer corresponds to the penetration depth of 
the bombarding ions. The carbonised layer consists of condensed aromatic structures 
like graphite. The edges of these structures are carbon atoms with unpaired electrons 
that are regarded as free radicals. These unpaired electrons are stabilised by π-electron 
cloud of the aromatic structures in such a way that the free radicals at the edges decay 
slowly and produce oxygen containing groups. However, these free radicals remain 
detectable for a long time. The kinetics of the chemical transformation with the 
storage time depends on the parameters of PIII treatment and the composition of 
polyurethane.  
 
The surface of the modified polyurethane implant becomes highly hydrophilic 
immediately after the PIII but recovers up to middle value over time. The modified 
surface has a complicated topography and is characterised by wave and crack 
structures depending on PIII treatment parameters. 
  
All these transformations show that the surface of the polyurethane implant changes 
dramatically after PIII, and that it can cause different interactions with protein 
molecules, cells and tissue of organism.  
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Chapter 5. In vitro biocompatibility of 
modified implants 
 
 
 
Modified polyurethanes were investigated as a prospective material for implants into 
organisms. This chapter is devoted to answering whether PIII treatment can improve 
biocompatibility in vitro. A successful incorporation of an implant into an organism’s 
tissue requires that the proteins and cells be attached to the implant’s surface. For this 
investigation, different proteins and endothelial cells were attached on the 
polyurethane surface and analysed. The results of the in vitro experiments in this 
chapter are the required preliminary stage for the in vivo experiments.  
 
The results in this chapter are partially published by I. Kondyurina, S.G. Wise, 
A.K.Y. Ngo, E.C Filipe, A. Kondyurin, A.S. Weiss, S. Bao, and M.M.M. Bilek in 
‘Plasma mediated protein immobilisation enhances the vascular compatibility of 
polyurethane with tissue matched mechanical properties’, Biomed. Mater., 12, 2017, 
045002.  
 
 
5.1. Interaction of proteins with implant  
 
The proteins selected for the investigation were albumin, fibrinogen and tropoelastin. 
The choice of protein was based on common attachment analysis of polyurethane 
surfaces, on an organism’s protein environment and as a way to improve the 
biocompatibility of the polyurethane surface. The albumin is the most common 
protein in the blood stream and the intercellular matrix. An attachment of albumin can 
be a critical test for polyurethane implant inserted anywhere inside a body. Fibrinogen 
is the third primary plasma protein following serum albumin and immunoglobulins 
which are key proteins for biocompatibility of blood-contacting implant devices. 
Fibrinogen takes part in the blood coagulation cascade, where the fibrinogen 
fragments are ultimately cleaved to yield insoluble fibrin monomers that polymerize 
into an intricate cross-linking structures. Also fibrinogen plays the role of a cell 
adhesive protein, which is an important requirement for biocompatibility. 
Tropoelastin is a monomer of elastin found in the extracellular matrix of elastic 
tissues. Tropoelastin is used in tissue engineering because of conformational 
flexibility and stability under medical-grade sterilization, for example, ultraviolet light 
sterilization. Also tropoelastin is a good candidate protein to modulate a number of 
processes including adhesion, spreading, proliferation, and migration in cell types 
such as fibroblasts and endothelial cells. These three proteins are an example of 
immobilisation onto polyurethane surface, but it does not exclude other protein 
immobilisation for future studies.  
 
The Bovine serum albumin (BSA) has been used in this attachment experiment. The 
polyurethane untreated samples and polyurethane samples treated by nitrogen ions 
with 20 keV energy with different fluence were used for the protein experiments. 
After the PIII treatment the polyurethane samples were stored for 2 weeks to stabilise 
the polyurethane surface before the protein attachment. The stabilisation of the PIII 
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treated surface was done to minimise the difference of oxidation between the sample 
incubated in the buffer and the sample incubated in protein solution that can mask the 
protein lines in the differential spectra. The polyurethane samples were incubated 
overnight in 50 µg/ml BSA solution in PBS buffer at 25C in 45 ml polypropylene 
falcon tube. Then the polyurethane samples were rinsed in 3 different falcon tubes 
with the 45 ml buffer solution and in 45 ml mQ-water. The samples were dried 
overnight in Petri dishes. The control samples were incubated in buffer solutions only. 
These were prepared the same way and at the same time as the protein attached 
samples. The buffer samples were rinsed only in mQ-water once. Then the control 
samples were dried overnight the FTIR ATR spectra was recorded.  
 
The spectral lines of protein are not visible in row spectra of the samples as recorded 
due to high intensity of the polyurethane lines in comparison with the protein lines 
(Fig.5.1). The low intensity of protein lines corresponds to very thin BSA protein 
monolayer (about 5 nm) in comparison with the high intensity polyurethane spectrum 
corresponding to the infrared beam penetration depth into polyurethane (400-1000 nm 
in dependence on wavenumber of the spectral region). The spectra of buffer samples 
were subtracted from the spectra of protein samples treated at the same PIII treatment 
time with adjusted subtraction factor to minimise absorbance of polyurethane lines. 
The resulted spectra are presented in Fig.5.2.  
 
 
Fig.5.1. FTIR ATR spectra of untreated polyurethane PPG-DI PTHF with 0.35 
NCO/OH ratio soaked in buffer solution (red) and in Fibrinogen solution (blue) as 
recorded.  
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Fig.5.2. FTIR ATR spectra of attached BSA on untreated and PIII treated 
polyurethane of PPG-DI PTHF with 0.35 NCO/OH ratio. From bottom to top: (a) 
untreated polyurethane, (b) 40, (c) 80, (d) 200, (e) 400, (f) 800 s PIII treatment time 
with 20 keV nitrogen ions. The spectra of corresponding polyurethanes are subtracted. 
 
The subtracted spectra show Amide A line at 3300 cm-1, Amide I line at 1650 cm-1 
and Amide II line at 1540 cm-1. The line positions of Amide A and Amide II in the 
spectra of pure polyurethane and pure protein are similar. These lines in the 
subtracted spectra can be interpreted as related to both polyurethane and protein. 
Therefore these lines cannot be used for analysis of protein attachment. The Amide I 
line in the spectra of pure polyurethane was observed at 1720 cm-1, and the Amide I 
line in the spectra of pure protein was observed at 1650 cm-1. Due to these different 
positions, the Amide I line can be used for analysis of the protein attachment. The 
absorbance of Amide I line normalised on the line of polyurethane vibrations at 1100 
cm-1 as a stable intensive line is presented in Fig.5.3 according to PIII treatment time. 
The amount of attached BSA increases with PIII treatment time up to saturation level. 
The saturation level observed after 800 seconds of PIII treatment time is double than 
for the untreated polyurethane.  
 
The attachment of protein is provided due to interactions between the polyurethane 
macromolecules and the protein molecules on the surface. The interactions are based 
on physical forces (dispersic, polar and ionic) or/and can be based on chemical 
bonding if a reaction between the protein molecule and polyurethane macromolecule 
occurs. The contribution of the physical forces can be tested by washing the attached 
protein in strong detergent as this disturbs the physical forces. Such detergents used 
for washing chemicals including protein molecules are sodium dodecyl sulphate 
(SDS) and Tween 20. These detergents were successfully used for washing attached 
protein from many different surfaces. The detergent SDS was used for washing the 
attached BSA from the polyurethane surface.  
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Fig.5.3. FTIR ATR spectra absorbance of Amide I line of BSA attached to 
polyurethane of PPG-DI PTHF with 0.35 NCO/OH ratio with PIII treatment time: 
blue is attached BSA, red is BSA attached and then washed off in SDS 1 hour at 
700C. The absorbance of Amide I of protein was normalized on the absorbance of 
1100 cm-1 line related to vibrations in polyurethane.  
 
The experiment was done with the same samples of polyurethane after FTIR spectra 
recording. Both control and protein samples were washed in 45 ml of 2% SDS 
solution in mQ-water for 1 hour at 700C in individual Falcon polypropylene tubes 
which were placed into the water bath at controlled temperature. After washing in the 
detergent, all samples were rinsed in mQ-water 3 times, every time in new Falcon 
tubes and dried overnight in Petri dishes. Then the spectra of FTIR ATR were 
recorded. The spectra of buffer samples were subtracted from the spectra of protein 
samples as described above and presented in Fig.5.4. The absorbance of protein 
Amide I line was normalised on the absorbance of polyurethane 1100 cm-1 line and is 
presented in Fig.5.3.  
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Fig.5.4. FTIR ATR spectra of attached BSA and washed off in SDS detergent on 
untreated and PIII treated polyurethane of PPG-DI PTHF with 0.35 NCO/OH ratio. 
From bottom to top: (a) untreated polyurethane, (b) 40, (c) 80, (d) 200, (e) 400, (f) 
800 s PIII treatment time for 20 keV nitrogen ions. The spectra of corresponding 
polyurethanes are subtracted.  
 
The spectra of SDS washed samples show the Amide I line of the attached protein 
only for PIII treated polyurethane. The protein lines in the spectrum of untreated 
polyurethane are not observed, and are under the noise level of the spectrum. 
Therefore the protein was almost washed from the untreated polyurethane. It shows 
that the protein on untreated polyurethane attached due to physical forces was 
disturbed by the physical forces of the detergent’s molecules. Washing in detergent 
was sufficient to remove whole protein layers attached to the untreated surface due to 
physical forces.  
 
The amount of attached protein on PIII treated polyurethane after washing in 
detergent solution is lower than the amount of attached protein before the washing. 
However, a significant portion of the attached protein remains on the surface after 
washing despite the detergent’s physical forces. This shows that this protein is 
attached chemically to the surface. The ratio of attached to remained after detergent 
washing varies from 30% for 800 sec PIII treated sample to 95% for 400 sec PIII 
treated sample with average amount 63% for all PIII treated samples. This amount is 
consistent with previous amount of the covalently attached proteins on polyethylene 
[1], polystyrene [2], PTFE [3, 4], ePTFE [5], polyamide [6], polyethersulphone [7] 
and Polyether ester ketone [8] treated by PIII.  
 
The attachment of Fg protein on the polyurethane surface was done as described 
above for BSA protein with some variations. The polyurethane samples were 
incubated in the Fg protein solution on the same day of the PIII treatment because a 
monolayer of the Fg immobilised protein is thicker then the immobilised BSA protein 
due to higher molecular mass of Fg protein (~340 kD) then BSA protein (~66kD). 
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Therefore, the signal in FTIR ATR spectra is expected to be higher for Fg protein 
than for BSA, and the effect of different oxidation of the polyurethane sample after 
PIII treatment is less important for protein detection. In addition, the concentration of 
Fg protein was 20 µg/ml due to higher activity of the polyurethane surface freshly 
treated by PIII.  
 
The FTIR ATR spectra of Fg protein immobilised on the polyurethane surface are 
presented in Fig.5.5. The spectra of polyurethane was subtracted. The lines of protein 
backbone vibrations Amide A, I and II are clearly visible. The intensity of these lines 
is higher for Fg protein than for BSA protein (Fig.5.2), which corresponds to thicker 
Fg immobilised layer than BSA immobilised layer due to differences in size of the 
protein molecules.  
 
 
Fig.5.5. FTIR ATR spectra of attached Fibrinogen on untreated and PIII treated 
polyurethane of PPG-DI PTHF with 0.35 NCO/OH ratio. PIII treatment time for 20 
keV nitrogen ions is noted in secs. The spectra of corresponding polyurethanes were 
subtracted.  
 
The covalent immobilisation of Fg protein was analysed by FTIR ATR spectra after 
washing the polyurethane samples in SDS detergent. The washing conditions for Fg 
immobilised samples were the same as for BSA immobilised samples. The spectra of 
washed protein immobilised samples after subtraction of the polyurethane buffer 
samples spectra are presented in Fig.5.6. The lines of Amide A, I and II in the spectra 
of PIII treated samples are very clearly visible. In the spectra of untreated 
polyurethane these lines are observed at the noise level of the subtraction.  
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Fig.5.6. FTIR ATR spectra of attached Fibrinogen on untreated and PIII treated 
polyurethane of PPG-DI PTHF with 0.35 NCO/OH ratio and washed with SDS 
detergent. PIII treatment time for 20 keV nitrogen ions is noted in seconds. The 
spectra of corresponding polyurethanes are subtracted. 
 
The quantitative analysis of the immobilised protein was done on the absorbance of 
Amide I line. Other Amide A and II lines are overlapped with polyurethane lines and 
cannot be used for the analysis. The absorbance of protein Amide I line normalised on 
the absorbance of polyurethane 1100 cm-1 line and presented in Fig.5.7. The amount 
of Fg protein attached to the PIII treated samples was higher than that attached to the 
untreated polyurethane surface. The amount of attached protein depends slightly on 
PIII treatment time showing the maximal amount for 80 sec PIII treatment time. 
However, the difference between the time points is in a range of error bars.  
 
The amount of protein on PIII treated samples after SDS detergent washing is almost 
equal to the amount of attached protein. The difference between attached and 
remained after detergent washing is in the range of error bars. The average ratio of 
attached and remained protein for all PIII treated samples is ~95%. The ratio of 
remained protein after detergent washing on untreated polyurethane is about 26% 
from the attached protein amount, while the absorbance of the Amide I line is at the 
noise level and can be accepted as zero. 
 
It was proved that the Fg protein is attached physically on untreated polyurethane and 
this protein is almost completely washable with SDS detergent. The PIII treated 
surface of polyurethane attaches the Fg protein covalently.  
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Fig.5.7. FTIR ATR spectra absorbance of Amide I line of Fibrinogen attached to 
polyurethane of PPG-DI PTHF with 0.35 NCO/OH ratio with PIII treatment time: 
blue is attached Fibrinogen, red is Fibrinogen attached and then washed off in SDS 
for 1 hour at 700C. The absorbance of Amide I of protein was normalized on the 
absorbance of 1100 cm-1 line related to vibrations in polyurethane. 
 
The attachment of tropoelastin (TE) was detected by ELISA. The dependence of TE 
amount attached to untreated and PIII treated polyurethane is presented in Fig.5.8. An 
increase of TE concentration in the soaking solution increases the amount of attached 
TE up to saturation level. The saturation is achieved between 10 and 20 µg/ml 
concentration, consistent with the same dependence for other proteins attached on 
other polymers [9, 10]. The saturated level of attached TE is higher on PIII treated 
polyurethane then on untreated polyurethane. The concentration of TE higher then 10-
20 µg/ml does not increases the amount of attached TE under applied conditions of 
attachment (time, temperature and volume of solution).  
 
The strength of TE attachment was tested with washing in SDS detergent. ELISA 
shows that the attached TE on untreated polyurethane is washable with SDS 
detergent. The absorbance for untreated samples is lower then the detection level after 
washing of the samples in SDS solution (Fig.5.9). Under the same conditions, a part 
of the attached TE on PIII treated polyurethane remains on the surface.  
 
The amount of the covalently attached TE was analysed according to different PIII 
treatment times (Fig.5.10). The results show that after the 40 sec of PIII treatment 
time point the longer treatment time does not increase the amount of the covalently 
attached TE in a range of error bars. The attachment of TE was done 8 days after PIII 
treatment.  
 
0	
0.005	
0.01	
0.015	
0.02	
0	 200	 400	 600	 800	 1000	
Ab
so
rb
an
ce
,	a
.u
.	
PIII	treatment	9me,	sec	
A:ached	
SDS	washed	
 101 
 
Fig.5.8. Absorbance in ELISA test of tropoelastin protein attached on untreated (blue 
triangles) and PIII treated (red squares, N+ ions of 20 keV energy, 800 sec PIII 
treatment time) polyurethane in dependence on the tropoelastin solution concentration 
at soaking of polyurethane.  
 
 
Fig.5.9. ELISA test result of tropoelastin attached to untreated and PIII treated 
polyurethane (20 keV N+ ions during 200 sec of PIII treatment) before and after 
washing in SDS detergent. The washing was done with 5% SDS (w/v) at 95°C for 30 
min (black bars). The control samples results without tropoelastin are shown for 
comparison.  
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Fig.5.10. Ratio of covalently attached tropoelastin to total attached tropoelastin on 
polyurethane surface with time of PIII treatment by FTIR ATR data.  
 
As observed for BSA protein, the part of covalently attached TE is lower than 
observed for Fg protein. The dependence of the covalent attachment on storage time, 
after PIII treatment and before the polyurethane was soaked in the tropoelastin 
solution, shows that the largest amount of covalently attached molecules occurs 
straight after the PIII treatment and decreases with the storage time (Fig.5.11). 
However, after 30 days the activity of the polyurethane surface is sufficient to attach 
covalently 28% of the total attached protein.  
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Fig.5.11. Covalently attached tropoelastin amount ratio to total attached to 
polyurethane surface  with different time between PIII treatment and soaking in the 
tropoelastin solution. Polyurethane samples treated for 80 sec of PIII treatment time 
by nitrogen ions with 20 keV energy. Coating concentration was 10 µg/mL. SDS 
washing involved incubating in 5% SDS (w/v) at 950C for 30 min.  
 
Therefore, the polyurethane surface becomes active to attach protein covalently after 
PIII treatment and maintains its activity for a minimum of one month.  
 
 
5.2. Interaction of endothelial cells with implant  
 
Endothelialisation is an important factor of biocompatibility. A total 
endothelialisation a short time after first contact of the organism tissue with the 
implant surface is required for successful integration of the implant into the organism. 
The endothelialisation of the polyurethane implants was tested with human cell 
interactions with the polyurethane surface in vitro. The effect of PIII treatment on cell 
attachment, cell spreading and cell proliferation was investigated with human dermal 
fibroblasts (HDFs) and human endothelial cells (HCAECs).  
 
Polyurethane interacts with components of cell staining such as crystal violet and 
alcohol. This makes it difficult to get consistent results using such methods for the 
cell analysis.. In particular, the crystal violet assay diffuses into polyurethane and 
gives colour to the sample without the cells. A spectroscopic method gives false 
results of cell staining due to the strong variation of the background colour when the 
colour changes while there were no cells attached to the sample. To overcome these 
problems, the method of crystal violet staining was modified to exclude the colour 
change of the polyurethane samples due to assay diffusion into the polyurethane. The 
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staining time was reduced from 1 hour to 30 minutes and the washing time was 
increased from 3 short periods to 5 times for 30 minutes each. However, the 
quantitative results were not reliable. The crystal violet was washed out from 
polyurethane with the same speed as from cells.  
 
The cells experiments included a step of cell staining with organic solvents such as 
ethanol. The polyurethane was swollen in ethanol with a strong deformation of the 
polyurethane samples. This deformation put the surface attached cells under 
mechanical stress, which led to the cells detaching from the surface at staining. The 
result of the cell analysis was affected by the deformation of the polyurethane film. 
All known protocols of cell staining used in the laboratory required ethanol or other 
solvent application. In some cases, when the cells were visible without staining, the 
analysis was done with microscopy without staining. In other cases the results of the 
cell analysis was considered taking into account the effect of the solvent on cell 
staining.  
 
Due to the these problems with cell analysis on the polyurethane surface, the cell 
experiments were carried out with PTFE films treated by the same methods of ion 
beam implantation as a comparison. The experiments with cell adherence were started 
with PTFE films of 20 µm thickness which were treated by nitrogen ions of 20 keV 
energy.  
 
In the cells experiment, PTFE films of 0.58 cm2 surface area were used. The bovine 
aortic endothelial cell line GM7373 (Coriell) was used for the experiments. 4 x 104 
cells in 200 µL medium (MEM-Earle supplemented with 10% fetal bovine serum 
(FBS), 1 x MEM vitamins, 2 mM N-Acetyl L-Alanyl L-Glutamine, 1 x Amino acids) 
were seeded directly on the samples. They were allowed to adhere for 2 hours at 
standard cell culture growing conditions. The medium was then filled up to 1 mL per 
sample. Three days after seeding, the cells were fixed in 0.2% paraformaldehyde in 
PBS and stained with rhodamine. Images were taken by fluorescent microscopy with 
a video camera. The cells were counted by photos and cell density was averaged on 
10 photos taken randomly on the surface for each PTFE sample. The examples of the 
images are presented in Fig.5.12.  
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Fig.5.12. Fluorescent image of cells proliferated for 3 days on untreated (a) and ion 
implanted (b-d) PTFE with nitrogen ions of 20 keV energy and fluence of 6 x1013 (b), 
1x1014 (c) and 5x1014 (d) ions/cm2.  
 
The cells are sitting compactly on the untreated PTFE surface, and do not cover most 
of the surface. Cell bodies are rounded to minimise the contact with the surface. The 
images of the cells on ion beam treated surfaces are different. The cells are distributed 
on the PTFE surface. When there was a high fluence the cells formed a total cover on 
the surface and the cell density was mostly uniform on the overall surface. Here, the 
cell bodies were elongated and spread on the PTFE surface.  
 
Quantitative results showed that the cells adhere and grow on untreated and ion 
implanted PTFE surface from seeded density (0.7x105 cells/cm2). However the 
amount of cells on the ion implanted PTFE is higher than on untreated PTFE 
(Fig.5.13). The cells grew better on the PTFE treated surfaces with the lowest fluence. 
Similar results were expected on the PIII treated polyurethane.  
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Fig.5.13. Cell density attached on PTFE after 3 days of proliferation with fluence of 
ion beam implantation. The mark “*” corresponds to significant difference, p<0.05 
and “ns” to not significant difference, p>0.05.  
 
The human coronary artery endothelial cells (HCAEC) were attached to the untreated 
polyurethane samples, to the PIII treated with different fluence, and to the Tissue 
culture plastic (TCP) as a control. Before the cell attachment, some samples were 
coated with tropoelastin as described above. For the cell attachment, 0.5 ml aliquots 
of cells at a density of 1x105 cells/ml were added to the wells and placed at 370C in a 
5% CO2 incubator. The cells were proliferated for 2 days, and for 6 days, changing 
the media every second day. Then the cells were stained and observed with 
fluorescent microscopy.  
 
For staining, the cells were fixed in ice cold 80% Ethanol and washed with PBS 
buffer. Then the cells were permeabilized in 1% (w/v) Triton X-100 in PBS for 5 min, 
washed 3 times in 1 ml with PBS 5 mins each, then blocked with 1% (w/v) BSA for 
0.5 h. Cells were washed 3 times in 1 ml with PBS for 5 mins each. The cells were 
stained in Phalloidin-TRITC for 30 minutes in darkness. Samples were washed 3 
times in 1 ml with PBS, then mounted with DAPI between glass slides, sealed and 
viewed using a Zeiss LSM 510 Meta confocal microscope. The fluorescence exited at 
540-545 nm of light, and was observed at 570-573 nm for the cytoskeleton with actin-
filament, and at 350 nm and 470 nm respectively for cell nuclei.  
 
The selected images of the cells are presented in Fig.5.14-19. The low resolution 
images were used to analyse the cell density (Fig.5.14-17) and the high resolution 
images were used to analyse cell bodies (Fig.18-19).  
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TCP 
 
Untreated PU 
 
40 sec PIII treated PU  
 
80 sec PIII treated PU 
Fig.5.14. Fluorescent image of the cells adhered and proliferated in 2 days to 
polyurethane surface treated by PIII with different time. TCP control and untreated 
polyurethane samples are presented above.  
 
The images show that the cells were differently attached and proliferated on the 
untreated and PIII treated polyurethane surfaces without tropoelastin. After the 2 day 
period the cells on the untreated polyurethane were sitting in compact clusters. 
However, the cells on PIII treated polyurethane were spread as they were on the TCP 
control. The widest spread was observed when fluence was lowest, at 40 seconds of 
PIII treatment.  
 
After the 6 day period of proliferation, the surface of untreated polyurethane became 
totally covered by cells as they were on the TCP surface and the PIII treated 
polyurethane. 
 
It follows that the presence of tropoelastin coating increases the rate of 
endothelialisation and the proliferation leads to total coverage of the untreated 
polyurethane surface by the endothelial cells.  
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TCP 
 
Untreated PU 
 
40 sec PIII treated PU 
 
80 sec PIII treated PU 
Fig.5.15. Fluorescent image of the cells adhered and proliferated for 6 days on 
polyurethane surface treated by PIII for different times. TCP control and untreated 
polyurethane samples are presented above.  
  
 109 
 
 
TCP 
 
Untreated PU 
 
40 sec PIII treated PU 
 
80 sec PIII treated PU 
Fig.5.16. Fluorescent image of the cells adhered and proliferated for 2 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. 
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Untreated PU 
 
40 sec PIII treated PU 
 
80 sec PIII treated PU 
Fig.5.17. Fluorescent image of the cells adhered and proliferated for 6 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. 
 
The high resolution images (Fig.5.18-19) showed that the cell cytoskeletons were 
spread differently on the untreated and PIII treated polyurethanes. After 2 days of 
proliferation the cell bodies on the untreated polyurethane were rounded. The cells 
were sitting compactly to minimise contact with the untreated polyurethane surface. 
The cell bodies on the PIII treated polyurethane were elongated and spread on the 
surface.  
 
After 6 days of proliferation the cell cytoskeletons were similarly spread on untreated 
and PIII treated polyurethanes. No difference was observed between the cells 
proliferated on TCP control surface and polyurethane.  
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Fig.5.18. Fluorescent images of the cells adhered and proliferated for 2 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. Images on the 
left correspond to the cell nuclei staining. Images on the right correspond to the cell 
cytoskeleton staining. Image size is 0.68x0.5 mm2.  
 
TCP 
  
Untreated PU 
  
40 sec PIII treated PU 
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80 sec PIII treated PU 
  
Fig.5.19. Fluorescent images of the cells adhered and proliferated for 6 days on 
polyurethane surface treated by PIII for different times and with tropoelastin coating. 
TCP control and untreated polyurethane samples are presented above. Image size is 
0.68x0.5 mm2.  
 
The cells on high fluence PIII treated polyurethane were analysed without staining. 
The images are shown in Fig.5.20. The cells totally covered the 40 sec and 800 sec 
PIII treated polyurethane surface as they did on the control TCP surface. The cells 
were spread and cell bodies were elongated, providing a broad contact with the 
surface. The cells on the untreated polyurethane did not cover the whole surface and 
the cell bodies were compact and rounded, which minimised the contact with the 
surface. These results correspond to the staining results in Fig.5.14-5-19. Therefore, 
the high fluence PIII treatment does not improve the cell adherence when compared 
with low fluence PIII treatment.  
 
TCP plate 
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Untreated PU 
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0.68x0.5 mm2 image 
 
0.68x0.5 mm2 image 
40 sec PIII treated PU 
 
0.68x0.5 mm2 image 
 
0.68x0.5 mm2 image 
 
 
800 sec PIII treated PU 
 
1.37x1.04 mm2 image 
 
0.68x0.5 mm2 image 
Fig.5.20. Optical microscope image of the living cells attached to polyurethane 
surface treated by PIII for different times. No fixing or staining was applied.  
 
The cell density after the 2 and 6 day periods of proliferation on TCP, untreated and 
PIII treatment polyurethanes are shown in Fig.5.21 and Fig.5.22. The cell density 
after the 2 day period of proliferation on the control TCP surface and PIII treated 
polyurethane without tropoelastin cover was similar. The cell density on the untreated 
polyurethane was significantly less than on TCP and PIII treated polyurethane. The 
 115 
attachment of tropoelastin on the untreated and PIII treated polyurethane provided the 
same cell density as on the control TCP surface.  
 
The cell densities after the 6 day period of proliferation on the control TCP, untreated 
polyurethane and PIII treated polyurethane with and without the tropoelastin cover 
were similar.  
 
 
Fig.5.21. Number of cells on TCP and PU with and without tropoelastin after 2 days 
of attachment. The difference is significant (***), p<0.001 and not significant (ns), 
p>0.05.  
 
 
Fig.5.22. Number of cells on TCP and PU with and without tropoelastin after 6 days 
of attachment. The difference is insignificant, p>0.05.  
 
The cell adherence and proliferation showed that the PIII treatment provided higher 
cell density and cell spreading on polyurethane as on the control TCP surface. The 
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tropoelastin cover provided faster endothelialisation on the untreated polyurethane 
while the PIII treated polyurethane provided the same endothelialisation with and 
without tropoelastin. The influence of PIII fluence on endothelialisation of PIII 
treated polyurethane surface with and without tropoelastin cover was not observed in 
the investigated range of the fluence.  
 
5.3. Discussion 
Three different proteins were attached on the polyurethane surface. The amount of 
attached protein was measured with FTIR ATR spectra and ELISA assay methods. 
All proteins were well attached on untreated and PIII treated surfaces. The BSA and 
tropoelastin were better attached than Fibrinogen on untreated polyurethane. The 
protein attachment on untreated polyurethane corresponded to the theoretical data of 
protein attachment on hydrophobic surfaces when the attachment is strong due to non-
polar van-der-Waals intermolecular interactions between the protein molecule and 
polyurethane macromolecule [11-13].  
 
In contrast with untreated polyurethane surfaces, all tested proteins were well attached 
on PIII treated polyurethane. The amount of attached proteins on PIII treated 
polyurethane is twice or more than the amount of attached proteins on untreated 
polyurethane. The same difference was observed for untreated and PIII treated Teflon 
[14, 15], polyethylene [9], polystyrene [2] and other polyurethanes [16-18].  
 
The covalently attached protein was measured after washing in SDS detergent. The 
SDS detergent is widely known as a strong destroyer of physical interactions between 
the surface and protein molecules [19]. SDS destroys all van-der-Waals and Coulomb 
interactions due to both hydrophilic and hydrophobic end groups in SDS molecule. 
However, the covalent attachment via C-C and C-N bonds between the protein and 
surface cannot be destroyed by SDS detergent. The amount of protein remaining on 
the PIII treated polyurethane surface after strong washing in the SDS detergent shows 
that 40-70% of attached protein from the total attached amount was covalently 
bounded. For some samples, the 100% covalent attachment was observed. Similar 
covalent attachment was observed for PIII treated Teflon [14, 15], polyethylene [9], 
polystyrene [2] and other polyurethanes [16-18]. Thus, the PIII treated polyurethane 
surface adsorbs the proteins covalently.  
 
The mechanism of covalent attachment as discovered in [15] is based on free radical 
reaction between the free radicals on the edge of the graphitic clusters and hydrogen-
donating groups of protein. As a result of the reaction, the covalent bond C-C or C-N 
was formed and provided the stable attachment of protein to the surface. This 
mechanism of covalent attachment was observed for different polymers and proteins 
[20]. The PIII treated polyurethane contained similar graphitic clusters in the surface 
layer as these polymers. Therefore the formation of similar covalent bonds between 
the PIII treated polyurethane and attached proteins was expected. The dependence of 
the protein amount on PIII treatment time was not strong. The saturation of attached 
protein amount was observed for all proteins after short (40 or 80 sec) PIII treatment. 
The same saturation of the protein amount was observed for other PIII treated 
polymers [20]. The similar conditions of attachment, similar properties of the surface 
layer, similar dependence on PIII treatment parameters and similar amount of the 
covalently attached protein were evidence of the same covalent attachment 
mechanism.  
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The conformation of protein was not tested in the present study. The conformation of 
protein can be measured with FTIR spectra of Amide I line with analysis of α-helix, 
β-sheets, β-turns and random coils components but analysis of the strong overlapping 
protein and polyurethane Amide I lines does not provide useful information. 
However, the similar mechanism of covalent attachment of protein suggested that the 
conformation of the attached proteins to PIII treated polyurethane was expected to be 
active as observed in the attached protein to PIII treated polyethylene, polystyrene, 
Teflon and other polymers [20]. The high wettability of the PIII treated polyurethane 
supported this. Therefore, the research shows that the protein on PIII treated 
polyurethane attaches covalently on the mechanism of free radical reaction and its 
conformation is active.  
 
The activity of the carbon surface layer usually remains for a long time. For example, 
PIII treated Teflon attaches protein covalently after 2 years of storage [20]. The PIII 
treated polyurethane shows its highest activity straight after PIII treatment, and a 
reduction of activity from 55% of covalent attachment after 1 day of storage up to 
27% of covalent attachment after 1 month of the storage. Therefore, the polyurethane 
has to be used for the protein attachment as soon as possible after the PIII treatment.  
 
The experiments with cells showed that Human dermal fibroblasts and human 
endothelial cells are attached and successfully proliferated at 6 days on newly 
synthesised polyurethane. The cells are well spread on the surface however the cell 
number is significantly less than on the “gold standard” TCP plastic. Also the cell 
bodies are characterised with minimal contact cell area indicating insufficient 
adhesion of the cell proteins on the surface. However, after 6 days of proliferation, the 
cell number on untreated polyurethane become similar to the TCP plastic. This effect 
of cell attachment and growing on the untreated polyurethane is significantly better 
than on other untreated medical grade polymers [4, 21].  
 
The cell attachment and proliferation on PIII treated polyurethane is similar to the cell 
attachment and proliferation on TCP plastic. These results are similar to other PIII 
treated polymers [4, 21].  
 
The preliminary attachment of tropoelastin does not improve the cell attachment on 
PIII treated surface. Only in the case of untreated polyurethane does the preliminary 
attachment of tropoelastin improve the cell attachment at the beginning (in 2 days).  
 
Thus, the cell experiments showed that the PIII treatment improves the cell 
attachment and proliferation on the polyurethane surface. Therefore, the positive 
influence of PIII treatment on protein attachment and cell attachment and proliferation 
shows that the PIII treated surface is not toxic, as might be expected due to the 
presence of free radicals in the carbonised layer. The proteins from the cells 
themselves are attached to the PIII treated surface and then the cells are attached to 
their own protein layer. Therefore the protein that was attached to the PIII treated 
surface first before the cells’ attachment does not help much in the cell attachment. 
The preliminary attachment of the proteins from the cells themselves is preferable to 
that of other proteins (for example, tropoelastin) because of the reduced likelihood of 
a foreign body reaction. 
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The results show that the PIII treatment provides the covalent attachment of protein 
and improves the cell attachment and proliferation on the PIII treated polyurethane 
surface. These in vitro results show that PIII treated polyurethane can be used for in 
vivo experiments where a positive effect of PIII treatment on biocompatibility in 
living organisms is expected.  
 
 
5.4. Conclusions 
The in vitro experiments showed that PIII treatment provides a covalent attachment of 
proteins to the modified polyurethane implant. This makes the attached protein 
coverage non-washable from the surface. The protein amount corresponds to the total 
protein coverage of the surface. However, the ability of the polyurethane surface to 
attach the proteins covalently decreases with the storage time after the PIII treatment.  
 
The PIII treated polyurethane provides faster cell adherence and proliferation in 
comparison with the untreated polyurethane. The cell attachment on PIII treated 
polyurethane is the same as on the control TCP surface. For PIII treated implants, the 
pre-coating of the surface with tropoelastin does not improve the cell attachment and 
proliferation.  
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Chapter 6. In vivo biocompatibility of 
PIII modified polyurethanes implants 
 
 
 
The in vitro experiments using the newly synthesised polyurethane implants treated 
with PIII produced results which provide an opportunity to predict a positive response 
from an organism. This Chapter presents the next step of the biocompatibility 
analysis: in vivo evaluation of the polyurethane implants. The polyurethane implant 
treated by PIII has been tested in animal experiments. Polyurethane films and tubes 
were implanted in mice and rats, and an analysis of animal reaction, tissue reactions 
and PIII treated and untreated implants were made and compared.  
 
 
6.1. Mice surgery  
 
The reaction of an organism on PIII treated polyurethanes films was observed in the 
experiment with mice. This experiment has been approved by the University of 
Sydney Animal Ethics Committee (protocol number K20/12-2011/3/5634) and 
conducted in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purpose. The polyurethane samples of PPG-DI-PEG and PPG-
DI-PTHE with 0.35, 0.5 and 0.7 ratio of NCO/OH groups with and without PIII 
treatment were implanted in 15 mice. The size of the implants was 3.5 mm diameter 
with 0.3 mm thickness, which was estimated from the highest allowed weight for the 
artificial implant per weight of the average human body. The polyurethane samples 
were treated with PIII on the day prior to implantation.  
 
The samples were dipped into 70% solution of ethanol and air-dried prior to insertion. 
The mice were rapidly induced with good muscle relaxation. No bleeding was 
observed at the cuts. Polyurethane samples were implanted subcutaneously. All mice 
rapidly recovered after the operation.  
 
The ratio of each implant weight (5.5 mg) to mouse weight (20 g) corresponded to 
275 mg of implant per kg of animal. This value is high and could potentially disturb 
physiological processes in the organism. The mice recovered completely 1 day after 
the operation as is usually observed for mice after surgery. For the following 7 days, a 
clinical signs was monitored daily in the mice. No obvious abnormality was observed 
in these mice with surgery. Dynamic activity was normal. Coordination was normal. 
Body weight didn’t change. Breathing was normal. No change of coat or skin was 
observed. Eating and drinking was usual. Urine and faeces were normal. 
Communications between mice were normal, but mice did not show any interest in 
their scars. When palpated or touched no squeaking was observed. Therefore, no sign 
of the general physiological processes disturbance in a whole organism was observed.  
 
Detailed histological and immunochemical analysis of the tissue near the implants are 
further presented in this chapter.  
 
6.2. Rat surgery  
 121 
 
The newly synthesised polyurethane is very soft and different from materials used for 
implants. The handling of very soft polyurethane required extremely gentle 
manipulation during surgery as the graft collapsed easily when pressed with tweezers. 
The polyurethane graft stuck very well to the vessel wall at first touch. This made it 
easy to fix the graft on the vessel, but the position of the graft had to be precise at the 
first contact with the vessel wall.  
 
A polyurethane graft of 2 mm diameter and 5 mm length was implanted in a rat. The 
experiment has been approved by Sydney Local Heath District Animal Welfare 
Committee (protocol number 2014/028). For the implantation, a 5 mm segment of 
abdominal aorta was sectioned and the polyurethane graft was inserted and sewed 
with Nylon sutures. The operation was done using the operative microscope. Before 
the operation the heparin was administered intravenously before proximal and distal 
clamping below the renal arteries and above the aortoiliac bifurcation. The image of 
the polyurethane graft sewed with the aorta is shown in Fig.6.1.  
 
After the insertion, the blood flow was re-established. The haemostasis was checked. 
After the operation no post-operative coagulators were applied. The rat was 
monitored for 7 days after the operation. No abnormal activity was observed.  
 
 
Fig.6.1. Polyurethane graft sewed with aorta in rat.  
 
 
6.3. Tissue analysis and capsule thickness near the implant in mice  
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The histological images of the sections stained with Milligan’ trichrome show that a 
collagen capsule is formed around all samples of the polyurethane implants (Fig.6.2). 
The polyurethane implants were removed at the microtome cutting due to very elastic 
polyurethane properties in comparison with the surrounding tissues. In all the images, 
the polyurethane was in the centre of the empty ovals. In some cases, the residuals of 
the polyurethane implants remained in the sections and stained slightly. The capsule 
continuously covers the implants, isolating the implant from the tissue. The observed 
ruptures in some capsules are due to the microtome cutting as shown by the character 
of the ruptures. The capsule for untreated polyurethane implants had more intensive 
colouring and was broader than for PIII modified implants. However, the capsule 
thickness appeared to be independent of what surrounded the implants, whether 
muscle or connectivity tissues.  
 
 
Untreated, PPG-DI-PEG-0.35 
 
Untreated, PPG-DI-PEG-0.7 
 
Untreated, PPG-DI-PTHF-0.35 
 
Untreated, PPG-DI-PTHF-0.7 
 
40s PIII treated, PPG-DI-PTHF-0.35 
 
80s PIII treated, PPG-DI-PTHF-0.35 
Implant	
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400s PIII treated, PPG-DI-PTHF-0.35 
 
800s PIII treated, PPG-DI-PTHF-0.35 
Fig.6.2. Images of the histological samples of polyurethanes stained in Milligan. 
Objective x4. The implant position was in the centre of the ovals. For example, the 
position of the implant in PPG-DI-PEG-0.7 sample is marked as “Implant”. Usually, 
the polyurethane sample was removed at the microtome cutting, but sometimes the 
small pieces of the polyurethane samples remain.  
 
The thickness of the capsule was analyzed quantitatively using the high resolution 
images of the tissue near the implants. The representative examples of the section 
stained with Milligan’ trichrome in high resolution for polyurethane implants with 
different PIII treatment times are presented in Fig.6.3-6.8.  
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(a) mouse 12, bag 1, section 4 
 
(b) mouse 12, bag 2, section 6 
 
(c) mouse 12, bag 3, section 8 
 
(d) mouse 12, bag 4, section 11 
 
(e) mouse 12, bag 5, section 18  
 
(f) mouse 12, bag 6, section 08 
Fig.6.3. Microphotographs of the histological tissue samples stained in Milligan for 
untreated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures is the 
implant position.  
 
The collagen shell stained Milligan’s trichrome was well developed in the tissue 
surrounding the untreated polyurethane implants (Fig.6.3). The collagen fibres were 
structured and directed parallel to the implant surface on a distance of 40-60 µm. This 
part of the shell was characterised by dense collagen structure. The collagen fibres 
were disordered at a distance of 60-120 µm from the implant surface. This part of the 
shell was less dense but denser than the collagen and elastin fibre structures in the 
normal tissue. In some samples (examples are at Fig.6.3 b and e) the very dense 
collagen structure was observed in the first approximately 10 µm layer from the 
implant surface.  
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(a) mouse 22, bag 4, section 19 
 
(b) mouse 23, bag 4, section 14 
 
(c) mouse 24, bag 4, section 20 
 
(d) mouse 25, bag 4, section 2 
Fig.6.4. Microphotographs of the histological tissue samples stained in Milligan for 
40 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position.  
 
 
(a) mouse 31, bag 1, section 9 
 
(b) mouse 31, bag 2, section 15 
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(c) mouse 32, bag 1, section 7 (d) mouse 32, bag 2, section 2 
 
(e) mouse 33, bag 1, section 10 
 
(f) mouse 34, bag 1, section 6 
 
(g) mouse 34, bag 2, section 6 
 
(h) mouse 35, bag 1, section 2 
 
(i) mouse 35, bag 2, section 2 
 
Fig.6.5. Microphotographs of the histological tissue samples stained in Milligan for 
80 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position.  
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(a) mouse 22, bag 6, section 15 
 
(b) mouse 23, bag 6, section 27 
 
(c), mouse 24, bag 6, section 6 
 
(d) mouse 25, bag 6, section 3 
Fig.6.6. Microphotographs of the histological tissue samples stained in Milligan for 
200 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position.   
 
The short PIII treatment time (40 seconds) of the polyurethane implant changed the 
collagen shell in the organism (Fig.6.4). The dense collagen shell was not observed. 
The collagen shell near the implant surface was not developed and the collagen fibres 
were not directed but were disordered and rare. The whole collagen shell was thinner 
than for the untreated polyurethane implant.  
 
The 80 second PIII treated polyurethane implant changed the collagen further 
(Fig.6.5). The shell was thinner and for some samples the shell was observed in 1-2 
cell layers between the implant surface and the muscle cells (Fig.6.5 d as an example). 
In some samples the dense collagen shell was observed in the thin surface layer (up to 
about 10 µm), which is in closest contact with the implant (for example, Fig.6.5 e and 
i). All these difference in the collagen shell were observed in different animals and are 
not attributed to a specific immune reaction of one mouse.  
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(a) mouse 31, bag 3, section 16 
 
(b) mouse 31, bag 4, section 6 
 
(c) mouse 32, bag 3, section 20 
 
(d) mouse 32, bag 4, section 19 
 
(e) mouse 33, bag 3, section 11 
 
(f) mouse 33, bag 4, section 6 
 
(g) mouse 34, bag 3, section 18 
 
(h) mouse 34, bag 4, section 5 
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(i) mouse 35, bag 3, section 32 
 
(j) mouse 35, bag 4, section 39 
Fig.6.7. Microphotographs of the histological tissue samples stained in Milligan for 
400 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position.  
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(a) mouse 31, bag 5, section 7 
 
(b) mouse 31, bag 6, section 20 
 
(c) mouse 32, bag 5, section 1 
 
(d) mouse 33, bag 5, section 9 
 
(e) mouse 33, bag 6, section 5 
 
(f) mouse 34, bag 5, section 36 
 
(g) mouse 34, bag 6, section 24 
 
(h) mouse 35, bag 5, section 4 
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(i) mouse 35, bag 6, section 10 
 
Fig.6.8. Microphotographs of the histological tissue samples stained in Milligan for 
800 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on the figures 
is the implant position.  
 
When PIII treatment time was increased up to 800 seconds, the collagen shell did not 
change significantly. In some samples the shell was very thin, up to 1-2 cells layer 
between the implant and other tissues such as muscle cells (Fig.6.6 c, Fig.6.7 b and 
Fig.6.8 g). In some samples the collagen shell was not observed at all (Fig.6.7 c, e, f, 
g, Fig.6.8 e). In some samples the dense thin layer of the collagen shell was observed 
(Fig.6.6 c and d, Fig.6.7 d, i and j, and Fig.6.8 a, c and h). Unlike the shell for the 
untreated polyurethane implants, the shell was thinner and rare for all these PIII 
treated samples. These changes were observed for all animals. The differences 
between the tissues in different animals were smaller than between the treated and 
untreated tissue samples.  
 
The average thickness of the collagen shell was calculated and is presented in Fig.6.9. 
The staining of all the slides was done in one day, the microphotographs were done in 
one microscope in one day with adjusted intensity and optical elements of the 
microscope, and the analysis of the images was done for all microphotographs 
simultaneously. This allowed the results between the different samples in the whole 
batch to be compared quantitatively.  
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Fig.6.9. Thickness of the collagen capsule near the polyurethane implant treated by 
PIII with different treatment time. “Ini” means the untreated (initial) samples.  
 
The results show that the thickness of the collagen capsule was significantly less for 
the PIII treated polyurethane implants (41 µm) than for untreated implants (102 µm) 
(p<0.001). The significant decrease in the thickness from 102 µm to 46 µm was 
observed after a short 40 second PIII treatment time (p<0.01). This difference 
between the untreated and PIII treated samples increases with the PIII treatment time.  
 
The microphotographs of H&E stained tissue are shown in Fig. 6.10-6.15. The tissue 
near the untreated polyurethane implant contains macrophages, monocytes and 
fibroblasts (Fig.6.10). Multi-nuclear foreign body giant cells were not observed. The 
macrophages and monocytes were mostly distributed near the surface of the implant 
in the capsule. Their concentration was highest in the capsule near the implant 
surface. The fibroblasts were positioned mostly on a distance from the implant 
surface, where the collagen fibres dominate. There was no cell lysis or necrosis.  
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Fig. 6.10. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the untreated PPG-DI-PTHF-0.35 polyurethane implants. An 
empty space on the figures is the implant position.  
 
The tissue near the 40 second PIII treated implant is less disturbed (Fig.6.11). Most 
cells in the capsule are fibroblasts and few cells were found in some spots like 
macrophages and monocytes (marked with arrows). The macrophages and monocytes 
were predominantly in the contact zone of the implant surface. In some images it is 
clear that the spots with macrophages and monocytes are distributed along the implant 
surface at the same periodicity as the cracks and waves of the polyurethane surface 
mentioned in Chapter 4. Similar cell distribution was observed for other PIII treated 
samples (Fig.6.12-6.15). Similar capsule images were observed in cases when the 
modified implant was in contact with the connective tissue or muscle tissue or 
adipocytes cells.  
 
 
Fig.6.11. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 40 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows.  
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Fig.6.12. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 80 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows.  
 
 
 
Fig.6.13. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 200 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows.  
 
In some places where the tissue contacted the modified implant the capsule was not 
observed at all. The cells, which were in contact with the implant surface, were 
fibroblasts or the connective tissue fibres (Fig.6.15).  
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Fig. 6.14. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 400 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the top figure is the implant position. Positions of 
macrophages are shown with arrows.  
 
 
 
Fig.6.15. Microphotographs of the histological tissue samples stained in 
Hematoxylin-Eosin for the 800 sec PIII treated PPG-DI-PTHF-0.35 polyurethane 
implants. An empty space on the figures is the implant position. Positions of 
macrophages are shown with arrows.  
 
 
 
6.4. Macrophages infiltration in the tissue 
 
The staining with F4-80 antibody showed a presence of macrophages in the tissue 
surrounding the polyurethane implants (Fig.6.16). The high macrophages activity was 
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observed in the collagen capsule near the surface of the untreated polyurethane 
implant (Fig.6.16 a).  
 
 
(a) untreated polyurethane, mouse 12, 
bag 5, section 9 
 
(b) 40s PIII treated polyurethane, mouse 
24, bag 4, section 5 
 
(c) 80s PIII treated polyurethane, mouse 
32, bag 1, section 9 
 
(d) 200s PIII treated polyurethane, mouse 
23, bag 6, section 15 
 
(e) 400s PIII treated polyurethane, mouse 
33, bag 3, section 10 
 
(f) 800s PIII treated polyurethane, mouse 
35, bag 6, section 1 
 
Fig.6.16. Microphotographs of the histological tissue samples stained in F4-80 
antibody for the PPG-DI-PTHF-0.35 polyurethane implants. An empty space on the 
figures is the implant position.  
 
The rest of the tissue outside of the collagen capsule showed low macrophages 
activity. The low macrophages activity was observed in the tissue surrounding the 
PIII treated implant (Fig.6.16 b-e) treated between 40 and 400 seconds of PIII 
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treatment time. For some samples (Fig.6.16 d) macrophages activity near the implant 
surface was not observed. The activity of macrophages in the tissue surrounding the 
800 second PIII treated implant was high when the distance from the implant was 
greatest. 
 
The integral area of the tissue with brown colour and the integral intensity of the 
colour was analysed to estimate the macrophages activity in the tissue. The results of 
activity macrophages dependence on the PIII treatment time is presented in Fig.6.17 
and Fig.6.18. The highest macrophages activity was observed in the tissue 
surrounding the untreated polyurethane implant and 800 second PIII treated sample. 
The lowest macrophages activity was observed for 200 second PIII treated implants. 
The difference between the untreated and 200 second PIII treated samples is 
significant (p<0.001).  
 
 
Fig.6.17. Relative area of the tissue stained by F4-80 antibody near the PIII treated 
polyurethane implants with time of PIII treatment (s). “0” means the untreated (initial) 
samples. 
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Fig.6.18. Relative staining density of the tissue stained by F4-80 antibody near the 
PIII treated polyurethane implants with time of PIII treatment (s). “0” means the 
untreated (initial) samples. 
 
 
6.5. Cell proliferation in the tissue 
 
The Ki-67 antibody was used for detection of the cell proliferation activity in the 
tissue surrounding the polyurethane implants. The example of characteristic images 
for untreated and PIII treated implants with different PIII treatment time are presented 
in Figs.6.19-6.24. The colour distribution and intensity shows a high cell proliferation 
activity in the tissue near the untreated polyurethane implants. The maximum activity 
is observed in the collagen capsule and the activity gradually decreases with the 
distance from the implant, see for example Figs 6.19 a and b). The activity was also 
observed in newly formed vessels a bit further away from the capsule (Fig.6.19 d).  
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(a) mouse 12, bag 2, section 14 
 
(b) mouse 12, bag 4, section 46  
 
(c) mouse 12, bag 6, section 74 
 
(d) mouse 14, bag 3, section 111 
 
(e) mouse 14, bag 4, section 120  
 
(f) mouse 14, bag 6, section 143  
Fig.6.19. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for untreated polyurethane PPG-DI-PTHF-0.35. An empty space on the 
figures is the implant position.  
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(a) mouse 23, bag 4, section 152  
 
(b) mouse 24, bag 4, section 166  
 
(c) mouse 25, bag 4, section 176  
 
(d) mouse 25, bag 4, section 187  
Fig.6.20. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 40s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position.  
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(a) mouse 32, bag 2, section 281  
 
(b) mouse 33, bag 1, section 286  
 
(c) mouse 35, bag 1, section 349 
 
(d) mouse 35, bag 2, section 357  
Fig.6.21. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 80s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position.  
 
The lowest cell proliferation activity was found in 40 second PIII treated implants 
(Fig.6.20). In some samples the activity was observed only in a thin surface layer 
corresponding to the capsule thickness. Most intensive activity was observed in fields 
of new vessel formation. With increases in the PIII treatment time the cell 
proliferation activity decreased (Fig.6.21-6.24). From 200 sec PIII treatment time, the 
cell proliferation activity was almost not observed in the capsule although it was 
spread throughout the entire tissue sample (Fig.6.22). The lowest cell proliferation 
activity was observed in the tissue surrounding the 800 second PIII treated 
polyurethane implant as separate cells, as for normal tissue (Fig.6.24).  
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(a) mouse 22, bag 6, section 195  
 
(b) mouse 23, bag 6, section 216  
 
(c) mouse 24, bag 6, section 224  
 
(d) mouse 25, bag 6, section 235  
Fig.6.22. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 200s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position.  
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(a) mouse 31, bag 3, section 376  
 
(b) mouse 32, bag 4, section 408  
 
(c) mouse 34, bag 3, section 435  
 
(d) mouse 34, bag 4, section 452  
Fig.6.23. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 400s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position.  
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(a) mouse 31, bag 5, section 493  
 
(b) mouse 33, bag 5, section 547  
 
(c) mouse 34, bag 6, section 589  
 
(d) mouse 35, bag 5, section 593  
Fig.6.24. Microphotographs of the histological tissue samples stained in Ki-67 
antibody for 800s PIII treated polyurethane PPG-DI-PTHF-0.35. An empty space on 
the figures is the implant position.  
 
For a quantitative analysis of the cell proliferation activity the colour area and density 
of the Ki-67 staining was analysed and is presented in Fig.6.25-Fig.6.26. The activity 
decreases with PIII treatment time and gets a minimal value at 400 seconds of the 
treatment time (p<0.001). This trend was observed in the area and the density of 
stained cells.  
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Fig.6.25. Relative area of the tissue stained by Ki-67 antibody near the PIII treated 
polyurethane implants with time of PIII treatment (s). “0” means the untreated (initial) 
samples. 
 
 
Fig.6.26. Relative staining density of the tissue stained by Ki-67 antibody near the 
PIII treated polyurethane implants with time of PIII treatment (s). “0” means the 
untreated (initial) samples. 
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6.6. Von Willebrand Factor activity in the tissue 
 
Von Willebrand Factor (vWF) as a proinflammatory protein and a key player in 
hemostasis was analysed in the tissue surrounding the polyurethane implants. The 
microphotographs of the tissue stained in the vWF antibody are presented in Figs. 
6.27-6.32.  
 
 
(a) mouse 12, bag 3, section 12 
 
(b) mouse 12, bag 4, section 17  
 
(c) mouse 12, bag 5, section 10  
 
(d) mouse 12, bag 6, section 10  
 
(e) mouse 12, bag 6, section 11   (f) mouse 12, bag 1, section 7  
Fig.6.27. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for untreated polyurethane PPG-DI-PTHF-0.35. An empty space 
on the figures is the implant position.  
 
The tissues near the untreated polyurethane implants accumulated a large amount of 
the vWF (Fig.6.27). Some samples show the highest concentration of the vWF in the 
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capsule (Figs.6.27 d and e), but some samples show a distribution of the vWF in the 
whole tissue far from the capsule (Figs.6.27 a, c and f). The vWF high amount was 
also observed in the new vessels (Figs.6.27 c, e and f). 
 
 
(a) mouse 23, bag 4, section 3  
 
(b) mouse 24, bag 4, section 10 
 
(c) mouse 25, bag 4, section 11 
 
(d) mouse 25, bag 4, section 12 
Fig.6.28. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 40 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty 
space on the figures is the implant position. 
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(a) mouse 31, bag 1, section 3 
 
(b) mouse 31, bag 1, section 19 
 
(c) mouse 32, bag 2, section 19 
 
(d) mouse 33, bag 1, section 12 
 
(e) mouse 34, bag 2, section 120 
 
(f) mouse 35, bag 2, section 263 
Fig.6.29. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 80 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An empty 
space on the figures is the implant position.  
 
A similarly high amount of vWF was observed in some samples of the tissue near the 
40 second PIII treated implants (Fig.6.28 a and b). In other samples the vWF was 
concentrated in spots outside the capsule (Fig.6.28 c and d). However, in all samples 
the vWF was not concentrated in the capsule as observed for the untreated 
polyurethane implants.  
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(a) mouse 22, bag 6, section 7 
 
(b) mouse 23, bag 6, section 27 
 
(c) mouse 24, bag 6, section 3  (d) mouse 25, bag 6, section 10 
Fig.6.30. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 200 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position.  
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(a) mouse 31, bag 3, section 6 
 
(b) mouse 32, bag 3, section 13 
 
(c) mouse 33, bag 3, section 7 
 
(d) mouse 34, bag 3, section 159 
 
(e) mouse 35, bag 3, section 275  (f) mouse 35, bag 3, section 276 
Fig.6.31. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 400 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position.  
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(a) mouse 31, bag 5, section 3 
 
(b) mouse 31, bag 6, section 18 
 
(c) mouse 32, bag 5, section 18  (d) mouse 33, bag 5, section 48 
 
(e) mouse 33, bag 5, section 52 
 
(f) mouse 34, bag 6, section 205 
 
(g) mouse 35, bag 6, section 357  (h) mouse 35, bag 6, section 361 
Fig.6.32. Microphotographs of the histological tissue samples stained in von 
Willebrand Factor for 800 sec PIII treated polyurethane PPG-DI-PTHF-0.35. An 
empty space on the figures is the implant position.  
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Much lower amount vWF was observed in the tissue surrounding the 80 second PIII 
treated polyurethane implants (Fig.6.29). There were some spots observed in the new 
cross-sectioned vessels (Fig.6.29 a, b and f) and in the along-sectioned vessels 
(Fig.6.29 d). In some samples, the coloured area was not observed at all (Fig.6.29 e). 
In all these samples the capsule did not contain vWF.  
 
The stained tissues surrounding the polyurethane implants with 200 seconds, 400 
seconds and 800 seconds of PIII treatment time were similar and showed very low 
amounts of vWF (Fig.6.30-6.32). The vWF spots were visible in areas where new 
vessels were formed (Fig.6.30 b, Fig.6.31 a, e, f, and Fig.6.32 a, c, h). However, in 
some samples a high amount of vWF was observed in a very thin layer of the tissue 
(1-2 cells layer), which was in contact with the polyurethane implant (Fig.6.30 d, 
Fig.6.31 c and Fig.6.32 b, e). This layer was much thinner than the capsule for these 
samples. In all other samples the capsule did not contain vWF.  
 
For quantitative measurements the area of vWF stained tissue was calculated 
(Fig.6.33). The measurements show that the tissue near the implants of 80-800 s range 
of PIII treatment time has a significantly lower area of vWF than the tissue 
surrounding the untreated and 40 s PIII treated implants (p<0.001). The difference 
between the tissues near the PIII treated implants in 80 second - 800 second range was 
not significant (p>0.05).  
 
 
 
Fig.6.33. Result of von Willebrand Factor staining analysis of the tissue near the PIII 
treated polyurethane implants with time of PIII treatment. “0” means the untreated 
(initial) samples. 
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6.7. Discussion 
 
The newly synthesised untreated polyurethane implant shows a minor foreign body 
reaction with formation of the capsule filled with macrophages and fibroblasts. The 
giant cells or necrosis were not observed in any samples. The thickness of the capsule 
of 100 µm surrounding the implant corresponded to the literature data for 
biocompatible implants used in medical practice [1-2]. Therefore, the newly 
synthesised untreated polyurethane corresponds to the biocompatible materials 
following the organism reaction. The softness of the new polyurethane does not 
influence the foreign body reaction.  
 
However, the host response to PIII treated polyurethane was significantly reduced, 
showing that the average thickness of the capsule was significantly less near the 
treated polyurethane than near the untreated polyurethane. In some cases the capsule 
was not formed near the PIII treated polyurethane surface at all. In addition separate 
macrophages were observed on the surface with large distances between them 
whereas in other cases only normal tissue was observed. In some cases only one 
irregular layer of fibroblasts with thin not-structured collagen fibres was observed. 
 
Acute inflammation and capsule formation are usually observed 5-7 days after 
surgery. Chronic inflammation is observed following this period with a formation of 
thick isolating capsule around the implant. However, if the capsule around PIII treated 
polyurethane is not observed 7 days from the operation, it is possible that the capsule 
might be not formed later because a delayed formation of the capsule is less likely. 
Therefore, there are cases when the capsule is not formed or has significantly less 
thickness with a significantly lower amount of immune cells.  
 
For discussion of the histochemistry results this study considered a general scheme of 
immune reaction on an implant (Fig.6.34) [3] where the reaction is characterised by 
stages of the organism response, which becomes more complicated and intensive with 
time up to the total isolation of the implant from the body.  
 
The histochemistry results showed the significant difference in immune response of 
the mice organism on untreated and PIII treated polyurethane implants. At first, Von 
Willebrand Factor concentration in the tissue near the PIII treated implants differed 
from that near the untreated implants. The literature [4] demonstrates that the Von 
Willebrand Factor is closely related to recruitment of the neutrophils in the injured 
tissue near the implant. When the Von Willebrand Factor concentration increases, the 
neutrophils are collected in the injured tissue and activated. The images of Von 
Willebrand Factor assay in the tissue near the untreated polyurethane implant 
correspond to a moderate immune reaction on the implants as seen in the literature [5-
6]. The lower Von Willebrand Factor concentration in the tissue near the PIII treated 
implant means that there is a less intensive inflammation and lower concentration and 
activity of neutrophils. Therefore the stage 2 has lower intensity for PIII treated 
implant than for the untreated implant.  
 
The macrophages are recruited at the next stage of the immune reaction. The role of 
macrophages is to remove the foreign body and/or to utilise the cell apoptosis 
products. The macrophages are recruited and activated via expression of cytokines 
released by neutrophils when the foreign body could not be destroyed in the body. 
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The concentration and activity of the macrophages near the untreated implant show a 
moderate reaction of an organism consistent with the literature data [7-10]. The lower 
concentration and activity of macrophages in the tissue near the PIII treated implant 
means that the macrophages are recruited and activated with much fewer signals from 
the neutrophils. Therefore the stage 3 of the immune response has a lower intensity.  
 
The new vessels formation and cell proliferation at the next stage provide a transport 
of immune cells to the injured tissue. These processes are ignited by released 
cytokines from the immune cells, which could not exclude the foreign body. At this 
stage the immune response includes deep transformation of surrounding tissues, 
which become involved into the healing process. The organism prepares to intensify 
the immune attack. The cell proliferation process in the tissue surrounding the 
untreated implant is much more intensive than in the tissue far away from the implant. 
The intensity at this stage is consistent with the literature on other implanted materials 
[7-10]. However, the cell proliferation activity in the tissue surrounding PIII treated 
implant is much less. The cell proliferation is not detected, suggesting that the 
organism does not recognise the implant as a foreign body.  
 
With time the implant is encapsulated with collagen fibres. The fibroblasts are 
activated and build a cross-linked collagen capsule around the implant. At this stage 
the organism tries to isolate the foreign body from the tissues. The immune response 
is transformed to chronic inflammation. The thickness of the capsule depends on the 
intensity of the foreign body reaction. The capsule around the untreated polyurethane 
implant is about 100 µm, which corresponds to the moderate immune reaction for 
most of polymer implants [1-2].  
 
The capsule surrounding the PIII treated implants is much thinner. This collagen 
capsule consists of rare disordered fibres whereas a capsule of dense ordered collagen 
fibres surrounds the untreated implant. In some cases the capsule near the PIII treated 
implant was not observed at all. Therefore, the host does not recognise the PIII treated 
implant as a foreign body, which must be isolated.  
 
All these observations are related to acute inflammation observed in the 7 days after 
the operation. According to the literature [1-2], capsule thickness for untreated 
implants grown after the acute stage, increases during the chronic stage. In addition, 
previous long-term investigations with ion beam treated hard polyurethane showed 
the absence of immune response in the organism after 6 months. Because of this 
absence in these long-term experiments with the new polyurethane, we predict that 
the intensive chronic inflammatory reaction on PIII treated polyurethane is unlikely 
due to the low inflammatory reaction during the acute stage. Therefore, the low and 
absent foreign body reaction is achievable.  
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Untreated Polyurethane 
 
 
PIII treated Polyurethane 
 
Fig.6.34. Scheme of foreign body reaction with main stages from the time of first 
contact of the implant with organism tissue. The scheme is adapted from literature 
data [3] for untreated and PIII treated polyurethane. Red crosses show low or absent 
activity observed in the experiments with PIII treated implants.  
 
 
6.8. Conclusions 
 
The investigations of the host response on the untreated and PIII treated polyurethane 
implant show that all implants do not cause physiological dysfunctions in the mice or 
rats. The polyurethane graft was successfully implanted as a vascular graft in the rat. 
The polyurethane graft is sewable and sticky, easily adhering to the vessel wall.  
 
The PIII treated implants in mice show a weaker immune response of the organism, in 
particular: 
1. The capsule around the PIII treated implant is significantly thinner (p<0.01).  
2. The macrophages activity near the PIII treated implants is significantly weaker 
(p<0.001).  
3. The cell proliferation activity near the PIII treated implants is significantly weaker 
(p<0.001).  
4. The pro-inflammatory activity by vWF test is much weaker near the PIII treated 
implants (p<0.001).  
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Therefore, the changes in the organism response on PIII treated implant in 
comparison with the untreated polyurethane implant are statistically significant.  
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Chapter 7. General discussion and 
prospective 
 
 
 
Foreign Body Reaction (FBR) is a key problem for modern artificial implants [1]. It 
does not only limit the implant development but it limits the number of patients to 
whom the implants can be applied. An absence or reduction in the FBR would 
significantly improve the implant’s capacity to save life. However, despite how all 
modern implants satisfy physical and chemical stability, non-immunogenicity and 
non-toxicity requirements [2], all these implants still cause an immune response in an 
organism. This is why there is a widely held opinion that FBR cannot be avoided [3]: 
“All materials implanted into humans and animals elicit ‘foreign body’ interactions, 
surrounding the materials with a protective capsule.”  
 
Attempts to avoid or decrease the immune reaction on artificial implants can be found 
in the literature [4-6]. All these attempts were based on stopping the immune reaction 
at some stage. For example, systemic corticosteroids decreases immune function and 
fibrosis, in particular it decreases the number of myofibroblasts [7]. However, our 
knowledge of the mechanism of the immune reaction is limited. The immune reaction 
is complicated and self-regulated with multiple ways and steps. Blocking one step in 
the immune response will not prevent the protective capsule formation. 
  
The histology results in this thesis on the untreated polyurethane correspond to the 
results discussed above. The analysis of the tissue surrounding the untreated 
polyurethane implant shows a classical picture of the immune reaction. The 
macrophages’ activity clearly increased near the implant. The cell proliferation 
increased. The vWF was released in the tissue near the implant. The collagen capsule 
formed.  
 
The observed reaction on unmodified polyurethane implant has moderate character, 
which shows a moderate immune response on the implant. It corresponds to the 
literature on polyurethane implants. There are no giant cells, there is no necrosis or 
high level of cell lysis. However, the thick collagen capsule forms as a usual tissue 
response to a foreign body.  
 
The immune reaction on PIII treated polyurethane implants is different (Chapter 6). 
The capsule is significantly thinner than for the untreated implant. In some cases, the 
capsule is not observed at all or only one layer of cells can be attributed to the 
capsule. The macrophages’ activity is much lower or negligible for some samples. 
The cell proliferation activity is significantly lower than for the untreated implant and 
in some cases the proliferation activity is observed at the level of undisturbed tissue. 
The level of expressed vWF is much lower for PIII treated implant than for the 
untreated implant. In some cases, the level of vWF is the same for undisturbed tissue. 
Most significantly, the FBR in this study was shown to be much lower or negligible. 
  
The thin capsule on ion beam treated implant is observed from the implant side 
(Appendix II). The collagen capsule is well attached to the untreated polyurethane 
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implant. However, the capsule is not found on ion beam implanted polyurethane 
surfaces with the carbonised top surface. The collagen structures are observed in the 
bottom of the crack of the carbonised layer, where the patches of untreated 
polyurethane are accessible by host proteins, phagocytes and fibroblasts.  
 
A similar weak immune reaction was observed for ion beam treated polyurethanes in 
the experiments of Suzuki and colleagues [8]. Polyurethane treated by Ar+ were 
implanted into a rabbit for 16 days and a weak intensity of inflammatory reaction was 
observed. A similar effect of biocompatibility of polymer materials after the ion beam 
treatment was observed in vivo experiments with ePTFE grafts. ePTFE graft was 
treated by an ion beam and implanted in dogs’ femoral artery. The control sample 
showed thrombosis after 3 days, where the modified was clear after 180 days [9]. 
However, the mechanism responsible for the weak immune reaction was not 
discovered at that time.  
 
In the present study the attempt to prevent the phagocyte activation is based on the 
knowledge of specific adsorption of the host proteins on the PIII treated implant 
surface.  
 
It is clear now that the immune response of an organism starts from a specific 
adsorption of host proteins on the surface of the artificial implant [10]. Then the 
phagocytes recognise the adsorbed proteins on the implant surface and become 
activated. The activated phagocytes release specific cytokines, chemokines, 
interleukins and other factors, which ignite the next steps of the inflammation 
reaction. The activation of phagocytes is a complex process and includes local 
cytokine expression, transformation of the macrophages and giant cells. At some 
stage the fibroblasts are activated, proliferated and ignited to produce collagen to form 
a capsule around the implant.  
 
The host proteins in organisms exist in hydrophilic environment such as cytoplasm, 
extracellular liquids, blood and lymph. The biologically active conformation of the 
protein molecule is optimised for such an environment. When the host proteins come 
in contact with a surface of the artificial implant, the environment for the host proteins 
is changed: the protein is in contact with the implant, not with water molecules [11]. 
The protein molecule is adsorbed on the implant surface and changes the 
conformation due to different intermolecular interactions with the implant surface in 
comparison with the organism (hydrophilic) environment [12]. The conformation of 
absorbed protein depends on the surface properties [13]. However, all artificial 
implants have a surface energy in a range of 20-45 MJ/m2 corresponding to the 
surface energy of the implant material [14]. This is much lower than the water surface 
energy of 72 MJ/m2. Therefore, the protein conformation changes to adjust the 
hydrophobic interactions with the implant.  
 
In contradiction with the untreated polyurethane, the PIII treated polyurethane implant 
is highly hydrophilic. The contact angle of the carbonised surface is 35-45 degrees for 
freshly treated PPG-DI-PTHF-0.35 polyurethane. The surface energy of the treated 
polyurethane 10 minutes after PIII treatment is 60-65 MJ/m2. Such a high surface 
energy and hydrophilicity is enough to absorb the water molecules and keep the 
hydrophilic intermolecular interactions with proteins in such a way that the protein is 
surrounded by water molecules and does not change the initial conformation at the 
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point of absorption. This effect of hydrophilicity was observed for other polymers 
after PIII, ion beam treatment and plasma treatment [15]. For example, the literature 
shows a surface energy of 71 MJ/m2 for the freshly PIII treated Nylon [16] and 77.9 
MJ/m2 for the freshly treated polyvinyl chloride (PVC) [17]. It maintains the 
conformation of the absorbed protein and its activity. For example, the conformation 
of Horseradish peroxidase (HRP) attached to PIII treated polyethylene remains 
unchanged or close to the biologically active conformation as observed by Amide I 
line in the FTIR ATR spectra [18]. The enzyme activity of the HRP attached on PIII 
treated Teflon remains high [19].  
 
At the same time protein is attached covalently to the PIII treated polyurethane 
implant. The covalent attachment is key to the strong anchoring of the protein to the 
implant surface. The protein attachment to the untreated implant can be provided with 
different kinds of intermolecular interactions. The van-der-Waals forces, dispersic 
interactions, dipole-dipole interactions, ionic interactions or hydrogen bonds can hold 
the protein on the surface. However, these interactions are flexible and can be easily 
replaced with water-protein interactions. The more hydrophilic the surface, the easier 
the protein can be washed with detergent or just a buffer [20.]. Such a weakness of the 
intermolecular interaction is a reason for the Vroman effect where the proteins can be 
easily replaced with other proteins in the protein mixture solutions or in an organism 
[21]. Such a flexibility of the protein adsorption can lead to unpredictable attachment 
of proteins, including signal proteins for igniting the immune reaction. 
 
The covalent attachment of protein is available with artificial chemical linkers [22-
24]. The linker molecule is designed in such a way that one reactive group fixes the 
linker molecule on the surface and the second reactive group anchors the protein 
molecule to the linker. However, the chemistry of linker molecules is complicated. In 
most cases the linker molecules are toxic and cannot be used in an organism. Also the 
effectiveness of the linkers to bind the protein is much less than the total coverage. In 
such cases, part of the surface is not covered and the immune system can recognise 
the surface as foreign body.  
 
The PIII treated polyurethane surface can be covered completely. The protein 
monolayer forms a total coverage (carpet) on the PIII treated polymer surface [25] 
including polyurethane. The protein layer covalently attached to the PIII treated 
polyurethane implant is not washable. The protein molecules covalently attached to 
the PIII treated surface cannot be replaced with other proteins and the Vroman effect 
is observed [26].  
 
The covalent attachment of protein on PIII treated polyurethane is provided via the 
reactions of free radicals which are formed when the polyurethane macromolecule is 
destroyed under high energy ion bombardment with formation of condensed aromatic 
structures like grapheme or graphite. The free radicals are observed in the 
polyurethane implant after a long period of storage (Chapter 4). The free radicals on 
the edges of the graphitic planes can be stabilised by π-electrons of the aromatic 
structure [27-28] and remain active before the protein molecule approaches the 
modified surface. The literature shows that the reaction of free radicals appeared in 
polyethylene after ion beam treatment with aminoacids [29]. When the free radicals 
react with the protein molecule a covalent bond is formed [18]. As a result, the protein 
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molecule bonds to the carbonised surface layer of the PIII treated polyurethane 
implant.  
 
The molecules with free radicals in solution are widely considered to accelerate aging 
of an organism because the host protein molecules can be damaged in free radical 
reactions [30]. The result of the protein damaging and oxidation can accelerate cell 
lysis and necrosis. These effects were not observed in surrounding implant tissue. The 
effect of free radicals on the protein requires the free radicals to be mobile in a 
solution. The free radicals in the polyurethane implant are associated with the 
condensed aromatic structures which are stable in polyurethane, and cannot propagate 
in the solution. When the protein is bonded with the surface, the protein does not 
migrate into the solution. The damaging of protein or decay of the protein activity was 
also not observed. Therefore, the free radicals in the polyurethane surface do not 
influence the organism’s tissues.  
 
The endothelialisation of the implant surface is one of the important factors of the 
biocompatibility [31]. Endothelialisation is considered a method of reducing the 
immune response [32]. The attachment of active protein can significantly improve 
cell adhesion [33]. A fast and total endothelialisation in an organism is the primary 
aim for the biocompatibility of implants. 
 
In the case of the newly synthesised polyurethane, the endothelial cells are spread and 
proliferate on the surface without PIII treatment. The endothelial cells also grow well 
on the PIII treated polyurethane surface. However, the untreated polyurethane is 
observed totally covered with the endothelial cells only after 6 days, while the PIII 
treated polyurethane is totally covered after 2 days as observed on the control tissue 
culture plastic (TCP).  
 
Similar cell attachment and proliferation was observed for other ion beam and PIII 
treated polymers. For example, the ion beam treatment of polystyrene by Na and Ne 
ions of 150 keV energy improved the endothelial cell spreading, attachment, 
proliferation and resistance to detaching with tripsin [34]. However, this research did 
not explain the mechanism by which this occurred. The adhesion and proliferation of 
endothelial cells and astrocytes on polyether sulphone and polyurethane by ion beam 
due to carbonisation of the polymer surface was reported in [35]. The endothelial cell 
adhesion and proliferation on PIII treated polyurethane was reported in [36]. The 
mechanism of improved cell adhesion via protein attachment due to free radical 
reactions was proposed in [37]. Thus, the attachment of protein with biologically 
active conformation leads to faster endothelialisation of the PIII treated polyurethane 
implant.  
 
The observed improvement of the polyurethane implant with PIII treatment can be 
considered for future soft tissue implants such as breast implants, testicular implants, 
cardiovascular implants, vascular grafts, diaphragms, finger joints, ear implants, nose 
implants and others. The mechanism for reducing the immune response based on free 
radical reaction is critical to successful implantation.  
 
First, the free radicals reduce with time after PIII treatment. Therefore, the best result 
for implantation is expected when the implant is treated by plasma and installed 
immediately. Therefore, implants should be treated just before surgery.  
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Second, the free radicals are sensitive to any surface contamination after the PIII 
treatment. Specific environmental conditions and limited contact with any other 
materials and devices are required before implantation into an organism. 
 
Third, the sensitivity of free radicals limits sterilisation methods. Sterilisation by 
chemicals or gases reduces the concentration of free radicals and consequently the 
success of the implantation. Therefore, the sterilisation of the implant would be 
preferred before the PIII treatment. Taking into account that a plasma method is used 
for sterilisation [38], the PIII treatment can be done in sterile environments such as an 
operating theatre. 
 
The polyurethane can be used as a coating on existing and new medical devices (see 
Appendix IV and V). The PIII treatment of these devices can be useful not only for 
the immune response decay, but also for drug release regulation (Appendix IV) to 
stop dewetting of the coatings (Appendix VII) and improve cell growth (Appendix 
VIII).  
 
To develop further the PIII treated polyurethane implants will need an optimisation of 
the PIII treatment regimes, long-term animal experiments, optimisation of surgery 
methods, clinical studies and corresponding approval.  
 
In general, the potential of implants without FBR cannot be overestimated. 
Cardiovascular implants including heart valve, blood vessel, catheter, pacemaker and 
defibrillator which do not generate FBR can be applied without immunosuppressants. 
Patients would not be at a risk of infection after implantation. A category of patients, 
who are at risk of corresponding diseases and for whom the implantation has not been 
recommended, will be able to be treated with the implants. The risk of inflammation 
and thrombosis can be significantly reduced. The breast, lips and other cosmetic 
implants would not cause contracture. Implants with electrical connection to the tissue 
such as cochlear, spine neurostimulator, implantable brain stimulator, different 
sensors in organs and blood would never lose electrical conductivity through the 
fibrotic capsule in an organism. The implantable drug release devices would never 
lose the drug penetration rate through the fibrotic capsule. Only insulin permanent 
releasing devices will save millions of patients with diabetes.  Consequently, these 
improvements affect some millions of patients and can significantly influence our 
health, medical treatment and medical industry.  
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Appendices						The	Appendices	presented	in	this	thesis	are	my	unpublished	and	published	work	done	prior	to	admission	to	the	University	of	Sydney	for	PhD	study.	The	results	
presented	in	Appendices	are	related	to	this	thesis,	but	do	not	form	a	part	of	
it.	However,	the	results	of	this	previous	work	are	connected	to	this	PhD	thesis	as	they	led	me	to	this	research.			Appendix	 1	 and	 2	 contain	 unpublished	 work	 carried	 out	 at	 the	 Institute	 of	Continuous	Media	Mechanics	 and	Children	Centre	 “Detstvo”	 in	Perm,	Russia	 in	1995-2001.	 Appendix	 3	 contains	 a	 published	 article	 that	 presents	 work	 also	carried	 out	 at	 this	 time.	 Appendix	 4	 and	 5	 contains	 published	 articles	 that	present	work	carried	out	at	the	Rossendorf	Research	Centre	Dresden,	Germany	in	2001-2003.	The	published	articles	 in	Appendices	6-10	present	work	carried	out	at	the	University	of	Sydney	before	and	during	my	PhD	study	in	2005-2017.		
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Appendix	I		
Surface	of	polyurethane	implant	
exposed	in	human	organism					An	usual	study	of	the	artificial	 implants	 in	organism	includes	an	analysis	of	the	organism	 reaction	 such	 as	 immune	 response,	 toxicity,	 functionality,	 etc.	 Less	attention	 is	 paid	 to	 the	 implant	 after	 the	 functionality	 of	 the	 implant	 is	successfully	provided.	However,	the	analysis	of	the	implants	after	it	has	been	in	an	organism	can	be	 informative	 to	understand	 the	reaction	of	 the	organism.	 In	particular,	 we	 have	 analysed	 the	 polyurethane	 implants	 after	 exposure	 in	 the	living	organisms.	The	investigations	have	been	done	in	Perm	State	University	in	cooperation	 with	 Perm	 Medical	 Academy	 and	 Institute	 of	 Continuous	 Media	Mechanics	(Perm,	Russia).	The	samples	of	implants	after	human	organism	were	received	 from	 Perm	 Medical	 Academy	 (Prof.	 S.	 Plaksin).	 The	 sample	investigations	 were	 done	 with	 approval	 of	 Ethics	 Committee	 of	 Perm	Medical	Academy.			The	 polyurethane	 has	 been	 synthesised	 from	 polyglycol	 based	 on	polyoxitetramethylene	(POTM)	and	polyoxipropylene	(POP)	glycols	(trademark	PF-OP-15,	MM=2000)	with	an	oxitetramethylene/oxipropylene	monomer	chain	ratio	 of	 85:15.	 The	 polyglycol	 hydroxyl	 groups	 were	 terminated	 with	 toluene	diisocyanate	 (TDI).	 Then	 hardener	 3,3’-dichlor,4,4’-diaminediphenylmethane	(DA)	with	dibutyl	dilaurate	of	Stannum	(DBD)	as	catalyst	was	used	 to	cure	 the	polyurethaneurea	shell.	The	shell	was	used	for	breast	implants.	The	trade	name	of	 the	 polyurethane	 shell	 is	 SKU-PFL.	 The	 shell	 was	 filled	 with	medical	 grade	silicone	resin	and	glued.	The	implants	and	production	process	were	certified	for	medical	 usage	 in	 the	 human	 body	 for	 long-term	 use.	 The	 implants	 were	successfully	 installed	 in	 the	 patients.	 The	 operations	 and	 following	 post-operational	periods	up	to	25	years	showed	satisfying	results	of	implantation	and	a	stable	functionality	of	the	implants.			The	implants	used	for	the	investigation	were	removed	for	different	reasons	from	the	patients	at	different	 times	after	 implantation.	The	 implants	were	permitted	for	 an	 investigation	 following	 patient	 agreement.	 After	 removing	 the	 implant	from	 the	 patient	 the	 implant	 was	 washed	 out	 in	 a	 buffer	 solution,	 dried	 and	tested	 with	 FTIR	 ATR	 spectra,	 XPS,	 optical	 microscopy	 and	 scanning	 electron	microscopy.	 The	 polyurethane	 shell	 stored	 under	 the	 same	 time	 in	 normal	conditions	and	newly	synthesised	polyurethane	shells	were	used	as	the	control	samples.			FTIR	 ATR	 spectra	 show	 that	 the	 polyurethane	 shell	 exposed	 in	 organism	 is	covered	by	the	collagen	cover	(Fig.1).	It	is	well	observed	by	disappearance	of	the	Amide	 I	 line	 of	 polyurethane	 (1727	 cm-1)	 and	 appearance	 of	 Amide	 I	 line	 of	
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protein	 (1640	 cm-1).	 The	 ratio	 of	 Amide	 I	 lines	 related	 to	 polyurethane	 and	protein	molecules	can	be	used	for	quantitative	analysis	of	the	collagen	cover.	The	dependence	of	this	ratio	is	shown	in	Fig.2.	The	relative	intensity	of	the	collagen	cover	increased	with	time	in	an	organism	during	the	first	5	months	and	then	it	was	stabilised.	However	 the	variation	of	 the	protein	 line	 intensity	 from	sample	compared	to	the	sample	is	high.			
	Fig.1.	 FTIR	 ATR	 spectra	 (KRS-5	 ATR	 crystal)	 of	 polyurethane	 SKU-PFL	 after	human	organisms.	Initial,	1	month,	4	months,	10	months,	34	months,	36	months,	46	months,	56	months,	56	months	(other	patient).			
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	Fig.2.	Ratio	of	Amide	I	line	absorbance	of	the	collagen	shell	(1640	cm-1)	to	the	Amide	I	line	absorbance	of	polyurethane	(1727	cm-1)	by	FTIR	ATR	(KRS-5)	spectra	of	polyurethane	SKU-PFL	after	implantation	in	human	organisms.			The	collagen	cover	on	the	polyurethane	surface	is	robust	and	cannot	be	removed	by	washing	it	in	buffer,	detergents	or	organic	solvents.	The	spectra	of	the	washed	implants	show	the	same	spectra,	just	like	the	unwashed	sample.			A	successful	decay	of	the	protein	line	intensity	was	observed	when	the	implant	was	treated	by	sodium	hydroxide	solution,	which	degraded	the	collagen	cover	on	hydrolysis	 mechanism	 (Fig.3).	 The	 intensity	 of	 the	 protein	 Amide	 I	 line	decreased	 with	 NaOH	 treatment	 time.	 However,	 after	 10	 hours	 in	 the	 NaOH	solution,	 the	 collagen	 Amide	 I	 line	 remained	 in	 the	 spectrum	 that	 shows	 the	collagen	cover	has	a	strong	adhesion	to	the	polyurethane	surface.	The	adhesion	is	stronger	then	the	collagen	molecule	itself.			
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	Fig.	3.	FTIR	ATR	spectra	of	SKU-PFL	shell	of	the	breast	 implant	after	2	years	 in	human	organism.	Black	(a)	is	water	washed	and	dried	implant.	Green	(b)	is	the	implant	after	10	min	in	10%	NaOH	water	solution.	Red	(c)	is	the	implant	after	10	hours	in	10%	NaOH	water	solution.			Therefore,	 the	 surface	 of	 the	 untreated	 polyurethane	 in	 the	 human	 organism	becomes	covered	with	a	collagen.	The	collagen	cover	is	strong	enough	that	it	can	be	removed	by	degrading	the	collagen	molecules	only.				 	
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Appendix	II	
	
Surface	of	ion	beam	treated	
polyurethane	implant	exposed	in	
organism					The	 analysis	 of	 the	 implants	 after	 some	 exposure	 to	 an	 organism	 can	 give	additional	 information	 about	 the	 immune	 response	 of	 the	 organism.	We	 have	analysed	the	polyurethane	implants	after	the	exposure	of	the	implant	in	rats.	The	investigations	were	done	in	Perm	State	University	in	cooperation	with	Children	Centre	 “Detstvo”,	 Institute	 of	 Technical	 Chemistry	 and	 Institute	 of	 Continuous	Media	Mechanics	(Perm,	Russia)	in	1995-1997.	The	investigations	with	animals	were	 done	 as	 a	 required	 stage	 for	 an	 approval	 of	 biomedical	 implants	 for	 the	following	clinical	studies	in	the	human	body.			The	 polyurethane	 has	 been	 synthesised	 from	 polyglycol	 based	 on	polyoxitetramethylene	(POTM)	and	polyoxipropylene	(POP)	glycols	(trademark	PF-OP-15,	MM=2000)	with	an	oxitetramethylene/oxipropylene	monomer	chain	ratio	 of	 85:15.	 The	 polyglycol	 hydroxyl	 groups	 were	 terminated	 with	 toluene	diisocyanate	 (TDI).	 Then	 hardener	 3,3’-dichlor,4,4’-diaminediphenylmethane	(DA)	with	dibutyl	dilaurate	of	Stannum	(DBD)	as	catalyst	was	used	 to	cure	 the	films	 on	 glass	 substrate.	 Crosslinking	 the	polyurethane	was	done	by	 annealing	the	films	at	1200C	for	3	hours	in	a	vacuum	oven.	After	peeling	off	and	washing	it	from	unreacted	residuals,	the	films	have	been	treated	by	nitrogen	ions	of	20	keV	energy	in	a	Pulsar	ion	beam	implanter	from	both	sides.	The	size	of	the	films	was	5	mm	diameter	with	a	0.2	mm	thickness.	Straight	after	 the	 treatment	 the	 films	were	implanted	subcutaneously	to	the	rats.	The	polyurethane	samples	with	and	without	the	ion	beam	treatment	were	implanted.	The	samples	were	sterilised	in	70%	solution	of	 ethanol	and	dried	 in	air	prior	 to	 inserting.	All	 the	 rats	 rapidly	recovered	after	the	operation.			The	 rats	 after	operation	 completely	 recovered	within	 a	day,	which	 is	usual	 for	rats	 after	 a	 surgery.	 In	 the	 following	 5	months	 after	 the	 surgery,	 clinical	 signs	severity	score	protocol	was	used	for	the	rats	monitoring	on	the	every	day	basis.	The	 rat	 dynamic	 activity	was	 normal.	 The	 coordination	was	 normal.	 The	 body	weight	 didn’t	 change.	 Breathing	 was	 normal.	 No	 change	 of	 coat	 or	 skin	 was	observed.	 The	 eating	 and	 drinking	 was	 usual.	 Urine	 and	 faeces	 were	 normal.	Communications	between	animals	were	normal.	When	palpated	or	 touched	no	squeaking	 was	 observed.	 Therefore,	 it	 was	 a	 sign	 that	 a	 disturbance	 of	 the	general	physiological	processes	in	whole	organism	was	not	shown	by	the	rat.		
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The	 polyurethane	 films	 were	 removed	 after	 5	 months.	 After	 removing	 the	implants	from	the	rats,	the	films	were	washed	out	in	a	buffer	solution,	dried	and	tested	 with	 FTIR	 ATR	 spectra,	 optical	 microscopy	 and	 scanning	 electron	microscopy.	The	polyurethane	 films	with	and	without	 the	 ion	beam	treatments	were	stored	for	the	same	time	under	normal	conditions	as	the	control	samples.			FTIR	ATR	 spectra	of	 the	 control	polyurethane	 film	with	 and	without	 ion	beam	treatment	 show	 Amide	 I	 peak	 at	 1725	 cm-1	 corresponding	 to	 urethane	 group	vibrations	(Fig.1,	top).	The	spectra	of	untreated	polyurethane	film	show	Amide	I	peak	 at	 1640	 cm-1	 corresponding	 to	 protein	 vibrations	 (Fig.1,	 bottom).	 The	protein	layer	corresponds	to	a	collagen	covering	on	the	polyurethane	surface,	it	is	observed	after	implantation	into	human	organism.			
		Fig.1.	 FTIR	 ATR	 spectra	 of	 ion	 beam	 treated	 Polyurethane	 SKU-PFL	 after	implantation	in	rat	for	5	months.	The	fluence	of	20	keV	nitrogen	ions	is	shown	in	ions/cm2.	 The	 curve	 marked	 as	 initial	 corresponds	 the	 polyurethane	 sample	before	the	operation.	The	arrows	mark	the	positions	of	Amide	I	lines	for	protein	and	polyurethane	macromolecules.			The	spectra	of	ion	beam	treated	polyurethane	films	after	being	in	the	organism	show	 these	 two	 lines	 with	 different	 ratio	 of	 the	 intensity.	 The	 spectra	 of	 the	polyurethane	 treated	 with	 highest	 fluence	 is	 closer	 to	 the	 spectra	 of	 the	untreated	polyurethane	after	organism.	The	spectra	of	the	polyurethane	treated	with	 lowest	 fluence	 is	 closer	 to	 the	 spectra	 of	 initial	 polyurethane	 before	 the	organism.	 The	 quantitative	 measurement	 of	 this	 ratio	 in	 dependence	 on	 ion	beam	 treatment	 fluence	 is	 presented	 on	 Fig.2.	 It	 is	 clear	 that	 the	 ion	 beam	
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treatment	preserve	the	ratio	from	the	organism	influence.	It	means,	the	collagen	covering	 is	 less	 seen	 by	 ion	 beam	 treated	 polyurethane,	 than	 for	 untreated	polyurethane.			
	Fig.2.	 Ratio	 of	 absorbance	 of	 Amide	 I	 line	 of	 collagen	 shell	 and	 absorbance	 of	Amide	 I	 line	 of	 polyurethane	 in	 FTIR	 ATR	 spectra	 of	 ion	 beam	 treated	Polyurethane	SKU-PFL	after	implantation	in	rat	for	5	months.	The	fluence	of	20	keV	nitrogen	 ions	 is	 shown	 in	 ions/cm2.	 The	 full	 sign	 (initial)	 corresponds	 the	polyurethane	sample	before	the	operation.			Similar	results	were	observed	 in	optical	microphotographs	of	 the	polyurethane	films	 before	 and	 after	 being	 in	 the	 organism	 (Fig.3).	 The	 surface	 of	 initial	polyurethane	 is	 sufficiently	 smooth	 in	 the	 scale	 of	 the	 image.	 The	microphotograph	of	the	untreated	polyurethane	after	5	months	in	rat	organism	shows	 a	 developed	 surface	 structure,	 which	 is	 interpreted	 as	 the	 collagen	coating.			The	 microphotographs	 of	 the	 ion	 beam	 treated	 polyurethane	 before	 the	organism	show	the	crack	structure,	which	corresponds	to	the	cracking	of	brittle	carbonised	 top	 layer.	High	 fluence	 treatment	 gives	deeper	 and	 frequent	 cracks	on	the	surface	than	the	low	fluence	treatment.			After	 the	 organism	 the	 surface	 of	 the	 ion	 beam	 treated	 polyurethane	 does	 not	show	 the	 collagen	 covering.	 The	 surface	 of	 the	 ion	 beam	 treated	 polyurethane	does	not	show	any	changes	after	the	organism	implantation.			
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	Untreated	polyurethane	SKU-PFL,	no	organism.		 	Untreated	polyurethane	PU	SKU-PFL,	implanted	in	rat	for	5	months	
	Polyurethane	SKU-PFL	after	Ion	beam	treatment	with	1013	ions/cm2	fluence	of	20	keV	nitrogen	ions,	no	organism.	
	Polyurethane	SKU-PFL	after	Ion	beam	treatment	with	1013	ions/cm2	fluence	of	20	keV	nitrogen	ions,	implanted	in	rat	for	5	months.	Fig.3.	 Optical	 microscopy	 images	 of	 polyurethane	 after	 ion	 beam	 treatment	implanted	to	rat	for	5	months.			The	 scanning	 electron	 microscopy	 (SEM)	 images	 show	 similar	 results	 (Fig.4).	The	 untreated	 polyurethane	 becomes	 covered	 by	 the	 collagen,	 while	 the	 ion	beam	 treated	 polyurethane	 keeps	 the	 same	 surface	 like	 it	 was	 before	 it	 was	implanted	 into	 the	 organism.	 However,	 the	 bottoms	 of	 each	 crack	 show	 the	attached	 layer.	 Corresponding	 to	 FTIR	 ATR	 spectra	 the	 attached	 layer	 in	 the	crack	 bottoms	 is	 probably	 the	 collagen	 coverage,	 which	 appeared	 during	 the	exposure	 in	 organism,	 because	 the	 crack	 bottoms	 are	 untreated	 bulk	polyurethane,	where	the	organism	cells	can	contact	the	untreated	polyurethane.			
	 X	
	a.	Initial	untreated	polyurethane		 	b.	Untreated	polyurethane	after	5	months	in	rat	organism	
	c.	Polyurethane	after	ion	beam	treatment	with	1016	ions/cm2	fluence	of	20	keV	nitrogen	ions		
	d.	Polyurethane	after	ion	beam	treatment	with	1016	ions/cm2	fluence	of	20	keV	nitrogen	ions	and	after	5	months	in	rat	organism	Fig.4.	Scanning	electron	microscopy	(SEM)	images	of	polyurethane	after	ion	beam	treatment	and	implantation	in	rat	for	5	months.			The	results	of	the	investigations	show	that	the	untreated	polyurethane	causes	a	formation	 of	 the	 collagen	 covering	 as	 a	 result	 of	 immune	 response	 of	 the	organism.	 The	 ion	 beam	 treatment	 decreases	 the	 collagen	 coverage	 on	 the	polyurethane	 surface.	 Only	 the	 bottoms	 of	 the	 cracks	 in	 the	 carbonised	 layer	where	the	untreated	polyurethane	is	accessible	to	the	organism	cells,	is	covered	by	the	collagen.				
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Abstract—A crosslinked polyurethanurea (PUU) coating was synthesised from a solution on metal
vascular stents. In the model system the glucocorticoid prednisolone was inserted into the  lm by
the equilibrium swelling method; after this plasma immersion ion implantation (PIII) was applied to
modify the coating for improved release kinetics. This treatment causes the formation of oxygen-
containing and unsaturated carbon–carbon groups in the PUU and a destruction of the drug in the
surface layer. As a consequence, the release rate of prednisolone to water becomes more stable with
time than it is at the untreated coating. In this drug release system PIII treatment prevents an initial
toxically high release of the drug. By this it allows the incorporation of a higher amount of the drug
and an extended action.
Key words: Stent; polyurethane;drug release; plasma.
INTRODUCTION
The application of stents in combination with angioplasty of arteriosclerotic blood
vessels has become a standard technique which is widely equivalent to by-pass
surgery [1]. However, the application of a stent in the body often induces a local
in ammatory reaction, proliferation of the smooth muscle cells and neointima for-
mation [2–4]. This reaction can be reduced by application of a stent with polymer
coating which contains anti-in ammatory or antiproliferative drugs. These drugs
are released over a long time and reach effective concentrations only locally [5, 6]
¤To whom correspondenceshould be addressed. Tel.: (49-351) 4658-528. Fax: (49-351) 4658-298.
E-mail: kond@mailcity.com
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at the vessel, without achieving effective concentrations systemically. One possi-
ble polymer for the coating is polyurethane, which has a high elasticity and a high
strength. The residual deformation is low, high adhesion on metal, high resistance
to water and to biological media can be obtained, further polyurethanes already
have a good application as material for endoprosthetics [7]. As coatings on stents
nowadays a linear polyurethane is used [8].
Drugs, like antibiotics [9], already have been incorporated in polyurethanes
with good success. Usually this is done by adding the drug to a solution of the
polyurethane. After evaporation of the solvent a layer of polyurethane incorporating
the drug is formed. In particular, this technology is used for intravascular catheters.
Catheters have a high risk of bacterial infection and polymers with antibiotics
decrease the probability of catheter-associated infections.
An alternative method for inserting the drug is swelling of a linear polyurethane
in a solution of the drug. In this case the swelling must be carefully controlled
because the polyurethane may be dissolved and the coating destroyed [10]. This
technology leads to an inhomogeneous distribution of the drug in the polyurethane
and the kinetics of the drug release also will be non-uniform by time. Besides that,
the linear polymer may become dissolved by blood lipids and soluble compounds
are released into the blood  ow [11].
A further technology to insert the drug is possible for a drug molecule, which
is not reactive with the isocyanate groups of the prepolymer of the polyurethane.
In this case the drug can be added to the reactive mixture before the reaction
of the isocyanate groups of prepolymer with the active hydrogen group of the
hardener [12]. In this case the distribution of the drug will be homogeneous
in the polyurethane. By changing the reaction conditions the structure of the
polyurethane and drug release kinetics can be modi ed. Further, the polyurethane
can be synthesised with crosslinks, making it insoluble in any solvent and lipids.
The kinetics of drug release from a polymer to blood is generally described by the
so-called ‘frontal process’ of water diffusion into the polymer. According to this
model the release process is determined by the water front, which penetrates into
the PUU  lm when it is exposed to water. The rate of the frontal process depends on
the water diffusion coef cient into the PUU  lm, on the maximal swelling of PUU
in water and on the solubility of prednisolone in water.
The  rst theoretical model of the drug release process was developed by
Higuchi [13]. By experimental estimation, 80% of the drug is released by the frontal
law and 20% of the drug amount is released by diffusion [14]. In general, the ki-
netics of the drug release from a swelling polymer are very complex. They depend
on the solubility and the swelling of the polymer in water, the concentration limit
of the drug in water and the distribution of the drug in the polymer [15]. Therefore,
for real polymer–drug systems an experimental study is more preferable.
The regulation of the drug release is an important point for the development of
a polymer-drug system. This regulation is possible by coating of the polymer with
another polymer with a lower diffusion coef cient for water and the drug [16]. For
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this technology a diffusion barrier layer slows down the drug release process from
the polymer to the blood, so the drug release can be regulated by modi cation of
the diffusibility and thickness of the barrier layer.
A change of the diffusion coef cient can also be achieved by various methods of
polymer surface treatment [17]. In particular, ion-beam treatment of the polymer
surface seems to be promising [18]. In this case, a very thin polymer layer
is modi ed. The thickness of the modi ed layer can be adjusted by the ion
species and their energy. Besides the diffusion coef cient regulation, it has been
show that the ion-beam treatment can also increase the biocompatibility and the
blood compatibility of polymers [19, 20]. Ion-beam treatment of polystyrene and
polyurethane leads to a carbonisation of the surface layer, an increased wettability,
improved adhesion of adherent growing cells and reduced blood-clotting activation.
A similar structure formation is observed in polymers after plasma immersion ion
implantation (PIII) as an alternative method of ion implantation [21, 22].
Therefore, the application of PIII treatment of polymer coating is promising for
both the aspect of biocompatibility, as well as for the regulation of the diffusion
of drug through polymer surface. In this study it is intended to insert a drug to
a polyurethaneurea (PUU) coating of vascular stents and to study the drug-release
kinetics before and after PIII treatment of the polyurethane surface. Prednisolone
has been chosen as a model drug that decreases in ammatory reactions of the vessel
wall in contact with the stent; however, the technique will be applicable also for
some other, more effective drugs. The use of PIII treatment to obtain a smoother
drug release pro le should work also for other drug/polymer combinations.
MATERIALS AND METHODS
Synthesis of polyurethane
The synthesis of polyurethaneurea was made in two steps [23]. As a  rst step
a prepolymer with active isocyanate groups was synthesised. A co-polymer of
polyoxitetramethylene (POTM) and polyoxipropylene (POP) glycol (PF-OP-15,
MM D 2000, Russia) with an oxitetramethylene/oxipropylene monomer chain
ratio of 85 : 15 was used. Before synthesis the co-polymer was dried under
CaCl2. A 2,4-toluenediisocyanate (TDI) of industrial purity was used. This
copolymer was a colourless transparent liquid without sediment. The purity of 2,4-
toluenediisocyanate was determined by IR spectra. The synthesis of the prepolymer
from the PF-OP-15 copolymer and 2,4-toluenediisocyanate was made in a vacuum
chamber at 45±C over 6 h. After synthesis the prepolymer was stored refrigerated
in closed glass container. The concentration of isocyanate groups in the prepolymer
was determined by IR spectra and by titration.
As a second step a polyurethaneurea  lm was prepared from the synthesised pre-
polymer and 3,30-dichlor,4,40-diaminediphenylmethane (DA). The DA was recrys-
tallised from benzene and stored light protected. For synthesis a reaction mixture of
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DA and the prepolymer was prepared with a NCO/NH2 molar ratio of 1 : 0.7. After
mixing the composition was dissolved in distilled ethylacetate to a concentration of
10–30%, then the solution was applied on stents, glass, metal or Te on substrates.
After evaporation of the solvent the PU  lm was dried at 22±C and 50% moisture
during 24 h. The  lm was put into a thermobox at 120±C to complete the polymeri-
sation reaction. After annealing crosslinking of the polyurethaneurea was veri ed
by swelling in tributylphosphate and dimethylformamide.
The synthesised polyurethaneurea has the following structure:
-[POTM]n-[POP]m-CO-NH-[TDI]-NH-CO-NH-[DA]-NH-CO-NH-[TDI]-
where n D 24:31 and m D 4:29.
Polyurethane  lms based on butylglycol (BGly), diphenylmethandiisocyanate
(MDI) and ethylendiamine (EDA) with crosslinked and linear structures were used
as polyurethaneurea coating for comparison. Contamination and characteristics of
 lms of different PUU are presented in Table 1.
The PUU  lms with wide range of thickness were synthesised for different
experiments. The thickness of PUU coating on metal stents could be done as low
as 5–7 ¹m. PUU  lms for swelling and drug-release experiments with 400 ¹m
thickness were prepared on glass substrate. The PUU  lms for strength test
experiments were synthesised with thickness from 100 ¹m to 800 ¹m on glass,
metal and Te on substrates. The roughness of PUU surfaces was about 1 ¹m
by electron microscopy measurements, their homogeneity was observed by optical
microscopy. FT-IR spectra were used to control the PUU  lm structure between
the different batches. In the experiment with different ion treatment dose, the PUU
 lms were taken from a single batch. The swelling measurements of the  lms in
alcohol were done in triplicate. A control of the swelling measurements was made
for every sample at drug inserting procedure. The presence of the solvent in PUU
 lm was checked by its characteristic spectral lines in the IR spectra. For drug
release experiments, three samples of PUU for each of the 6 PIII different dose
treatments were used.
Table 1.
Composition and characteristics of polyurethaneurea  lms
N Formula Polymer Concentration of hard Maximal swelling
network blocks (% of MM) in ethanol (%)
1 BGCTDICDA crosslinked 12.6 90
2 BGCMDICED crosslinked 17.2 75
3 BGCMDICED linear 20.0 55, destroyed
4 BGCMDICDA crosslinked 22.0 50
5 PF-OP15CTDICDA crosslinked 12.0 40
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Drug incorporation
For prednisolone incorporation the PUU  lm was swollen to equilibrium state in a
solution of prednisolone in ethanol. Ethanol was chosen as solvent, because it has
the following properties: a good solvent for prednisolone, a suf cient compatibility
with the polyurethaneurea  lm for swelling but no dissolution of the PUU, good
evaporation from the polyurethaneurea  lm and no toxicity. Prednisolone-21-
hydrogensuccinate (Solu-Decortin, Merck, Darmstadt, Germany) was used as
solution of the powder in ethanol. For this method, a chemical reaction of
prednisolone with active groups of polyurethane was excluded because a drug
is inserted into the inert PUU. As the  lm showed maximum swelling and the
solvent was at equilibrium concentration through the whole thickness of the  lm, the
distribution of prednisolone was more uniform than for non-equilibrium swelling.
After the synthesis, the polyurethane samples were allowed to swell in ethanol.
Swelling was observed by measuring the mass of polyurethane disks with 35 mm
diameter and 300 ¹m thickness. Weight measurements were made on an analytical
balance (Sartorius). A kinetics curve of swelling is presented in Fig. 1. The rate
of swelling and the maximal swelling depends on the type of polyurethane. All
PUUs have suf cient compatibility with ethanol and swell to 40–100% by mass.
The linear polyurethane did not dissolve in ethanol either, but due to swelling the
internal stresses in  lm lead to cracks and destruction of the sample. In the case
of polyurethane coating an increase in thickness of the polyurethane  lm leads to
Figure 1. Swelling of polyurethane  lms in ethanol. The number of the curves corresponds to the
PUU number in Table 1.
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the formation of internal stresses in the coating and peeling of the coating from the
substrate. Therefore, for the following experiments the polyurethaneurea based on
PF-OP15 with lowest swelling in ethanol was chosen.
Before incubation with the drug the polyurethane samples were swollen in pure
ethanol for 24 h and dried from ethanol to continuous weight. This treatment is
intended to wash out low molecular products which could remain after the synthesis
of the polyurethane. To incorporate the drug, a polyurethane was swollen in an
ethanol solution of prednisolone with the prednisolone concentration of 1% by
mass. The prednisolone concentration was calculated from a high-dose systemical
treatment with 250 to 1000 mg per 70 kg body weight. The local prednisolone
concentration in vessel wall of 14.2 ¹g/g was used for a calculation of the
prednisolone concentration in PUU. This concentration should allow a prednisolone
concentration available locally at the drug release system to be in the same range as
it would be at medium to high systemic therapeutic application. For the calculation
the maximum swelling of polyurethane in ethanol and a medium to high therapeutic
concentration of prednisolone in the blood  ow was used. However, real dose-
 nding studies must be subject of animal and clinical studies, as the distribution in
blood and vessel wall may be not equal depending on the hydrophily of the drug.
Plasma immersion ion implantation
Plasma immersion ion implantation (PIII) was used for the treatment [24, 25] of
the PUU coating on stents and PUU  lms. The PIII treatment is a well known
method for modi cation of wide range of materials. The PIII treatment differs from
usual plasma treatment due to high energy of ions [21]. By action of high energetic
ions the PIII treatment has similar effects as ion beam treatment [22]. At PIII
treatment a polymer sample is placed on an electrode in a high vacuum chamber.
After evacuation to a base pressure of 10¡3 Pa, a nitrogen plasma discharge is
generated by a microwave source and negative high-voltage pulses are applied to
the electrode with the samples, which is immersed in the plasma. The ions from
the plasma get accelerated towards the electrode by the high-voltage pulses and
bombard the polymer sample. The equipment of PIII is cheaper compared with ion
beam accelerators. PIII already has industrial application for surface treatment.
For these experiments a nitrogen plasma was generated by a plasma source based
on electron cyclotron resonance (ECR), with the density of 1010 cm¡3 and an
electron temperature of a few electron volts. The gas pressure during the treatment
was 10¡2 Pa. High-voltage pulses of 20 kV were applied to the sample holder
which was immersed into the plasma. The PUU  lm were treated on both sides.
The current density during the pulses was 16 mA/cm2, the pulse duration was 5 ¹s,
the frequency of pulse repetition was varied from 0.3 to 50 Hz, the dose of treatment
was varied from 1013 to 1016 ion/cm2 .
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Structure analysis
Optical microphotographs of the polyurethane surface were made (Axioskop, Carl
Zeiss Jena with CCD camera, KS-100-3.0 Zeiss software). ATR–FT-IR spectra
were recorded with Ge and KRS-5 crystals (trapezium, 450 re ection angle, 18
re ection number) at Bruker IFS-66s and Nicolet Magna 750 spectrometers with
the corresponding software OPUS and OMNIC.
Determination of prednisolone release from polyurethane
For kinetics analysis a  lm of polyurethane was incubated in de nite volumes of
distilled water for a de nite period of time. After that, the  lm was placed in the
next aliquot of water and so on. Due to the low concentration of prednisolone in
each volume of water solution (less than 10¡4 mol/l) this method is close to the real
blood  ow, where the concentration of prednisolone does not in uence the drug
release kinetic.
A 300-¹l droplet of each water aliquot after eluting the drug was posited on the Ge
ATR crystal, distributed on the crystal surface and dried in a thermobox with air  ow
at 40±C. After evaporation of the drop the ATR–FT-IR spectra of the crystal were
recorded. For quantitative analysis a calibrated curve was prepared with standard
solutions with a de ned concentration of prednisolone.
The intensity of the lines at 1720.7 cm¡1 of carbonyl group vibration, at
1656.1 cm¡1 and 1581.6 cm¡1 of unsaturated C C group vibrations, at 2936.5 cm¡1
of C H group vibration and at 3400 cm¡1 of O H group vibration for pred-
nisolone, were used to determine the concentration. Calibrated curves by line in-
tensity are presented in Fig. 2. From the drop volume and the concentration of
prednisolone in the calibrated solutions it can be calculated that the thickness of the
prednisolone layer in this study is lower than the penetration of the IR beam [26]
and a linear part of the calibration curve is observed for this concentration range. In
this study the linear part of the calibrated curve from 0.001 to 0.01 of FT-IR spec-
tra optical density was used to determine the prednisolone concentration. At these
concentrations the Bouger–Lambert–Beer law for optical density can be used for
the quantitative analysis by intensity of IR spectral lines. At a high prednisolone
concentrations (>0.1%), a thick layer is formed on the Ge crystal, so that the IR
beam does not penetrate this  lm and the calibration curve looses its linear char-
acter. The average Prednisolone concentration was calculated from optical den-
sity of all analysed spectral lines. The signal/noise level of spectra for analysed
lines was varied from 8 for spectra with lowest intensity to 100 for spectra with
highest intensity. The repetition of FT-IR spectra showed that the optical den-
sity of analysed lines was reproducible with errors in the range of the background
noise.
152 A. V. Kondyurin et al.
Figure 2. Calibration curve for different spectral lines (cm¡1/ of ATR–FT-IR spectra of prednisolone
from an aqueous solution.
RESULTS AND DISCUSSION
Kinetics of prednisolone release
Spectra of the sample volumes are presented in Fig. 3. The spectra of the probes
contain the lines of the prednisolone at 1720.7, 1656.1 and 1581.6 cm¡1. This
corresponds to the initial structure of the prednisolone molecules released from
PUU. The  rst spectra of the sample volumes contain some additional lines in the
regions of 1750–1550 cm¡1 and 1470–1420 cm¡1, corresponding to low-weight
molecules of PUU, which were formed during the polymerisation. These products
appear in water only during the  rst day of elution; however, their concentration
is too low for quanti cation. In the probes of the following days the low-weight
PUUs were no more observed. The spectral lines of the prednisolone molecule and
of the low-weight polyurethane molecules are clearly distinct, so the prednisolone
concentration in the sample volumes can be determined by comparing with the
standard.
The kinetics curve of the prednisolone release has a non-linear character with a
very high concentration in the  rst sample volume (Fig. 4). In other words, the
release rate is not constant, but it is highest in the beginning (Fig. 5). The kinetics
curve of the prednisolone release corresponds to the frontal process of the drug
release from a solid matrix by the theoretical model of Higuchi [13]. According
to the frontal process theory, the non-uniform release of prednisolone into water is
observed due to a quick diffusion of prednisolone from surface layer of PUU.
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Figure 3. ATR–FT-IR spectra of prednisolone released from initial PUU to water at different points
of time (from bottom to top): between 0 and 1 h, between 2 and 4 h, between 4 and 8 h, between 8 and
23 h, between 126 and 146 h, and between 263 and 341 h. The strokes show 3400, 2936.5, 1720.7,
1656.1 and 1581.6 cm¡1 lines.
Figure 4. Kinetics of the drug release from PUU: light, initial PUU; full, PIII-treated PUU, dose is
1016 ions/cm2.
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Figure 5. Rate of drug release from PUU: light, initial PUU; full, PIII-treated PUU, dose is 1016
ions/cm2.
The principle of these drug-eluting stents is that a highly toxic drug is applied
at high concentration only at the place where it is needed. At some distance the
dilution is already so high, that there is no more toxic effect. In order to obtain
long-term effective concentrations below the toxic threshold, a regulation of drug
release, especially in the  rst period of time, is necessary.
PIII of polyurethaneurea
The PUU surface gets a metallic colour after plasma immersion ion implantation
at doses of 1015 ions/cm2 and higher, what is a common effect for carbon-chain
polymers at ion-beam treatment [21]. It indicates the carbonisation of the PUU
surface layer by PIII.
At increasing PIII doses the characteristic lines of PUU in the ATR–FT-IR
spectra loose intensity (Fig. 6). An additional shoulder appears in the spectra at
the 1730 cm¡1 line of amide 1 vibrations in the region 1730–1600 cm¡1 after
normalisation of the spectra of PIII-treated PUU by the intensity of carbonyl and
ether groups lines. The intensity of this shoulder increases with the dose of PIII
treatment. In analogy to the spectra of carbon-chain polymers after PIII treatment,
this shoulder indicates the appearance of new oxygen-containing and unsaturated
carbon–carbon groups. These groups result from the destruction of the PUU
macromolecules by the ion beam. With appearance of this shoulder, there is no
obvious change in the ratio of ether, urethane and urea groups, indicating a weak
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Figure 6. ATR–FT-IR spectra of PUU after PIII: not-treated, 1014, 5 £ 1014 , 1015, 5 £ 1015 and
2£ 1016 ions/cm2 .
selectivity of the destruction processes by PIII. This is in contrast to the destruction
of polyurethane by environment factors like UV-light and thermal treatment, where
de ned reactions of depolymerisation and destruction of polyurethane by urea and
urethane groups occur [28].
However, there are some small differences in the intensity of the different
lines. A slight relative increase of the 1456 cm¡1 line intensity is observed
with increase of the PIII dose above 1015 ion/cm2 . This line corresponds to
the deformation vibration of methyl and methylene groups in the ether part of
the PUU macromolecule. The increase shows the higher stability of methyl and
methylene groups in comparison to urea and urethane groups with heteroatoms in
the main chain of the macromolecule. This corresponds to the inferior stability
of polymer macromolecules with heteroatoms in the main chain under destructive
conditions [29].
The intensity of the 1500 cm¡1 line, corresponding to the vibration of aromatic
rings at urea and urethane groups, has a slight tendency to decrease compared
with the other lines. The decrease demonstrates the more intensive destruction
of aromatic compounds near urea and urethane groups than of other groups. In
the high-frequency region of the spectra the intensity of the 2937 cm¡1 line,
corresponding to methylene group vibrations and the intensity of 2917 cm¡1 line,
corresponding to methyl group vibrations, show an increase of branch numbers in
macromolecules. Lines at 3000–3100 cm¡1, which correspond to C H vibrations
in aromatic structures, do not appear. Obviously, in the case of PUU the formation of
condensed aromatic groups occurs without a signi cant formation of C H groups.
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This is in contrast to the behaviour of polyethylene at PIII and ion beam treatment.
In the region of 3600–3100 cm¡1 a very wide band which overlaps with the stretch
º.NH) vibration lines (amide A) appears. This band corresponds to the vibrations of
hydroxyl groups, which appear in the surface layer of PUU after PIII. At high dose
of PIII the spectral lines become wider in all regions of the spectra. This indicates
an increased concentration of structural defects and a breakdown of periodical
structures in the PUU macromolecules.
These structural changes of polyurethane are different from the usual reaction of
polyurethane degradation by the ways of substitution and exchange reactions [28].
The destruction reactions in polyurethane under PIII are not selective due to
extremely high local energy transformations and high concentration of free radicals
in the track region of the penetrated ions. Therefore, at PIII treatment the
reactions of depolymerisation to oligomers and monomers are not possible, what
otherwise happens for polyurethanes. The surface layer of treated PUU has a higher
concentration of carbon structures with condensed aromatic groups and oxygen-
containing groups than other types of polymers. The concentration of hydroxyl
groups in the treated PUU, as observed by the intensity of the º.OH) line is higher
than, for example, in treated polyethylene [22]. Obviously, this high concentration
of OH groups is caused the by high concentration of oxygen in the macromolecule
of the polyurethane. The hydroxyl groups in PUU under PIII are formed mainly by
a substitution reaction and only to a minor degree by free radicals reactions with
air oxygen, what would be the usual way for carbon-chain polymers under PIII and
ion-beam treatment. The thickness of PUU layer modi ed by PIII was estimated
from calculation by TRIM codes as 100 nm.
In conclusion, after PIII the surface layer of PUU has a very different structure
compared with the initial PUU structure. These huge changes of the structure may
also change the diffusibility of the  lm surface of PUU for prednisolone.
Kinetics of prednisolone release from the modi ed polyurethaneurea
ATR–FT-IR spectra of water samples after immersion of PIII-treated PUU with
prednisolone are presented in Fig. 7. As in sample volumes of initial PUU, in
these spectra the lines of the released prednisolone are observed. The positions
and the intensity of the prednisolone lines correspond to the spectra of the initial
drug. In the spectra there are no additional lines, which would indicate degradation
products of the prednisolone molecule or of the PUU. The reason for missing lines
of destruction products may be the degradation of the drug molecule to very small
products. These products can evaporate to the vacuum chamber at PIII. Besides that,
some parts of the prednisolone molecule can be crosslinked with the carbonised
PUU layer during the PIII, so that they can not be released into the water.
The kinetics of the prednisolone release from the modi ed PUU still has a non-
linear character, as was observed for the initial PUU (Fig. 4). The frontal character
of the release kinetics remains, but the release rate in the beginning is lower. This is
caused by the destruction of the prednisolone molecules in the surface layer of PUU,
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Figure 7. ATR–FT-IR spectra of prednisolone released from modi ed PUU to water at different
times. From bottom to top: between 0 and 1 h, between 2 and 4 h, between 4 and 6 h, between 6 and
15 h, between 47 and 71 h, between 71 and 95 h, between 151 and 248 h, between 248 and 343 h, and
between 416 and 482 h.
Figure 8. Dependence of the prednisolone release rate from PUU from the ion dose. Filled squares,
at 2 h in water (left scale); open squares, at 400 h in water (right scale).
so at the  rst period of water diffusion no prednisolone molecules are available to
be washed out. In consequence the rate of prednisolone release from the treated
PUU the  rst period is suppressed in comparison to the untreated PUU (Fig. 5).
The release rate in the  rst period of the drug release is relatively independent from
the ion dose used (Fig. 8). Obviously, already at a low treatment dose most of
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the surface of prednisolone molecules are destroyed and an increase of the PIII
treatment dose can not further decrease the release rate.
The long-term release rate of prednisolone from PUU increases with the treatment
dose of PIII (Fig. 8). The reason may be in an increased diffusion coef cient of
water through the surface layer of the modi ed PUU. The carbonised and oxidised
layer of PUU is more hydrophilic than the initial PUU, this facilitates the penetration
of water and the release of prednisolone molecules.
The decrease of the prednisolone release rate at the  rst period of the kinetics and
the increased long term release rate leads to a more homogeneous release of the
drug. The concentration of the released prednisolone from the PIII-treated PUU to
water or to the organism of a patient will be more stable than from non-treated PUU.
Thus, even a higher concentration of prednisolone can be incorporated in the PUU to
assure therapeutic level for a longer time without initial toxic concentrations. This
will be important especially for other drug/polymer combinations currently under
investigation.
CONCLUSIONS
This study showed that the technology of synthesis of crosslinked polyurethaneurea
from solution can be used to create an elastic, drug-containing coating on stents.
The model drug prednisolone can be incorporated in the coating by the method
of equilibrium swelling in a solution of the drug. The drug release kinetics has a
frontal character corresponding to the model of Higuchi [13]. By means of plasma
immersion ion implantation a carbonised surface layer of the PUU is formed, which
allows a more constant drug release rate with time. This will permit to increase the
concentration of prednisolone in coating and to reach a longer action of the drug.
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Letter  to  the  Editor
With reference to article: “Impact of the ﬁrst-
generation drug-eluting stent implantation on
periprocedural myocardial injury in patients
with stable angina pectoris”. Dewetting problem
Biodegradable polymers are used as an effective matrix for drug-
eluting coating on vascular stents [1]. Such polymers degrade in
the human organism with a hydrolysis reaction that releases drugs
and products of polymer degradation. The released drugs prevent
an inﬂammatory reaction and thrombosis, suppress neointimal
hyperplasia, and reduce the risk of restenosis. The organism metab-
olizes the released products of polymer degradation safely. Due
to these advantages, drug-eluting stents have found a wide appli-
cation in vascular surgery in comparison with bare metal stents.
However, the question of whether drug-eluting stents show sig-
niﬁcant improvement in comparison with uncoated bare stents
remains and is discussed (for example, Okada et al. reported that
[2]: “. . .use of [drug-eluting stents] has not improved mortality in
patients with [angina pectoris] in spite of their notable suppressive
effect for neointimal hyperplasia compared to that of [bare metal
stents]”).
One reason for the contradiction could be due to a particularity
of the biodegradation process in polymer coating on metal sur-
face. A polymer coating has signiﬁcantly different surface energy
than a metal surface on the stent. Therefore, these two  substances
will minimize the contact area. The reason is a dewetting effect of
polymer coating on all metal surfaces including metal stents [3,4].
We  investigated vascular drug-eluting stents with poly(lactic-
co-glycolic acid) (PLGA) coating (polymer base for drug) as
well as a model PLGA coating on silicon wafer (http://arxiv.org/
pdf/1101.0659v1). The initial PLGA coating on silicon wafer is
smooth and stable. After exposure in water solution the PLGA
coating swells with water, becomes soft and mobile. As result of
mobility, the PLGA coating becomes ruptured, the ruptured parts
move and collect as separate drops with naked metal areas between
them (Fig. 1A). With time the drop sizes decrease due to biodegra-
dation of PLGA. The dewetting process takes about 1–3 days and
the biodegradation process takes 2–3 weeks. Therefore, the coat-
ing stands on stents as separate drops during most of the time of
biodegradation.
Kinetics of dewetting depends on thickness of the coating,
difference between surface energy of coating and metal, surface
tension of polymer, geometry of the surface, density, and viscosity
of the coating [3,4]. The distribution of the drops shows that the
dewetting occurs by spinodal mechanism. That means the coating
is unstable on the metal due to a difference in surface energy of the
metal and PLGA coating.
The separation of PLGA coating to small drops, a peeling off of
the drops from the stent surface, and a move to periphery vessels,
where the PLGA drops can block blood ﬂow, is strongly possi-
ble. The metal surface of the stent comes into direct contact with
blood after a short time in water solution. These changes could
cause periprocedural myocardial injury (PMI) as it was suggested
by Okada et al. [2]: “we  hypothesized that [drug-eluting stent]
implantation may  be associated with a higher incidence of PMI and
affect the clinical outcome after [percutaneous coronary interven-
tion]”.
The dewetting of PLGA coating on metal substrates can
be stopped. We  used ion beam implantation to modify the
PLGA coating. During modiﬁcation, high energy ions cause dam-
age to a number of chemical bonds in PLGA and replace
atoms from polymer macromolecules in the trace of ions.
Replaced atoms join together to each other and join to resid-
ual macromolecules so that the modiﬁed coating becomes highly
crosslinked. The ﬁlm becomes immovable. Dewetting stops
(Fig. 1B).
The ion beam modiﬁed PLGA coating remains smooth and stable
during the complete time of biodegradation. The coating is fully
crosslinked and does not dewet. The degradation process occurs
uniformly.
The same effect of dewetting is observed on metal stents. The
initial coating before biodegradation is smooth. After biodegrada-
tion the untreated stent has a ruptured coating and part of the stent
surface is naked up to metal (Fig. 1C). The ion beam treated coat-
ing remains stable on stents during biodegradation (Fig. 1D). The
dewetting forces cannot break crosslinked PLGA coating, but the
drug is released freely.
The study was supported by Boston Scientiﬁc, Natick, MA,
USA.
0914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Fig. 1. Microphotographs of silicon wafer ((A) and (B), size of photos is 1.2 mm × 0.95 mm)  and stents ((C) and (D), size of photos is 0.24 mm × 0.19 mm)  with poly(lactic-co-
glycolic  acid) coating. (A) The untreated coating is dewetted to separate drops after biodegradation; (B) the ion beam treated coating remains smooth after biodegradation;
(C)  the untreated coating on stent is dewetted to non-regular structures after biodegradation; and (D) the PIII-treated coating on stent is crosslinked and wrinkled, but
remains  continuous.
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Polytetraﬂuorethylene  (PTFE  and  ePTFE)  substrates  were  treated  by  ion  implantation  with  nitrogen  ions
of 20  keV  energies  and 1013–1016 ions/cm2 ion  ﬂuences.  The  modiﬁcation  of the  polymer  surface  was
analyzed  by FTIR  and  XPS  spectroscopy,  water  wetting  angle  measurements  and  AFM  images.  The surface
morphology,  wettability  and  chemical  activity  were  changed  due  to  surface  modiﬁcation.  The growing
of  endothelial  cells of  modiﬁed  surfaces  was  improved  in comparison  with  untreated  PTFE  and  ePTFE
substrates.  The  improved  cell adherence  on  the  modiﬁed  surface  is  based  on  the  improved  adhesion  of
cell proteins.
© 2014  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Polytetraﬂuorethylene (PTFE) is known for its excellent chem-
ical and bio stability and its bio inertness. The mechanically
stretched, expanded form (ePTFE) is microscopically porous, pos-
sessing otherwise the properties of standard PTFE [1]. ePTFE found
a large number of applications in surgery as ﬂaps in herniorrhaphy,
craniosurgery, etc., mainly because of its bioinertness, biostability,
both ﬂexibility and mechanical stability. However, a main domain
is in vascular surgery for as prostheses for smaller, i.e. infrainguinal
blood vessels, artiﬁcial AV shunts, as coating of vascular stents or
heart valve rings.
Despite of wide applications, there are still two main prob-
lems with ePTFE implant: thrombosis and anastomosis stenosis
by intima hyperplasia. The hemodynamic and a mismatch of the
elastic properties of the graft and native vessel were considered as
reasons for graft failure [2]. These problems could not be solved
by improved surgical techniques but are considered as materials
related. Especially thin vessel grafts are susceptible for these prob-
lems.
The extreme hydrophobicity of ePTFE and the low toxicity
is regarded as the reason for the good performance in bigger
∗ Corresponding author. Tel.: +61 2 93512484.
E-mail address: i.kondyurina@gmail.com (I. Kondyurina).
vessels, but a superhydrophobic modiﬁcation of ePTFE failed for
small diameter grafts and in bigger vessels it showed a higher
platelet adsorption than standard ePTFE grafts [3]. Additional sur-
face coating with biologically designed surfaces such as heparin or
hirudin can reduce platelet adherence and the intima proliferation
but has the problem of a physiological decay in biological activity
and in some cases iatrogenic inactivation by protaminsulfate [4–6].
Endothelial cells as the inner lining of blood vessels are known
to provide the best hemocompatible surface. All PTFE-like materials
do not support endothelialisation in vivo [7]. There is a concept is
in vitro tissue engineering, seeding of autologous endothelial cells
on the implant surface prior to implantation [8]. Various attempts
have been made to achieve an adherent layer of endothelial cells
on the surface. Seeding the cells in a system with dynamic pressure
and ﬂow [9,10] has been described as the easiest way to obtain an
endothelial lining, which resists the shear stress of physiological
blood ﬂow, an effect which also works in other systems [11].
Some ways of surface modiﬁcation of ePTFE have been suc-
cessfully attempted based on plasma method of modiﬁcation
[12]. An improved cell adherence and proliferation over untreated
ePTFE was  found as graft for intracranial arteries. In the lat-
ter case an increased adhesion of ﬁbrin-glue was found, which
allows better anchorage of the ﬂap. The trend is to surface
modiﬁcation, which provides speciﬁc cell adherence. These cells
adhere via protein receptors at the extracellular matrix (ECM)
and their basement membrane. The native extracellular matrix
http://dx.doi.org/10.1016/j.apsusc.2014.07.057
0169-4332/© 2014 Elsevier B.V. All rights reserved.
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[13] or selected ECM proteins, collagen [14], ﬁbronectin [15],
and laminin [16] should be adsorbed on the ePTFE surface. The
interaction of these proteins with the integrin is provided by a spe-
cial, highly conservative functional group of the ligand, the RGDS
sequence as well as a peptide of this individual sequence should
be immobilized [15]. In all cases endothelial cells were seeded
in vitro and an improved growth of the cells have been demon-
strated.
The preparation of PTFE surface for the increased growth of
endothelial cells can be achieved by ion beam implantation [17,18].
The method is based on structural modiﬁcation of a thin surface
layer of a polymer under the bombardment by high energy ions
[19–21]. The effect of the modiﬁcation is caused by the penetration
of the high energy ion into the polymer, cascades of collisions with
atoms of macromolecules and transfer of the kinetic energy of pen-
etrating ion to atoms and electrons of polymer macromolecules.
The transferred energy is high enough that atoms and electrons
leave macromolecules and ﬂy away with high kinetic energy caus-
ing new collisions with nearest macromolecules. As result, breaking
of chemical bonds, ionization, formation of free radicals, electron
and phonon excitation of macromolecules are observed [22]. The
ﬁeld of such strong structure changes of polymer is named an ion
track and the size of ion track depends on ion energy, kind of ion
and polymer. This is a ﬁrst stage of the ion beam implantation of
polymers.
After ion penetration, the track ﬁeld of polymer has a very high
concentration of free radicals, ionized and highly excited parts of
macromolecules. These active particles cause a number of chem-
ical reactions. As result, amorphous carbon, aromatic condensed
structures, stable and semi-stable free radical structures appear.
The properties of the polymer surface after ion beam implantation
are mostly connected with this second stage. The morphology of
the surface changes dramatically with formation of rough struc-
tures [23]. The water contact angle of PTFE and ePTFE surface after
modiﬁcation is observed higher [24] and lower [25], than the ini-
tial. The vibrational spectra show a number of new chemical groups
[26].
In general, the kinetics of free radicals takes sufﬁciently long
time (from minutes to days) then the ﬁrst stage (part of second)
due to long kinetics of free radical reactions in PTFE [27,28]. The
presence of free radicals in PTFE causes chain reactions of ﬂuorine
cleaving from initial macromolecules, chain breaking and crosslink-
ing [29–31]. Due to migration of free radicals, the modiﬁed area
can be shifted to signiﬁcantly deeper layers then the track of ion
[32]. In air the free radical reactions of modiﬁed polymer layer are
carried out with participation of oxygen when the stable oxygen-
containing groups appear in polymer [28]. Such modiﬁed polymer
surface is used for different applications [33] including medical
devices [21,34–36]. However, the structure transformation of ion
implanted PTFE and ePTFE and a biological response on the modi-
ﬁed PTFE have not been fully investigated as required for medical
applications.
In present investigation the ion implantation was  applied to
PTFE and ePTFE surfaces. The structure changes in PTFE and
ePTFE after ion implantation were investigated and linked to the
improved cell adherence.
2. Experiment
ePTFE sheets were provided by Boston Scientiﬁc SCIMED, USA.
PTFE ﬁlms of 20 m were provided by Halogen, Perm, Russia.
The PTFE ﬁlms were cleaned by ethanol and dried before using.
The ePTFE samples were used as provided and handled between
protective coatings to prevent contamination of the surface.
Acrylamide with 0.1% of Tetramethylethylenediamine inhibitor of
polymerization (Aldrich) was dissolved in deionized water with a
concentration of 100 g/L.
Ion implantation of PTFE was done on Pulsar implanter
described in [37]. The beam of nitrogen ions with 20 keV energy,
current density of 5 mA/cm2 in a pulse of 300 ns duration with
pulse-repetition frequency of 1 Hz was applied. The ﬂuence of ions
was measured with Faraday-cup.
For acrylamide attachment the modiﬁed samples were soaked
in 10% acrylamide water solution during 2 h at room temperature.
After soaking the samples were washed by deionized water 3 times
and dried on air overnight.
Plasma immersion ion implantation was used for modiﬁcation
of the PTFE and ePTFE substrates. The samples were placed on
the high voltage electrode and covered by stainless steel mesh.
The distance between mesh and sample surface was  30 mm.  The
mesh had the same electrical potential as electrode. The plasma
chamber was vacuumed up to 10−3 Pa and ﬁlled by nitrogen up
to 5 × 10−1 Pa. Plasma discharge was  generated by RF-frequency
generator of 200 W power at 13.75 MHz  frequency. The high volt-
age pulsed biases of 20 kV was  used. The pulse of 5 s duration with
50 Hz frequency of repetition was applied to high voltage electrode.
Ion ﬂuence estimates for the plasma immersion ion implantation
were obtained in an experiment on polyethylene using a proce-
dure described in [21]. The ﬂuence of one high voltage pulse was
determined by comparing UV transmission spectra from polyethyl-
ene ﬁlms after the plasma immersion ion implantation to samples
implanted with known ion ﬂuences in Pulsar ion implanter exper-
iments where the ﬂuence was  measured with a Faraday cup. The
pulse duration, pulse repetition frequency, average current, kind
and energy of ions were adjusted to match the both experiments.
One high voltage pulse of the plasma immersion ion implantation
under the present conditions was  found to correlate with a ﬂuence
of 2.8 × 1011 ions/cm2. The PTFE and ePTFE samples were treated
with 35–35,000 pulses, corresponding to implantation ion ﬂuences
of 1013–1016 ions/cm2. The plasma immersion ion implantation of
PTFE has shown similar results as for ion implantation of PTFE with
Pulsar implanter.
Fourier transform infrared attenuated total reﬂection (FTIR ATR)
spectra were recorded on Nicolet Magna spectrometer with Ge
ATR crystal with 45◦ of incident angle. Number of scans was 100,
spectral resolution was 2 cm−1.
The contact angles between a PTFE and ePTFE sample surface
and de-ionized water were measured using a Kruss contact angle
analyzer DS10 employing the sessile drop method.
X-ray photoelectron spectra (XPS) were recorded on Scanning
Auger electron spectrometer Microlab 310F (Fisons) with accessory
XPS-unit (Al/Mg – X-ray tube). Scanning step was 0.2 eV.
An atomic force microscope DI-3100 (Digital instruments Ins.,
Santa Barbara) was  used for surface morphology analysis of the
PTFE samples before and after ion implantation. The measurements
were carried out in a tapping mode. Silicon probes with 75 kHz
resonant frequency, 1.5–3.7 N m−1 spring constant and 10 nm cur-
vature radius were used. The initial PTFE ﬁlm was too rough for
AFM measurement. To get smooth PTFE surface, the initial PTFE
ﬁlm was pressed between Silicon wafers before the ion implanta-
tion. A surface topology of the PTFE ﬁlm after pressing was similar
to the silicon wafer surface topology.
In cells experiment, ePTFE discs with the surface area of 0.58 cm2
were mounted in Minusheets (Minucells and Minutissue, Bad
Abbach) and steam sterilized at 120 ◦C. The bovine aortic endothe-
lial cell line GM7373 (Coriell) was  used for the experiments [38].
4 × 104 cells in 200 L medium (MEM-Earle supplemented with
10% fetal bovine serum (FBS), 1 × MEM  vitamins, 2 mM N-acetyl
l-alanyl l-glutamine, 1 × amino acids) were seeded directly on the
samples. They were allowed to adhere for 2 h at standard cell cul-
ture conditions, then medium was  ﬁlled up to 1 mL  per sample. 3
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days after seeding the cells were ﬁxed in 0.2% paraformaldehyde
in PBS and stained with rhodamine. Images were taken by ﬂuores-
cent microscopy with video camera and the color was inverted for
better observation.
3. Results
Visually the effect of ion implantation for PTFE and ePTFE is
observed less than for hydrocarbon polymers like polyethylene and
polystyrene. The ion beam implantation changes the color of the
samples only at high ﬂuences (from 5 × 1015 ions/cm2 and higher).
Both PTFE and ePTFE samples become gray at ﬂuence of 1016–1017
ions/cm2. The distribution of the color on the PTFE and ePTFE sam-
ples shows uniform ﬂuence distribution on the sample surface. In
all our cases the ﬂuence was homogeneously distributed, excluding
corners where the samples were mounted to the sample holder.
The corner areas of the samples were excluded from subsequent
analysis of structure and cell experiments.
The analysis of the PTFE surface with using of atomic force
microscopy shows that the surface of PTFE becomes signiﬁcantly
rough after ion implantation when the initial PTFE surface is smooth
(Fig. 1a–c). The character and shape of the holes on ion implanted
PTFE surface are similar to the etched surface at plasma and ion
implantation observed earlier [26,30]. The untreated PTFE surface
is smooth with Root Mean Square (RMS) roughness of 0.59 that is
close to the silicon wafer roughness. The ion implanted PTFE with
1015 ions/cm2 ion ﬂuence shows RMS  roughness of 12 nm and PTFE
with 1016 ions/cm2 ion ﬂuence shows RMS  roughness of 20 nm.  The
histogram of the surface images (Fig. 1d) shows signiﬁcant broad-
ening of the frequency events of the height. The narrow histogram
of the untreated PTFE is transformed into broad curve with max-
imum at 55 nm after 1015 ions/cm2 ion ﬂuence and broad curve
with maximum at 87 nm after 1015 ions/cm2 ion ﬂuence. The single
maximum curves observed for all samples show, that the surface
features height have a random character corresponding to normal
distribution. The analysis of ﬁrst neighbor distance (FND) as aver-
age distance between hills gives a characteristic size (diameter)
of the holes is about 210 nm for 1015 ions/cm2 ﬂuence and about
440 nm for 1016 ions/cm2 ﬂuence. The Fourier ﬁltering (FFT) of the
surface image used for the image frequency components analy-
sis (Fig. 1a–c) gives narrow peak for untreated PTFE while the ion
implanted PTFE peaks are broader. The FFT image for all samples
are unidirectional that shows the unidirectional character of the
surface features. As the result of surface morphology changes, the
effective area of the PTFE surface increases to 1.06–1.07 times after
ion implantation.
The etching effect inﬂuences on the ePTFE surface structure.
The untreated ePTFE has a ﬁbril structure with micron-size nodes
(Fig. 2). The ion implantation breaks some ﬁbrils and round the edge
of the nodes on the top surface layer. However, the ﬁbril structure
of ePTFE surface remains.
The new lines in 1750–1650 cm−1 region appear in the FTIR ATR
spectra of ion implanted PTFE (Fig. 3). The modiﬁcation of the poly-
mers at ion implantation affects only a thin surface layer and the
new lines have weak intensity in FTIR ATR spectra. The changes
of FTIR transmission spectra of PTFE are invisible for all regimes of
treatment. The new lines are interpreted as stretching vibrations of
C O and C C groups in oxidized and carbonized PTFE surface layer.
The intensity of these lines increases with the ion implantation ﬂu-
ence that corresponds to increase a concentration of carbonized
and oxidized structures. The carbonization of the surface layer is
due to a loosing of ﬂuorine atoms in the PTFE macromolecule at
ion implantation and a conjugation of carbon atoms in aromatic
structures. The appearance of oxygen-containing structures is
caused by reactions of free radicals with atmospheric oxygen after
exposure of the treated PTFE samples on air. Due to the strong etch-
ing effect of the modiﬁed surface layer of PTFE, the concentration of
new groups in the modiﬁed PTFE and ePTFE surface layer is lower
in comparison with hydrocarbon polymers such as polyethylene or
polystyrene at the same conditions of ion implantation.
The element composition of the PTFE surface changes after ion
implantation as it is observed by XPS data (Table 1). The spectrum
of untreated PTFE shows only C1s and F1s lines in ratio correspond-
ing the chemical formula of PTFE macromolecule. The experimental
value of carbon (39%) is slightly higher than theoretical value (33%),
and the experimental value of ﬂuor (61%) is slightly lower than the
theoretical value (67%). The additional lines of O1s and N1s are
observed in the spectra of ion implanted PTFE. The concentration
of carbon atoms increases dramatically (60–70%) after ion implan-
tation due to deﬂuorination and carbonization of the surface layer.
The ﬂuorine concentration in PTFE signiﬁcantly reduces from 61%
for untreated PTFE to 4% after low ﬂuence of 1013 ions/cm2 and
recovers up to 21% with high ﬂuence of 1016 ions/cm2. The nitro-
gen and oxygen lines are observed in all spectra of ion implanted
PTFE. At low ﬂuence, the surface layer of PTFE contains signiﬁcant
concentration of oxygen (14%) and nitrogen (11%) atoms and keeps
it the same with higher ﬂuence. These XPS data show that the PTFE
surface layer becomes carbonized, nitrized and oxidized after ion
implantation. At highest ﬂuence (1016 ions/cm2) the element con-
tent becomes closer to the initial PTFE with higher ﬂuor (21%),
lower carbon (60%), nitrogen (8%) and oxygen (10%). It supports
AFM results showing the modiﬁed layer is etched signiﬁcantly at
high ﬂuence and the virgin bulk layer comes to the top.
The water wetting angle of PTFE changes from 120◦ for
untreated PTFE to about 70–80◦ for ion implanted PTFE (Fig. 4).
The lowest contact angle (73◦) is observed for the lowest ion ﬂu-
ence (1014 ions/cm2). At high ﬂuence (1016 ions/cm2) of nitrogen
ions the wetting angle increases.
The increase of the contact angle was  observed in PTFE after
ion implantation and laser ablation treatment [39,40]. A reason of
the increase is a roughness of the PTFE surface, which increases
due to etching of the PTFE macromolecules [41]. The regime of
the ion implantation inﬂuence on the etching and consequently
on wettability of the ion implanted PTFE surface [42].
The initial surface of ePTFE is extremely hydrophobic. The wet-
ting angle of water drop on ePTFE initial surface is 145◦. The water
contact angle of ion implanted ePTFE decreases up to 120–140◦
range without clear tendency of ﬂuence. These results of the wet-
ting angles on ePTFE surface (Fig. 4) cannot be used directly for
wettability analysis, because of the ﬁbril morphology of the mate-
rial (see Fig. 2). The drop partly contacts the polymer ﬁbers and
partly the air between the ﬁbers. Therefore, the ﬁbers obviously
cannot inﬂuence on the wetting angle signiﬁcantly. After ion
implantation, when the ePTFE ﬁbers become more hydrophilic, the
water can penetrate between the ﬁbers to ﬁll the space between
ﬁbers. When it is happened, the drop of water on the ion implanted
ePTFE surface contacts the ﬁbers and the water between the ﬁbers.
In this case the contact angle is extremely low about 20–30◦. These
cases were excluded from these results for ion implanted ePTFE.
Therefore, the results of ePTFE ﬁlm wetting angle cannot be used
directly. Because of equal chemical structure of PTFE and ePTFE, the
wettability properties of PTFE can be transferred to ePTFE ﬁbers.
The ion implantation changes a chemical activity of the PTFE and
ePTFE surface. To test it, the ion implanted PTFE was  immersed in
acrylamide solution at presence of an inhibitor of polymerization
(Tetramethylethylenediamine) without initiator of polymeriza-
tion. Then the samples were washed in deionized water to remove
the acrylamide and dried. The FTIR spectra of PTFE surface show
new lines at 2994, 2960, 2924, 2854 cm−1 interpreted as stretch
vibrations and 1465, 1452 cm−1 interpreted as deformation vibra-
tions of C H bonds of a polyacrylamide attached on the PTFE
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Fig. 1. AFM image of PTFE surface and statistical analysis. The ion implantation of 20 keV energy nitrogen ions is done with following ﬂuence: (a) untreated surface, (b)
1015 ions/cm2, (c) 1016 ions/cm2. The graphs (a–c) are AFM images (left) and FFT images (right). The graphs (d) is a histogram of the height event of the images. The roughness
and  effective area increase with ion implantation ﬂuence.
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Fig. 2. SEM image of (a) untreated and (b) ion implanted ePTFE. The ion implantation is done with 20 keV energy nitrogen ions of 1015 ions/cm2 ﬂuence. The size of images
is  0.3 × 0.3 mm2. The sharp edges become smoother after ion implantation due to etching PTFE, but the ﬁber structure remains.
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Table 1
Element content (%) in PTFE surface after ion implantation by 20 keV nitrogen ions.
The  integral intensity of C1s, N1s, O1s and F1s, lines in XPS spectra and theoretical
values by formula were used for the analysis.
Elements Formula of PTFE Untreated Fluence (ions/cm2)
1013 1014 1015 1016
C 33 39 70 71 63 60
N  0 0 11 11 12 8
O  0 0 14 14 14 10
F  67 61 4 4 10 21
surface (Fig. 5). A strong line of C C vibrations in acrylamide at
1630 cm−1 is not observed, while this is mostly intensive line in a
spectra of the acrylamide monomer. The weaker lines of C O car-
bonyl and NH amine groups can be overlapped with the C O and OH
lines of the modiﬁed layer of PTFE. The water contact angle of modi-
ﬁed PTFE after soaking in acrylamide solution decreases from 80◦ to
51◦ showing hydrophilic layer of the polyacrylamide. The spectra
of the untreated PTFE soaked in acrylamide solution and washed
in water do not show the lines of acrylamide. The water contact
angle of untreated PTFE soaked in acrylamide solution and washed
in water does not change. Because the presence of inhibitor and
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Fig. 5. FTIR ATR spectra of PTFE treated by nitrogen ions of 20 keV energy with
1016 ions/cm2 ﬂuence (bottom) and post-treated in acrylamide solution (top). Arrays
show additional lines appeared after acrylamide post-treatment. The C O and N H
acrylamide peaks are masked with C O and OH peaks of oxidized PTFE layer and
are not used for acrylamide analysis.
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Fig. 6. Microphoto of cells grown 3 days on untreated (a, b) and ion implanted (c–h) PTFE. The treatment was done by nitrogen ions of 20 keV energy with 6 × 1013 (c, d),
1  × 1014 (e, f) and 5 × 1014 (g, h) ions/cm2. The cells form a compact colony on untreated PTFE (low resolution image a). Cell body is circled, compact to minimize a contact
area  with untreated PTFE surface (high resolution image b). The cells are distributed uniformly on ion implanted PTFE (low resolution image c, e and g). The cell body is
elongated to maximize a contact with the ion implanted PTFE (high resolution image d, f and h). The original color was inverted for better observation.
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Fig. 7. Proteins are observed on the PTFE and ePTFE modiﬁed surface after cell
attachment and removing. Top spectra are FTIR ATR spectra of ePTFE surface after
cell  growing and removing: (a) untreated, (b) ion implanted. The arrays show Amide
A,  Amide I and II lines of proteins. The C–F lines of ePTFE are marked with “CF”.
Bottom spectra are XPS spectra of PTFE in S2p region of energy: bottom (black)
is  untreated PTFE, middle (red) is ion implanted PTFE, top (blue) is ion implanted
PTFE after cells growing. The cells have been removed. The S2p line in spectrum of
ion implanted PTFE after cell growing indicates a presence of attached ECM pro-
teins. (For interpretation of the references to color in this ﬁgure legend, the reader
is  referred to the web version of the article.)
absence of initiator of polymerization in the acrylamide solution
prevents a spontaneous polymerization of acrylamide monomer,
the polymerization of acrylamide on the ion implanted PTFE sur-
face is available only due to reactions of acrylamide monomer with
active groups in the modiﬁed surface. The absence of C C in the
attached layer shows that this group was spent for the attachment.
Similar reaction of C C group is a polymerization reaction of acryl-
amide with free radicals of initiator. In present experiment, the
initiator of polymerization could be free radicals of the modiﬁed
layer of PTFE, which were detected active in previous study [33].
Following the surface modiﬁcation of PTFE, the cells adhere
and grow differently on untreated and ion implanted PTFE surface.
The cells adhere and grow on both untreated and ion implanted
Table 2
Density of endothelial cells distribution on PTFE after 3 days growing.
Fluence of the treatment Cell density (m−2)
Seeded cell density for all samples 4 × 104
Untreated (490 ± 100) × 104
6 × 1013 ions/cm2 (2100 ± 500) × 104
1014 ions/cm2 (1500 ± 300) × 104
5 × 1014 ions/cm2 (1400 ± 400) × 104
PTFE, however the amount of cells on the ion implanted PTFE is
signiﬁcantly higher, than on untreated PTFE (Table 2). The cells
are growing better on PTFE treated with lowest ﬂuence (6 × 1013),
while on high ﬂuence treated PTFE (5 × 1014 ions/cm2) the amount
of cells is higher signiﬁcantly that on untreated PTFE. Similar
improvement of cell adherence was observed for rat smooth mus-
cle cells on PTFE after dielectric barrier discharge [43] and vascular
smooth muscle cells on PTFE with deposited carbon coating [44].
The cells are distributed differently on untreated and ion
implanted PTFE surfaces. The cells on untreated PTFE surface are
joined to compact colony and most surface remains free of cells
(Fig. 6). The cell density in the colony is high. The cell bodies are
small and round.
The cells cover whole surface of the ion implanted PTFE. The
cell density is mostly uniform overall surface. The cell bodies are
elongated and spread on the PTFE surface. Similar uniform cell
spreading is observed on the ion implanted ePTFE ﬁbrils. Such cell
improved picture is observed for low (6 × 1013) and high (5 × 1014)
ﬂuence of ion implantation.
The speciﬁc contact of cells with ion implanted ePTFE was  sup-
ported by FTIR ATR and XPS spectra of the ePTFE surface after cell
culture (Fig. 7). The substrates after the cell culture were washed
with buffer and distilled water. The FTIR ATR spectra showed the
presence of intensive lines at 3300, 1650 and 1540 cm−1 related to
Amide A, Amide I and Amide II vibrations of peptide groups. Such
groups are attributed to proteins, which were in contact with PTFE
surface when cells were adhered. After removing of the cells, these
proteins remain attached on the ion implanted ePTFE surface. The
spectrum of untreated ePTFE shows these lines with lower inten-
sity. The proteins after cell attachment were also observed by the
XPS spectra of modiﬁed ePTFE (Fig. 7). The lines of S2p at 169.8
and 172.8 eV are attributed to sulfur atom of proteins. Spectrum
of untreated ePTFE after cell growing does not show S2p line or
its intensity is undetectable. Both kinds of spectra show, that the
ion implanted ePTFE surface provides a strong protein attachment
from the cells when cells are adhered and grown.
4. Discussion
The total cell coverage of the implant surface is critical for organ-
ism respond. The integration of polymer implants into organism
needs a hosting for organism cells on the implantable material.
The materials of implant are selected to provide the functional-
ity of the medical device, when the surface of the material should
provide adherence, differentiation, viability of the cells for a long
period of time. The interaction of cell with the substrate surface is
complex and proceeds through a number of protein-surface inter-
actions and protein transformations in cell wall. The ﬁrst reaction of
extracellular matrix (ECM) protein on a presence of the substrate is
adsorption on the surface and a conformation of the protein reports
about suitability of the surface for the cell adherence. Therefore, the
respond of the ECM protein should correspond to the natural cell
functionality.
The untreated PTFE is hydrophobic materials with water contact
angle of 120◦. When a cell approaches the surface and the cell wall
protein is attached on the hydrophobic surface, the conformation
of the protein is adopted to maximize the hydrophobic interac-
tions, while before the protein was  surrounded by water and its
hydrophilic interactions were maximized. To switch to hydropho-
bic interactions, the protein should change a conformation. As
result, the cell could get a signal that the ECM protein changes the
conformation. The squashed cell shape, compact cell distribution
and low cell growing rate on untreated PTFE and ePTFE show, that
the hydrophobic interactions on the untreated PTFE surface are not
favorable for the cells.
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The ion implantation changes the chemical structure of the PTFE
and ePTFE surface layer dramatically. The surface becomes chemi-
cally active with appearance of free radicals, oxygen-containing and
nitrogen-containing groups. The water contact angle decreases to
70–80◦. When the protein molecule approaches this hydrophilic
surface, the rest of protein molecule remains surrounded by water
molecule and the water molecules remain in the interface between
the surface and attached protein molecule. The water core pre-
serves the protein hydrophilic interactions and consequently the
conformation, while the protein attachment is based on a free rad-
ical activity of the modiﬁed layer. It provides a strong attachment
of protein as it was shown in other studies [18,21,45–47]. Accord-
ing the active protein conformation, the cell gets right signal and
spreads on the surface. The total coverage of the modiﬁed polymer
with growing active cells gives a new opportunity for the medical
implants in future.
5. Conclusions
The ion implantation changes signiﬁcantly the structure of
ePTFE and PTFE surface layer. The PTFE surface becomes rough
due to etching of polymer surface layer under ion bombardment.
The ePTFE ﬁbrils become thinner. The surface layer becomes car-
bonized, oxidized and nitrized. As result, the surface becomes
hydrophilic and chemically active with free radicals, as it is
observed by polymerization free radical reaction of acrylamide.
The cell adherence to ion implanted PTFE and ePTFE is enhanced
through the attached proteins from cells. The results on cell adher-
ence and growing show, that ion implanted PTFE and ePTFE can be
suitable materials for cell growing and cell spreading on the sur-
face, when a medical implant is required to be totally coated by the
cells.
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Abstract. Modification of the surface layer of polyurethane with plasma-immersion ion 
implantation (PIII) and studying its physical and chemical changes have been discussed in this 
paper. The goal of the research was to obtain carbonized layer allowing creating biocompatible 
polyurethane implants. The experiments of PIII treatment in various modes were performed. 
The investigation of the modified surface characteristics was carried out by observing the 
kinetics of free surface energy for two weeks after treatment. The regularities between 
treatment time and the level of free surface energy were detected. The explanation of high 
energy level was given through the appearance of free radicals in the surface layer of material. 
The confirmation of the chemical activation of the polyurethane surface after PIII treatment 
was obtained. 
1. Introduction 
The necessity of restoring or substitution the damaged human tissues by artificial device produced 
using different polymers or metal alloys, has determined the development of a separate section of 
modern medicine – the implantology. 
    The main purpose of such type of surgery is to restore lost characteristics and properties of tissue or, 
if possible, its improvement. The most important requirements to the characteristics of the implantable 
material are biocompatibility, mechanical properties (strength, elasticity or hardness, coefficient of 
friction, durability), chemical properties (corrosion resistance, the absence of toxic emissions), the 
weight and the economic aspect [1].Nowadays many research groups are carried out investigations 
aimed at studying the possibility of applying polymer materials in medicine (food grade polypropylene 
(Anulon-92) [2], polystyrene [3], polymethylpentene [4, 5], polyethylene [6, 7], polyethylene 
terephthalate (PET) [8], thermo-plastic polyurethane (Elastollan ® 1180A50) [9], polyhydroxybutyrate 
(PHB), poly-L-lactic acid (PLLA) [10, 11], polytetrafluoroethylene (PTFE) [12], biodegradable 
polymer [13]). Polymeric materials are becoming more popular due to the fact that it satisfies almost 
all specified requirements [14-16]. Its surface may provide immobilization of biologically active 
molecules and living cells, however, this quality requires significant improvements [17,18]. Rational 
way to solve this problem is to develop a technique of treatment the outer layer, modifying it so that it 
becomes a safe, friendly, biocompatible capsule for the body and the inner part of the implant would 
have the rest of the required parameters. 
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    Among a number of ways to modify the surface (chemical exposure, temperature processing, the 
corona discharge, ultraviolet irradiation [19, 20]), one of the most promising areas of research is also 
the use of plasma-immersion ion implantation (PIII). With this technology, it is possible to create on 
the material surface the layer having the property of biocompatibility; moreover the process itself is 
clean and leaves no traces on the surface of by-products. Also, comparing with other conventional 
techniques, PIII advantage consists in the ability to precisely control the surface modification, 
regardless of its geometry [21]. 
    In numerous papers related to the study the possibilities of PIII technology, it is shown that the 
structure and surface chemical properties of the treated polymer are dependent on the gas from which 
the plasma is generated, and the time and intensity of treatment. It is considered the application of the 
following gases and its mixtures: helium [22], nitrogen [8], oxygen, argon and argon + oxygen mixture 
[23]. There is often the interest to analyse the influence of the experimental parameters within some 
range (the pressure of the plasma, gas flow, power, time of treatment). In our experiments we 
performed the treatment in the nitrogen plasma with ion energy of 20keV. Treatment time was varied 
from 80 to 800 seconds that corresponds to5∙1014– 1016 ions/cm2. 
    To analyse the effect of ion-plasma treatment on the surface of the material it is often used a 
combination of several methods of experimental studies such as optical microscopy [3], atomic force 
microscopy (AFM) [2, 4], scanning electron microscopy (SEM) [2, 3], x-ray photoelectron 
spectroscopy (XPS) [3, 4], infrared spectroscopy (FTIR) [2], the study of the surface energy by 
measuring the contact angle [2, 4], tensile test [2], thermal analysis (Differential Scanning Calorimetry 
TA) [2], spectrophotometry [2], Rutherford backscattering spectroscopy (RBS) [4], electrokinetic 
analysis [4], goniometry [4], ablation of PMP surface layers determined by gravimetry [4].For 
biocompatibility study experiments with mouse embryonic fibroblasts [2, 6], human osteosarcoma 
cells [3] and human blood (haemolytic potential, thrombogenicity) [2, 8] are performed. In our work, 
we have applied the analysis of the kinetics of the surface energy, including its polar and dispersive 
components, as a function of the past time after treatment; in addition we plan to take advantage of 
XPS and infrared spectroscopy. 
    The above studies have shown that, depending on the purpose, in one case, ion-plasma treatment 
can dramatically increase the number of adhered cells or bioactive molecules as well as positively 
affect the uniform distribution of cells on the surface of the material and their viability. In another 
case, decrease of platelet adhesion is confirmed that causes the improvement of the blood 
compatibility. 
2. Materials and methods 
2.1. PIII treatment of PU samples 
For the treatment on PIII device we used the samples of size 1×2 cm2. Experimental investigations 
include set of PIII-treatments of polyurethane samples for 40, 80, 400 and 800 s (corresponding to an 
ion fluency of 5∙1014, 1015, 5∙1015, 1016 ions/cm2). The source of ions was inductively coupled radio-
frequency nitrogen plasma powered at 13.56 MHz. The nitrogen gas used for PIII was 99.99% pure. 
The plasma power was 100W with reverse power of 12W when matched. The plasma density during 
treatment was monitored by a Langmuir probe with rf-block from Hiden Analytical Ltd. The base 
pressure was 10
-6
Torr (∼10-4 Pa); the pressure of nitrogen during implantation was 2⋅10-3Torr 
(∼4.4⋅10-2 Pa). 
    The samples were treated in plasma chamber by ion beam, which was extracted from plasma by the 
application of high voltage (20kV) at a frequency of 50Hz with duration of pulses of 20μs. The 
polyurethane samples were placed on a holder with a mesh. The mesh was electrically connected to 
the holder and held in front of the sample on the distance of 5 cm. 
 
 
3rd International Conference on Competitive Materials and Technology Processes (IC-CMTP3) IOP Publishing
IOP Conf. Series: Materials Science and Engineering 123 (2016) 012003 doi:10.1088/1757-899X/123/1/012003
2
2.2. Contact angles and surface free energy 
The contact angles of two liquids (de-ionized water and diiodomethane) on the surface of PU were 
measured by contact angle analyzer Kruss DS10 based on the sessile drop technique. For calculating 
the surface free energy and its polar and dispersive components the Rabel model with regression 
method was used. There was a set of 11 measurements of 5 drops of each liquid per sample. After ion-
plasma treatment the kinetics was being monitored during 2 weeks (20, 30, 40 minutes, 1, 2, 5, 7, 23 
hours, 2, 4, 11 days after treatment). 
3. Results 
The first contact angle measurement was carried out immediately after extracting the sample from the 
PIII device, which process included injection of air into a vacuum chamber and took 20 minutes. The 
obtained data showed an inverse dependence between the values of contact angles of water and 
treatment time. The contact angle for the sample treated for 40 seconds was equal to 48±2º, for 80 
seconds: 47±1.5º, for 400 seconds: 45±0.9º, for 800 seconds: 38±0.4º.After 2 weeks the contact angle 
has increased and reached a stable value. For the sample treated for 40 seconds, the contact angle 
became equal to 63±2.3º, for 80 seconds: 73±1.7º, for 400 seconds: 66±1.3º, for 800 seconds: 64±1.4º 
(figure 1). 
 
 
Figure 1. Kinetics of water contact angle after treatment samples in 4 modes of PIII 
 
In this case, the correlation between the treatment time and the contact angle remained only for three 
treatment modes (80, 400, 800 seconds). The sample treated over the shorter time of 40 seconds, has 
showed the lowest value of the contact angle, standing out from the overall trend. 
    Kinetics of diiodomethane contact angle was significantly different from water and it was 
nonmonotonic. Although as in the case of water the treatment also decreased the contact angle but to a 
lesser degree. The correlation between the angle and the plasma treatment time is not observed, and 
after two weeks after treatment the contact angle has reached the level of 44±0.5° for all the samples, 
regardless of treatment time (figure2). 
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 Figure 2. Kinetics of diiodomethane contact angle after PIII treatment during two weeks 
 
The dependence between the total free energy and the treatment time has the correlation similar to the 
dependence of water contact angle. After 2 weeks for 3 PIII modes there was a direct dependence 
between the treatment time and energy value: the sample treated for 80 seconds had 45.5 mJ/m
2
, for 
400 seconds: 48 mJ/m
2
, for 800 seconds: 49.5 mJ/m
2
. But the treatment during 40 seconds gave the 
highest value: 50.5 mJ/m
2
. 
    Analysis of the experimental data was carried out by approximation (figure3) using a function 
(equation (1)) represented as a sum of two exponential functions: 
 0 1 1 2 2( ) a a exp( / k ) a exp( / k )f t t t      (1) 
where f  is a total free energy;t is time after PIII treatment; k1and k2are the rate constants of the two 
characteristic stages; a0, a1and a2are the constants to be defined. 
    The effectiveness of such method of approximation was demonstrated in [24], in which the 
observed phenomenon isqualitatively similar. 
 
 
Figure 3. Exampleof data and its fitting Figure 4. Kinetics of total surface free energy 
 
Analysis of the kinetics of the surface free energy (figure4) revealed that after PIII treatment of PU 
two characteristic relaxation processappeared, the first of which was predominant over the second one, 
but faded rapidly,after which only the second process occurred.This is confirmed by the fact that the 
characteristic time for the first process (k1) although has a large spread (from 24.3 to 45 min) but 
Data 
Fitting 
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comparing to the second one (k2variesfrom 1258.5 to 3177.8 min) has significantly (by two orders of 
magnitude) smaller value (Table 1). 
 
Extrapolation of the data allows determining the value of free energy at the time immediately after 
treatment, f (0) (Table 1). This value is essentially independent of the treatment time and equals 
66±1mJ/m2. Similar way we determined the level, which energy reached at the expiration of arbitrarily 
large period of time, f(∞). It is equal to 50.5, 45.5, 48, 49.5 mJ/m2, respectively for 40, 80, 400, 800 
seconds oftreatment. 
    The qualitative behavior of the total energy is caused by polar component, because a 
dispersivecomponent remains during two weeks practically constant.Its value was inside the range of 
40±5 mJ/m2 and had no dependence on the treatment time. 
Polar component after 2 weeks decreased significantly (by 35-55%).Moreover, there was a direct 
correlation between the reduction of energy and the PIII mode: for the sample treated for 40 seconds, 
reduction was 35% (from 20 to 13 mJ/m
2
) for 80 and 400 seconds: 53% (8 to 17 mJ/m
2
 and from 21 to 
10 mJ/m
2
, respectively) for 800 seconds: 55% (from 26 to 12 mJ/m
2
). 
    After 2 weeks remaining values of polar components were 3, 8, 10, 12 mJ/m
2
, respectively for 40, 
80, 400, 800 sec. Thus, we can trace the situation similar to total free energy, where the 40 seconds 
treatment is out from theoverall trend (Table 2).  
 
Table 2.The constants of fitting function and its values in limiting cases for polar component of the 
surface free energy 
 
4. Conclusion 
In this work the investigation of polyurethane modification to create chemically activesurface layer in 
material was performed. By monitoring the kinetics of surface free energy and its polar and the 
dispersivecomponents itwas established that treatment of the material leads to significant and 
irreversible changes in the surface layer.It results in a sharp increase of the surface energy after PIII 
treatment and preserving its sufficiently high, in comparison with untreated PU, level 
thatreflectssignificant chemical changes on the surface of polymers.At the same time, such a 
considerable increase of energy (up to a level of about 67 mJ/m
2
)and behavior of its polar and 
dispersive components can be attributed to only the appearance of free radicals in the material, which 
in turn makes it possibleto add, using existing techniques, to polyurethane the property of 
biocompatibility.Using a level f(∞), which is reachedby energy after a sufficiently long period of time, 
as a criterion of selecting a treatment mode, we can make the assumption thatamong all variants of 
treatment the briefest one (40s) may be the most preferable for us by the fact that stored energy and, 
therefore, the concentration of free radicals onto the surface has the highest level among all the 
considered variants. 
Table 1. The constants of fitting function and its values in limiting cases fortotal surface free energy 
Time of treatment, s f(0), mJ/m
2
 f(∞), mJ/m2 k1, min k2, min 
40 67±1.1 50±0.7 24.3±5.3 1258.5±438.3 
80 65.5±0.9 45.5±0.5 89.9±14.3 3177.8±1805.9 
400 65±0.5 48±0.2 80.5±9.6 1638.6±841.7 
800 66±1.2 49.5±0.5 45±10.8 1789.9±815.2 
Time of treatment, s f
P
(0), mJ/m
2
 f
P(∞), mJ/m2 k1
P
, min k2
P
, min 
40 24±0.4 13±1.1 20±4.8 767±388.1 
80 20.5±0.3 7.5±0.5 107±21.2 3121±1265.3 
400 23±0.8 10±0.7 42.9±16.8 2224±574.5 
800 28±0.5 12±1.3 43.8±16.9 5494.2±4559.4 
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At this stage of research it can be claimedthat the application of PIII technology has enabled to 
activatesurface layer of polyurethanethat offers the prospect of further modification of the surface to 
the level of biocompatibility. 
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Abstract
Polyurethanes are a diverse class of polymers, with independently tunablemechanical and
biodegradation propertiesmaking them a versatile platformmaterial for biomedical implants.
Previous iterations have failed to adequately embody appropriatemechanical and biological
properties, particularly for vascularmedicinewhere strength, compliance andmultifaceted
biocompatibility are required.We have synthesized a newpolyurethane formulationwithﬁnely tuned
mechanical properties, combining high strength and extensibility with a lowYoung’smodulus.
Additional cross-linking during synthesis enhanced stability and limits leaching. Under cyclic testing,
hysteresis wasminimal following completion of the initial cycles, indicating the robustness of the
material. Building on this platform,we used plasma immersion ion implantation to activate the
polymer surface and functionalized it with recombinant human tropoelastin.With tropoelastin
covalently bound to the surface, human coronary endothelial cells showed improved attachment and
proliferation. In the presence of heparinizedwhole blood, tropoelastin-coated polyurethane showed
very low thrombogenicity in both static andﬂow conditions. Using this formulation, we synthesized
robust, elastic prototype conduits which easily retainedmultiple sutures andwere successfully
implanted in a pilot rat aortic interpositionmodel.We have thus created an elastic, strong biomaterial
platform, functionalizedwith an important regulator of vascular biology, with the potential for further
evaluation as a new synthetic graftmaterial.
1. Introduction
Modern polyurethanes (PUs) are block copolymers
with ‘hard’ and ‘soft’ blocks, having glass transition
temperatures above and below room temperature
respectively. They are extensively used in medicine
due to their biological inertness and the wide range of
mechanical properties and biodegradation rates that
can be attained [1]. Modern PUs are used for short
term devices such as blood and urinary catheters [2],
syringe tips, pipes and bags for blood circulation
systems, tissue scaffolds [3], as well as long term
devices such as artiﬁcial diaphragm membranes,
artiﬁcial joints, meniscal prosthetics [4], breast pros-
thetic shells [5], artiﬁcial hearts [6], bone and other
orthopaedic devices [7].
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PU has also been widely used in the manufacture
of vascular grafts [8–11], beneﬁting from the opportu-
nity to create compliant, durable materials. Past itera-
tions of PU constructs have suffered from a
combination of the lack of appreciation of their biolo-
gical destination and a failure to tune their biological
interface prior to implantation [12]. PUs that have
polyester soft segments degrade rapidly [13] and so are
used for applications where a temporary presence is
required, such as wound closure adhesives. PUs that
have polyether soft segments degrade more slowly in
the body and are used for longer term implants [3].
Most of these types of polyurethanes contain methy-
lene diphenyl diisocyanate as the hard segment and
have a high strength and a high Young’s modulus. A
reduction in strength and Young’s modulus is
obtained by using toluene diisocyanate (TDI) as the
hard segment [14]. However, even this does not pro-
vide a Young’s modulus low enough to avoid bio-
mechanical failure at locations where the implant
material contacts with soft tissue. Soft tissuemoduli in
a range between 2 and 1000 kPa have been reported
[15–17], while modern medical grade polyurethanes
have moduli in a range of 4.7–80MPa [18, 19] and
other polymers that have been used or proposed have
moduli in the range 1.5–1200MPa [20–22]. None of
the modern polymers that are suitable for use as bio-
stablemedical implants has low enough Young’smod-
ulus. Although a recently proposed arborescent block
copolymer, TPE1, has a Young’s modulus (0.6 MPa)
in the appropriate range [23], the need for new long-
term biostable polymers with low Young’s modulus
for long-term, soft-tissue implants remains
signiﬁcant.
For applications in vascular medicine, there are
also important biological requirements, including
favorable cell interactions and low thrombogenicity.
Current synthetic vascular graft materials, including
Dacron and expanded polytetraﬂuoroethylene
(ePTFE), are intrinsically unsuited to implantation as
they are highly thrombogenic, fail to recover a func-
tional endothelial cell layer and invoke a profound
immune response [24]. In the long-term, uncon-
trolled smooth muscle cell proliferation inexorably
contributes to a gradually occluded conduit, accen-
tuated at the suture points where synthetic materials
join the native vasculature. This lack of vascular com-
patibility and mismatched mechanical properties
together translate to the uniform failure of commer-
cial synthetic conduits for small diameter (<6 mm)
grafting applications [25].
The compatibility and integration of artiﬁcial
grafts with native tissue can be improved with surface
modiﬁcation of the graft. Ion implantation with ener-
getic ions has been found to be a successful method for
the surface modiﬁcation of polymer materials. More
recently, it has been shown that ion implantation can
provide the polymer surface with an ability to cova-
lently immobilise bioactive compounds on its surface
without any further chemistry [26]. Compared to
using traditional linker chemistry to achieve biological
functionality, the plasma immersion ion implantation
(PIII) approach is environmentally friendly and
achieves biological functionalisation without degrada-
tion of the bulk polymer. This is a relatively new tech-
nologywith emerging applications and good prospects
for the practical production of biocompatible materi-
als [27].
As the energetic ions implant into a polymer, they
break chemical bonds in the polymer macromolecules
and displace atoms and electrons. As a result volatile
components are evolved from the structure, leaving a
carbonized and densiﬁed surface layer [28] that con-
tains sufﬁciently long-lived radicals to react with pro-
tein molecules upon contact such that they become
covalently attached to the treated polymer surface
[26]. Due to the dense monolayer of covalently immo-
bilized protein, cells do not recognize the polymer
material underneath as foreign. We have demon-
strated these effects for a number of polymer materials
including polyethylene, polystyrene and Teﬂon. Here
we apply this method to activate the surface of poly-
urethane as a prospective material for a biomedical
implant.
We show here the synthesis and characterization
of a new polyurethane formulation combining tensile
strength with elasticity, using non-toxic precursors.
We used PIII to activate its surfaces so that they can be
easily functionalized in one simple step. After using
PIII to activate the polymer, we covalently immobi-
lized recombinant human tropoelastin (rhTE) to the
surface by incubation in buffer solution.We chose this
vascular matrix protein because it is known to be a
potent multi-faceted regulator of vascular biology
[29], promoting endothelial cell adhesion and growth
[30] while inhibiting smooth muscle cell proliferation
[31]. There is also increasing evidence for the haemo-
compatibility of elastin and its derivatives [32],
demonstrated in vitro and in clinically relevant models
of prostheses thrombogenicity [33, 34]. This combina-
tion of properties suggests its usefulness for blood-
contacting materials such as cardiovascular grafts.
Hence, we propose that this combination will yield a
suitably elastic and strong synthetic polyurethane with
the potential to regulate important aspects of vascular
biology.
2.Materials andmethods
2.1. Chemicals
rhTE corresponding to amino acid residues 27–724 of
GenBank entry AAC98394 (gi 182020) was expressed
and puriﬁed as previously described [35]. Polyur-
ethane precursors poly(propylene glycol), tolylene
2,4-diisocyanate terminated (PPG-TDI), polytetrahy-
drofuran (PTHF) and dibutyltin dilaurate (DBD)were
purchased from Sigma-Aldrich (USA). Human
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coronary artery endothelial cells (HCAEC) were
purchased from Cell Applications (San Diego,
CA,USA).
2.2. Polyurethane synthesis
Pre-polymers PPG-TDI and PTHF were mixed in
molar ratios of 1:0.35, 1:0.5 and 1:0.7 in the presence
of DBD as a catalyst (0.01% of the mixture), and
applied to a glass surface in a humidity controlled
environment (under CaCl2). Polymerization pro-
ceeded at room temperature for 3 days, and then at
100 °C for 2 h in a vacuum oven. The thickness of the
ﬁlm was 0.3 mm. To remove any unreacted products
and catalyst, the PU ﬁlms were swollen in toluene for
24 h, dried in air for an additional 24 h and ﬁnally in a
vacuumoven for 2 h at room temperature.
2.3. Leaching analysis
PU samples were pre-weighed and placed in milli-Q
water (MQW) for 7 days in a sealed glass beaker.
Samples were then dried in air for 24 h and then in a
vacuum oven for 8 h. The samples were then re-
weighed and the relative mass loss attributed to
leached components was calculated. For an analysis of
leached components, water from the beaker was
placed on a germanium ATR crystal and dried.
Attenuated total reﬂection Fourier-transform infrared
(ATR-FTIR) spectra were measured using a Digilab
FTS7000 FTIR spectrometer ﬁtted with a multi-
bounce ATR accessory with a trapezium germanium
crystal at an incidence angle of 45°. To obtain sufﬁcient
signal/noise ratio and resolution of spectral bands,
500 scans were taken at a resolution of 1 cm−1. A
control spectrum was taken using water from a beaker
stored in the same environment butwithout PU.
2.4. Swelling
PU ﬁlm samples (0.3 mm thick) were weighed before
swelling in dimethylformamide and hexane in sealed
beakers, to assess cross-linking efﬁcacy. Samples were
allowed to swell for 24 h. The samples were weighed
immediately after removal from the beakers, then
dried for 24 h in open air and re-weighed.
2.5.Mechanical testing
Mechanical properties of synthesized polyurethanes
(1 × 0.8 × 5 cm, n = 3) were tested using an Instron
5943 with a 100 N load cell according to the ASTM
D412-06a (ASTM International, 2006) protocol. The
load sensor and extensometer calibrations were per-
formed prior to the test. To prevent specimen slipping
during the test, hydraulic clamps were used. The PU
was loaded at a constant strain rate of 500 mmmin−1
to 100% stretch and then relaxed to 0% stretch. This
cycle was repeated 3 times, before the PU samples were
stretched to failure. The Young’s modulus was
obtained by calculating the slope of the stress–strain
curve at 100%. The tensile strength and modulus at
breakage was calculated using the maximum strain at
the breaking point. A lower load cycling test was also
carried out to assess performance during loads compa-
tible with those experienced in the vasculature. One
hundred cycles up to 10% strain at a constant strain
ratewere applied at a frequency of 1 Hz.
2.6. PIII treatment
The PU samples were placed on a stainless steel holder
with a mesh made of the samematerial. The mesh was
electrically connected to the holder and held in front
of the sample parallel to its surface. The distance
between the sample and the mesh was 5 cm. Plasma
ionswere accelerated by the application of high voltage
(20 kV) bias pulses of 20 μs duration at a frequency of
50 Hz, drawing an average current of 1.2 mA to the
substrate holder and its mesh. The PU samples were
treated for 40–800 s corresponding to ion implant-
ation ﬂuences of 5× 1014–1016 ions cm−2 and subse-
quently stored in air at room temperature. The
penetration depth of the nitrogen ions (20 keV) into
the PU ﬁlm and the distribution of displaced hydrogen
and carbon atoms were calculated using SRIM soft-
ware. ATR-FTIR spectra were measured using a
Digilab FTS7000 FTIR spectrometer as described
above.
2.7. Surface characterization
PU samples were sputter coatedwith a 20 nm gold ﬁlm
and imaged with a Zeiss EVO 50 scanning electron
microscope. The contact angles between the PU
surface and two liquids (de-ionized water and diiodo-
methane) were measured using a Kruss contact angle
analyzer DS10 employing the sessile drop method.
The surface free energy and its polar and dispersive
components were calculated using the Owens–
Wendt–Rabel–Kaelblemodel.
2.8. Tropoelastin coating and detection
Polymer samples were incubated with various concen-
trations of tropoelastin (from 0 to 50 μg ml−1) in
phosphate buffered saline (PBS) at 4 °C overnight. For
ELISA, untreated and PIII-treated polyurethanes were
cut into 0.6× 0.8 cm samples and placed into wells of
a 48-well plate, and treated as previously described
[36]. Covalent attachment was determined using
stringent washing in 5% sodium dodecyl sulfate
(SDS), incubated for 10 min at 90 °C. Non-speciﬁc
binding was blocked with 3% BSA (w/v) and tropoe-
lastin detected with anti-tropoelastin primary anti-
body BA-4 (1:2000 dilution). A secondary anti-mouse
IgG antibody conjugated with HRP (1:5000 dilution)
was used for visualization, in conjunction with ABTS.
The plate was agitated and the absorbance read at
405 nmwith amicroplate reader (BioradModel 680).
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2.9. Cell culture
For attachment studies, 300 cells mm−2 were allowed
to attach for 90 min in Dulbecco’s Modiﬁed Eagle
Medium. In proliferation assays, 150 cells mm−2 were
plated for 3 and 5 days. Attachment and proliferation
of cells to untreated and PIII-treated polyurethane
were analyzed, with no protein, and coated with rhTE.
Samples were blocked with 1% heat-denatured bovine
serum albumin (dBSA) where indicated. At each time
point, cells were washed, ﬁxed with 3.7% formalde-
hyde and stained with 0.1% (w/v) crystal violet
solution for 1 h at room temperature [37]. The dye was
washed with distilled H2O, solubilized with 10% (v/v)
acetic acid, and the absorbance measured at 570 nm.
Results were normalized to day 3 PUonly surfaces.
2.10. Thrombogenicity assessment
Whole blood was obtained from healthy, non-smok-
ing male volunteers who had not consumed aspirin
twoweeks prior to donation, with informed consent in
accordance with the Declaration ofHelsinki. Approval
for this work was granted by The University of Sydney,
Human Research Ethics Committee (protocol 05-
2009/11668). Experiments were conducted in tripli-
cate with blood from different donors. Samples of
untreated and PIII-treated polyurethane were incu-
bated overnight at 4 °C in PBS for non-protein treated
and 20 μg ml−1 tropoelastin for protein-coated sam-
ples. Surfaces were rocked with heparinized whole
blood (0.5 Uml−1) for up to 60 min at 37 °C as
previously described [38]. Evaluation of surface
thrombogenicity was also performed using a modiﬁed
Chandler loop [39]. Pre-weighed surfaces were
inserted into loops constructed of Tygon S-50-HL
tubing (SDR, Australia). Loops were ﬁlled with
heparinized human whole blood (0.5 Uml−1),
enclosed with 1 cm silicon connectors and rotated at
34 rpm at 37 °C for 60 min to simulate mean coronary
artery ﬂow rate (85 ml min−1). Surfaces and thrombi
were removed, surfaces rinsed in PBS and dried before
re-weighing. Alternatively, heparinized whole blood
(0.5 Uml−1) was centrifuged for 15 min at 1000 rpm
in swinging rotors. The supernatant, platelet rich
plasma (PRP) was mixed in equal volumes with PBS
and ﬂuorescently labeled (Alexa Fluor® 488) ﬁbrino-
gen from human plasma to a ﬁnal concentration of
25 μg ml−1, before assessment in the Chandler loop,
also for 60 min.
2.11. Conduit production andburst pressure testing
Conduits were produced on glass rods of 2 mm
diameter, cured for four days at room temperature
(23 °C) in low humidity (5%–10%), annealed for 2 h
at 120 °C under vacuum, washed in toluene for 1 h
and dried on open air for 24 h. 2.5 cm conduit sections
were ﬁxed to an 18 G cannula and connected to a
pressure transducer (Cambridge Electronic Design,
UK) and bio-ampliﬁer (BMA-931; Cambridge
Electronic Design, UK). Pressure in the graft was
increased by increasing volumes of saline introduced
into the graft at a rate of 0.5 ml min−1. The pressure
was recorded as a continuous wave-form using Spike2
acquisition and analysis software (version 8.03; Cam-
bridge ElectronicDesign, UK) and digitised at 250 Hz.
2.12. Pilot in vivo implantation
Study approval was obtained fromSydney LocalHeath
District AnimalWelfareCommittee (protocol number
2014/028). PU conduits (1.5 mm by 10 mm length)
were implanted as rat aortic interposition grafts in
male Sprague-Dawley rats [40]. Brieﬂy, heparin
(100 U kg−1) was administered intravenously, before
proximal and distal clamping, just below the renal
arteries and above the aorto-iliac bifurcation. A 1 cm
segment of the abdominal aorta was resected, before
grafts were inserted with 10-0 nylon interrupted
sutures under sterile conditions using an operative
microscope of X25 magniﬁcation. Flow was re-
established and haemostasis checked. Following com-
pletion of implantation, the wound was irrigated with
saline and the skin closed with subcutaneous and
subcuticular sutures. No post-operative anti-coagula-
tion was used and grafts were explanted after 1 week.
At the time of retrieval, grafts were ﬂushed with
normal saline only.
2.13. Statistical analysis
All data were expressed as mean ± standard error of
themean (SEM) and analyzed using statistical software
in GraphPad Prism Version 5.0 (GraphPad Software,
CA,USA). Student’s t-tests and two-wayANOVAwith
a Bonferroni post-test were used to compare between
groups and within groups respectively. Statistical
signiﬁcancewas accepted as p< 0.05.
3. Results
3.1. Polyurethane synthesis andmechanical
characterization
PPG-TDI and PTHF precursors were combined in
three different stoichiometric ratios, 1:0.35, 1:0.50 and
1:0.70. Each of the synthesized PUs formed a ﬂexible
transparent ﬁlm. The chemical structure after the ﬁrst
stage of the synthesis is shown in ﬁgure 1(a). In the
second stage, when the ﬁlms are annealed, the reaction
of residual isocyanate groups with urethane groups
leads to the formation of allophanate groups
(ﬁgure 1(b)).
Instron mechanical testing produced character-
istic stress-stain curves for PTHF 0.35, 0.50 and 0.70
(ﬁgure 2(A)). Young’s modulus values were derived
from these curves and showed each of the newly syn-
thesized PUs to be signiﬁcantly more elastic than sev-
eral currently used medical polyurethanes and
silicones (ﬁgure 2(B)). PTHF 0.35 (0.41 ± 0.07 MPa),
0.50 (0.56 ± 0.03 MPa) and 0.70 (0.37 ± 0.06 MPa),
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were close to published values for soft tissue
(0.01–0.1 MPa) and TPE 1 (0.60 MPa), and sig-
niﬁcantly more elastic than silicone (1.8 MPa) and
commercial polyurethanes such as Sibstar PSU (1.50
± 0.1 MPa), Bionate PCU (6MPa) and Biospan PSU
(14.0 MPa). The Young’s moduli of our three synthe-
sized PUs were not signiﬁcantly different to each
other.
However, clear differences in stress at break, and
elongation were observed (ﬁgure 2(C)). PTHF 0.35
had the highest stress at breakage (1030 ± 250 kPa),
greater than either PTHF 0.5 (924± 158 kPa) or PTHF
0.70 (482± 90 kPa). Similarly, elongation at breakage
was also reduced with increasing PTHF ratio, from a
high of 583 ± 1% (PTHF 0.35), down to 316 ± 62%
(PTHF 0.5) and 204 ± 19% (PTHF 0.70). This differ-
ence is a result the linear macromolecules crosslinking
into a 3D polymer network due to the presence of resi-
dual isocyanate groups at the second stage of the
synthesis. The crosslinking is increased as the con-
centration of residual isocyanate groups increases,
resulting an increase in the mechanical strength of the
ﬁlm and the Young’s modulus. The increased strength
and extensibility of PTHF 0.35 for a comparable
Young’s modulus led us to favor this variant for fur-
ther investigation.
Repeated cycling of PTHF 0.35 up to 100% tensile
strain for three cycles shows a nonlinear character of
the stress–strain curve and mechanical hysteresis after
relaxation of the load (ﬁgure 2(D)). After the ﬁrst cycle
the residual elongation was 11% and did not change
over the following cycles. Minimal changes in strain–
stress curve and hysteresis were seen in the second and
third cycles. Repeated cycling of PTHF 0.35 up to 10%
strain to simulate physiological conditions for 100
cycles was carried out to determine the resilience of the
material and the degree of hysteresis. After 100 cycles
the load for 10% tensile strain decreased by 10%
showing the relaxation of the PU structure
(ﬁgure 2(E)). Minimal changes in strain–stress curve
and hysteresis were seen after the ﬁrst ten cycles
(ﬁgure 2(F)).
3.2. Leaching and cross-linking
Leaching over seven days into MQW showed that the
leached components were less than 0.1% of the sample
weight. The FTIR ATR spectra of the leached compo-
nents (ﬁgure 3) found in solution showed that the
main leached component is non-reacted PTHF—lines
at 3350 cm−1 (OH group); in the 2975–2875 cm−1
region (CH groups); and at 1106 cm−1 (ether group).
There are some low intensity lines related to vibrations
of PTHF bonded to PPG-TDI appear also at
1728 cm−1 (carbonyl group) and at 1603 cm−1 (aro-
matic ring). No isocyanate components were seen
(absence of signal at 2270 cm−1) indicating that these
potentially toxic components were not leached from
the material. The swelling test showed that the PU
ﬁlms were not dissolved and rather swelled in DMFA
to 874.4 ± 1.3% and in hexane to 121.9± 1.8%. This
indicates that the PU ﬁlm was robustly chemically
cross-linked.
3.3. Effect of PIII treatment
One of the main advantages of PIII surface treatment
is that it preserves the bulk properties of the surface
modiﬁed materials. For the ion energy used in our
work, the thickness of the modiﬁed layer, as calculated
by TRIM/SRIM simulations, is about 70 nm [41].
Since the thickness of the PU ﬁlm used for mechanical
testing is 8 mm, the contribution of the modiﬁed layer
is not detectable by the Instron mechanical test (5%–
Figure 1. (a)PU chemical formula, containing a polypropylene glycol terminated tolylene diisocyanate as the pre-polymer. The pre-
polymerwas curedwith polytetrahydrofurane as a chain extender. (b)The cross-linking of the backbone chains occurs during
annealing which promotes the formation of allophanate groups.
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10% accuracy). Similarly, the thickness of a subse-
quently immobilized protein layer is about 5 nm, so its
inﬂuence on the mechanical properties of polyur-
ethaneﬁlm is also not detected.
PIII treatment reduced the hydrophobicity of the
PU surface from a starting contact angle of 95.3± 2.5°
(untreated), to a minimum of 70.8± 2.7° after a treat-
ment of 80 s. The contact angle remained close to this
value for treatment times beyond 80 s, measured as
73.5 ± 1.4° (ﬁgure 4(A)) after a treatment of 800 s.
SEM imaging following PIII treatment revealed that all
of the surfaces were generally featureless and smooth,
with some local imperfections. Following PIII treat-
ment, some surface fracturing was observed, increas-
ingly so with increasing treatment duration
(ﬁgure 4(B)).
ATR-FTIR spectra of PU revealed signiﬁcant
changes in the surface layer after PIII treatment. The
Figure 2.Mechanical testing of PUﬁlms. (A)Typical tensile stress–strain curves for three PU candidates of variousNCO/OHratio; a
1:0.35 ratio shows a combination of the highest strength and lowYoung’smodulus. (B)Young’smodulus of synthesized PUﬁlms
comparedwith reference data for soft tissue andmedical grade polymers including TPE1, SIBSTARPSU, Silicone, Bionate PCU and
BIOSPANPSU. (C) Stress and elongation of PU ﬁlms at break. (D)Cyclic testing up to 100% tensile strain for PTHF-PPG-TDI
0.35 PU. The observed nonlinear curve,mechanical hysteresis and residual stress are discussed in the text. (E) 100 cycles at tensile
strain of 10%.After theﬁrst cycles, the load curves are similar for the remaining 90 cycles. (F) Strain–stress curves for ﬁrst ten cycles.
Themechanical hysteresis decreased after the ﬁrst cycle andwasmaintained over subsequent cycles.
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spectra of untreated PU showed lines at 3300 cm−1
(Amide A), 1720 cm−1 (Amide I), 1530 cm−1 (Amide
II) corresponding to vibrations of the urethane group,
as well as a number of vibrations in the polyether and
aromatic rings of the macromolecule (ﬁgure 4(C),
red). After PIII treatment, broad bands in the
3600–2700 cm−1, 1800–1600 cm−1and
1450–900 cm−1 regions of the spectra appeared
(ﬁgure 4(C), black). These bands were clearer in the
differential spectrum (ﬁgure 4(C), green), with fea-
tures from the untreated PU subtracted from the spec-
trum of the PIII treated sample. Shoulders at 3604,
3425 and 3237 cm−1 corresponding to hydroxyl group
vibrations, 1744 and 1710 cm−1 for carbonyl group
vibrations and 1620–1590 cm−1 for unsaturated car-
bon–carbon group vibrations were observed. The cen-
ter spectral region contained broad, overlapping lines,
such that clear separation of individual lines was not
possible. These changes were attributed to the appear-
ance of hydroxyl and carbonyl groups as well as new
sp2 and sp3 carbon structures.
3.4. Covalent binding of tropoelastin
The binding of tropoelastin to the polyurethane
surfaces was characterized. Untreated and PIII-treated
polyurethane surfaces were incubated with increasing
tropoelastin concentrations and the relative amount of
adsorbed protein determined using ELISA
(ﬁgure 5(A)). A steady increase in the amount of
bound tropoelastin up to 20 μg ml−1 for both
untreated and PIII-treated PU surfaces was observed.
This increase was steeper for PIII-treated surfaces
compared to untreated samples. PIII-treated surfaces
bound a greater amount of rhTE at each concentration
compared to the respective untreated surface.
The covalent binding of rhTE to untreated and
PIII-treated polyurethane was examined using an
ELISA speciﬁc for rhTE, combined with stringent SDS
washing (ﬁgure 5(B)). PU surfaces without rhTE were
used as negative controls. After SDS washing the
amount of rhTE present on untreated PU returned to
baseline levels, while in contrast, 72.3 ± 4.8% of the
rhTEwas retained on PIII treated PU.
3.5. Endothelial cell interactions
3.5.1. Attachment
Adhesion of endothelial cells to polyurethane was
quantiﬁed using crystal violet staining (ﬁgure 6(A)). In
the absence of protein coating, untreated polyurethane
had relatively poor cell adhesion (28.7 ± 3.5%). This
was signiﬁcantly improved by PIII-treatment to 48.1
± 3.3% (p < 0.01). BSA blocking of PU returned cell
adhesion to less than 20%, irrespective of PIII
treatment. Tropoelastin coating of untreated polyur-
ethane, subsequently BSA blocked, improved cell
attachment relative to blocked PU (33.0 ± 4.6%).
Further, tropoelastin coating of PIII-treated PU, sub-
sequently BSA blocked, signiﬁcantly improved cell
attachment (56.0 ± 11.1%, p < 0.01), showing that
increased endothelial cell adhesion facilitated by PIII
treatment is further augmented by the presence of
tropoelastin.
3.5.2. Proliferation
Compared to untreated polyurethane, after 3 days in
culture, all PIII treated, protein coated surfaces
supported elevated levels of cell growth (ﬁgure 6(B)).
Tropoelastin coating of the PIII treated PU surface
resulted in a 31.2± 5.2% increase, relative to PU only,
not signiﬁcantly different toﬁbronectin (25.3± 10.4%
increase) coated on the PIII-treated PU, on day 3. After
Figure 3. FTIRATR spectra of components leached fromPU intoMQWover 7 days. Lines were identiﬁed forOH (3350 cm−1), CH
(2975–2875 cm−1 region), carbonyl (1728 cm−1), aromatic ring (1603 cm−1) and ether (1106 cm−1) groups. Themost abundant
substance was non-crosslinked PTHF to PPG-TDI component, with a low amount of PTHFbonded to PPG-TDI. The PPG-TDIwith
an active isocyanate groupwas not observed.
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5 days in culture, there was a further increase in cell
numbers for all conditions. Endothelial cell prolifera-
tion on PIII+rhTE polyurethane was 54.4 ± 17.3%
higher than on PU only, which did not signiﬁcantly
differ from ﬁbronectin-coated PIII-treated PU on day
5 (66.7± 13.3%higher than the PUonly control).
3.6. Blood compatibility
3.6.1. Static
The relative thrombogenicity of untreated and PIII-
treated surfaces, with and without tropoelastin was
assessed using heparinized whole blood. Following
90 min rocking at 37 °C, untreated PU surfaces
displayed a small amount of clotting, which was not
improved by tropoelastin coating. However, PIII-
treated surfaces were extremely thrombogenic with
almost uniform coverage of coagulated blood. Tro-
poelastin coating dramatically reduced the incidence
of this, back to the baseline level (ﬁgure 7(A)).
Scanning electron microscopy demonstrated pat-
chy coverage of erythrocytes on untreated poly-
urethane. PIII-treated polyurethane displayed a
dramatic rise in thrombus formation, with large
amounts of erythrocytes and associated ﬁbrin deposi-
tion completely obscuring the underlying surface
(supplementary ﬁgure 1, available online at stacks.iop.
org/BMM/12/045002/mmedia). When coated with
tropoelastin, untreated surfaces displayed patchy areas
of thrombus constituents as well as blood cell adhe-
sion. In contrast, PIII-treated surfaces with tropoelas-
tin coating resulted in themajority of the surface being
Figure 4.The effect of PIII treatment of the PU surface. (A)Water contact angle of the PUﬁlmwith PIII treatment time showing that
the surface became increasingly hydrophilic after PIII. The duration of PIII did not signiﬁcantly inﬂuence thewater contact angle. (B)
SEM images of the PU surfacewith time of PIII treatment. Scale bars represent 200 and 50 μmas indicated in the image. (c) FTIRATR
spectra of PUbefore (red, bottom) and after PIII treatment (black,middle). A difference spectrum (green, top) revealedOH, CN,
C=O,CHandCH in –C= groups.
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clear of blood components, with only occasional ery-
throcytes present (ﬁgure 7(A)).
3.6.2. Coronary artery ﬂow using aChandler loop
Thrombogenicity of surfaces under dynamic condi-
tions was assessed using a modiﬁed Chandler loop
assay, which aims to model coronary artery ﬂow
conditions.Untreated polyurethane surfaces displayed
low clotting (15.0± 1.5 mg thrombusweight), but PIII
treatment increased the thrombogenicity (30.0 ±
3.2 mg). However, tropoelastin coating of PIII-treated
surfaces resulted in restoration of non-thrombogeni-
city (10.4± 4.1 mg,ﬁgure 7(B)).
3.7. Translation for vascular grafting
PU conduits were generated by curing the polymer on
a cylindrical mandril. The resulting tubes were trans-
parent, smooth and appeared homogenous along the
length of the mandril (ﬁgure 8(A). SEM imaging
conﬁrmed the uniformity, demonstrating smooth
outer and luminal surfaces and consistent wall thick-
ness (ﬁgure 8(B)). Under increasing load, PU conduits
achieved a burst pressure of 384.1± 17.3 mmHg, well
in excess of physiological forces. To demonstrate the
feasibility of testing our new conduit in vivo, we
performed a pilot implantation in a rat aorta model.
The PU conduits handled well and retained ten
interrupted sutures at each anastomoses. Following
Figure 5. (A)ELISAdetection of tropoelastin on untreated (solid line) and PIII-treated (dashed line) polyurethane surfaces coated in
increasing concentrations of tropoelastin. (B)ELISA detection of tropoelastin bound to untreated or PIII-treated polyurethane
followingwashingwith 5%SDS at 95 °C for 30 min, without SDSwashing and a no tropoelastin control.
Figure 6.Endothelial cell interactions. (A)The percentageHCAEC attachment in the presence or absence of tropoelastin and dBSA
blocking wasmeasured after 90 min incubation on untreated and PIII PU. (B)Relative cell proliferation on polyurethane surfaces at
days 3 and 5 is shown onPUonly, PU+rhTE and PU+ FN. **= p< 0.01.
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removal of surgical clamps, normal blood ﬂow
resumed, observed through the transparent graft
material (ﬁgure 8(C)). Rats recovered normally after
surgery and showed no signs of abnormal behavior for
up to oneweek following the procedure.
4.Discussion
We aimed to synthesize new polyurethane formula-
tions demonstrating a combination of elasticity and
mechanical strength, suitable for development as
synthetic vascular grafts. The diversity in mechanical
properties of polyurethanes is derived both from the
ability to select various hard or soft segment precur-
sors, and to introduce additional cross-links between
the polymer chains. Classically, the hard segment
provides mechanical strength while the soft segment
imparts the elastomeric properties [42]. In this study,
we selected polyoxypropylene glycol, tolylene diiso-
cyanate terminated (PPG-TDI) as the hard segment
and polytetrahydrofuran (PTHF) as the soft segment.
PPG-TDI itself contains a polyol soft segment, poly
(propylene glycol), making our PU effectively bi-soft
segmented, allowing for enhanced tunability of
mechanical properties [43–45]. To further strengthen
the PU, an additional cross-linking reaction between
the isocyanate groups and urethane groups of the
prepolymers was performed at the annealing stage of
the synthesis.
Traditional PUs have a much higher Young’s
modulus and are stiffer than native soft tissue. Devel-
oping PUs with an increase in elasticity while main-
taining a high strength has been an ongoing challenge.
The optimal molar ratio of the isocyanate and hydro-
xyl groups in the current study of 1:0.35, in combina-
tion with additional cross-linking was found to
produce a PU with a Young’s modulus of (0.41 ±
0.1 MPa), close to the reported range for soft tissue
(0.01 to 0.1 MPa) [46]. In contrast, other new poly-
urethanes including TPE1 (0.6 MPa), SIBSTAR 103 T
(1.5 MPa) are less elastic, while medical grade PUs
such as Bionate (6MPa) and Biospan (14MPa) are
stiffer still [23].
Importantly, this highly elastic PU is also
mechanically strong, with a stress at breakage of 1030
± 250 kPa, and an elongation at breakage of 583%.
These values of breakage stress and strain greatly
exceed the loads expected for soft tissue (3%–8%
strain) [47], and the mechanical properties we deter-
mined are similar to those of native human vessels
such as the femoral vein which has a tensile strength of
Figure 7. (A)Macroscopic and representative SEM images of surfaces following 90 min incubationwith heparinizedwhole blood.
Scale bar denotes 50 μm. (B)Thrombusweight fromChandler loop analysis on untreated polyurethane, PIII-treated polyurethane
and PIII-treated polyurethanewith tropoelastin coating. Statistics are relative to untreated polyurethane. (C) Fluorescently labeled
ﬁbrinogen demonstrates the same trends, increased on PIII only but substantially reduced on untreated and PIII+rhTE samples. Scale
bar represents 100 μm.
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2–3MPa, and a Young’s modulus of 0.16–0.42 MPa
[48]. The residual strain in the PU after 100% elonga-
tion is about 11%, which is an expected value for a seg-
mented PU [49]. Further, our PU swells in DMFA to
874.4± 1.3% and in hexane to 121.9± 1.8%, indicat-
ing robust chemical cross-linking. Washing with
toluene removed unreacted precursors and reagents,
with the amount of washable low molecular fractions
was found to be approximately 3%. Cross-linking also
prevented leaching of PU side reaction products, as
conﬁrmed by FTIR spectra that showed no residual
isocyanate groups (2270 cm−1 line) or any toxic resi-
due in a sample of water in which the PU was incu-
bated for 24 h.
Our PUwas further modiﬁed with PIII to generate
radicals embedded in the surface, to facilitate covalent
binding of active biomolecules. Following PIII treat-
ment, the water contact angle on PU decreased mark-
edly from 95.3 ± 2.5° (untreated), to a minimum of
70.8 ± 2.7° after a treatment of 80 s. This effect was
driven by atmospheric oxidation of radicals emerging
at the surface, generating oxygen-containing groups,
such as carbonyls and carboxyls on the surface layer,
imparting polarity and a net negative charge, and has
been well described formany polymers [50–52]. Using
scanning electron microscopy we observed some sur-
face cracking after long treatment times, pre-
dominantly due to surface carbonization [53], but this
wasminimal for the 80 s treatment time.
The surface of PUwas subsequently functionalized
with tropoelastin, increasingly accepted to favorably
modulate multiple facets of vascular biocompatibility
[54]. Covalent retention of tropoelastin, optimally at
20 μg ml−1, was inferred after stringent washing in
SDS [51, 55], before a comparative evaluation of inter-
actions with human vascular endothelial cells and
heparinized whole blood. SDS is a detergent that
unfolds proteins [56]. It interferes with the physical
forces that result in the physisorption of proteins but
does not attack covalent bonds, leaving the protein’s
primary structure intact. SDS washing has been used
as a method to test whether biological molecules are
covalently attached to surfaces [57–59] and to detect
covalently bound drug–protein adducts [60]. In some
situations where there is a thick coverage of denatured
and aggregated protein blocking access to the interface
with the surface, steric hindrance may prevent SDS
from accessing all of the sites where physical forces
bind the protein. Because our PIII-treated surfaces are
relatively hydrophilic compared to the untreated poly-
mer controls from which our SDS wash successfully
removes all of the protein, it is unlikely that steric hin-
drance could be responsible for the SDS-resistant
binding observed on the PIII-treated surfaces. We
therefore deduce that the high proportion of tropoe-
lastin still adsorbed after SDS cleaning is covalently
bonded to the surface. The mechanism for this cova-
lent binding of the protein has been shown to be reac-
tion with embedded radicals in the ion implanted
surface layer that diffuse to the surface [26].
In its untreated form, PU supported only low
levels of endothelial cell attachment and spreading,
consistent with previous studies [61, 62]. PIII-treat-
ment only, improved cell adhesion, consistent with
the observed reduction in hydrophobicity, facilitating
greater cell contact with the surface. rhTE immobiliza-
tion on PIII treated PU further improved endothelial
cell interactions, augmenting attachment and sup-
porting proliferation, in agreement with previous stu-
dies showing this beneﬁt [29, 63]. For proliferation
studies, we also compared tropoelastin with ﬁbro-
nectin, which is a well-known cell adhesive extra-
cellular matrix protein featuring a canonical RGD cell
binding motif [64]. While ﬁbronectin coatings drive
improved cell interactions, they also initiate thrombus
formation, attracting and activating platelets, while
exerting no inhibitory effect on smooth muscle cells
[65]. This makes ﬁbronectin a poor candidate for the
multi-faceted regulation of vascular compat-
ibility [54].
Figure 8. (A)Macroscopic photograph of a PU conduit. Scale bar denotes 500 μm. (B)Representative SEM image of conduit cross-
section showing smooth inner and outer surfaces and uniformwall thickness. Scale bar denotes 200 μm. (C) Image of PU conduit
implanted as a rat aortic interposition graft, following the removal of the surgical clamps and resumption of blood ﬂow. Scale bar
denotes 1 mm.
11
Biomed.Mater. 12 (2017) 045002 I Kondyurina et al
Heparinized whole blood in vitro assays were used
to assess the blood response to PU, with and without
tropoelastin-coating. In several previous studies asses-
sing the relative thrombogenicity of new biomaterials
we have validated the use of heparinised whole blood
assays [38, 66, 67]. The assays demonstrate changes
relative to control, as absolute measurements of blood
compatibility in vitro remain elusive. In a recent study
[39] we showed that the whole blood assays used in
this paper were consistent with systems using fewer
components (e.g. isolated platelets, PRP) which have
limitations recognised by the leaders in the blood/
material interface community [68]. In both static and
ﬂow conditions, clinically used materials including
stainless steel and ePTFE have demonstrated clotting
proﬁles consistent with their behaviour in patients.
Similar whole blood assays are recognised as appro-
priate for testing of themost promising new biomater-
ials surfaces [69].
Untreated polyurethane showed some adhesion of
blood components, in agreement with the generally
accepted short-term blood compatibility of untreated
polyurethanes [70, 71]. In contrast, uncoated PIII trea-
ted surfaces generated a large network of blood clot,
resulting from reduced hydrophobicity of the surface
and the overall negative surface charge, whichmay sti-
mulate the activation of the plasma coagulation system
[72]. Tropoelastin coating of PIII treated PU, however,
resulted in a clot-free surface with only occasional red
blood cell adhesion. These results were conﬁrmed
under ﬂow, in a modiﬁed Chandler loop, with
untreated polyurethane displaying low thrombogeni-
city, forming little thrombus. PIII treatment resulted
in an even coverage of coagulated blood, which was
brought down to levels similar to untreated surfaces,
following tropoelastin coating. Representative images
of ﬂuorescently labeled ﬁbrin also clearly demonstrate
the effects of PIII treatment, and subsequent improve-
ment in the presence of tropoelastin. This is consistent
with previous reports showing the low thrombogeni-
city of tropoelastin-coated surfaces [38, 63].
Having developed a new PU formulation with
physical and biological properties optimized for vas-
cular applications we sought to demonstrate the feasi-
bility of producing conduits suitable for future in vivo
evaluation. Uniform grafts were produced with
smooth luminal and outer surfaces and uniform wall
thickness. The ﬁrst iteration of our PU grafts were
non-porous and demonstrated a burst pressure
greater than three times human physiological blood
pressure, but below the levels previously published for
other PU formulations such as Pellethane 2363 80A
(>550 mmHg) [10], Carbothane PC3575A
(1330 mmHg) and Chronoﬂex 80A (1680 mmHg)
[73] and for native saphenous veins (1250 ±
500 mmHg) and coronary arteries (2000 mmHg) [74].
We expect that further optimization of the manu-
facturing process, including screening of the best ratio
of diameter to wall thickness would improve this
parameter. Nevertheless, our untreated PU conduit
performed well in pilot testing in a rat aortic interposi-
tion model. The grafts handled and sutured well,
blood ﬂow was re-established and no signs of aneur-
ysm or leak were detected. Rats recovered well and
behaved normally out to sacriﬁce at one week. The
high ﬂow of the aorta precludes clot formation in this
model, even for highly thrombogenic materials such
as ePTFE. Re-endothelialisation is only meaningful at
three weeks, while neointimal hyperplasia at this early
timepoint is minimal. Accordingly, at the 1 week time
point of our pilot study, our ﬁndings demonstrate
appropriate handling, suturability and physical survi-
val of the graft. The promising results justify the full
assessment of our PU conduits, including those func-
tionalized with PIII and rhTE in an appropriately
powered study for up to 6 months in this well-estab-
lishedmodel [75].
5. Conclusions
Our results demonstrate a new PU platform with a
combination of strength and elasticity tuned to match
those of native soft tissue. We have shown that plasma
treatment followed by covalent immobilization of
tropoelastin on this material is sufﬁcient to satisfy the
requirements for vascular applications of positive cell
interactions and blood compatibility.We propose that
this promising composite material could be developed
further into a synthetic vascular graft, beneﬁting from
customizable mechanical properties and favorable
modulation of vascular biology. Our PU platform
combines high strength with a low Young’s modulus,
ﬁnely tuned to be suitable for vascular biomaterial
applications. PIII treatment facilitates an enhanced
biointerface, by enabling direct covalent immobiliza-
tion of tropoelastin to promote endothelial cell inter-
actions while maintaining good blood compatibility.
We propose that the combination of a mechanically
matched substrate with improved vascular biocom-
patibility could ultimately address the deﬁciencies
known for current synthetic graftmaterials.
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